[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$feJ7Bb8S4DMWHdjwBn73aXMeTOXNCpSOn3IBf8qbxA9I":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":37,"phaseBuckets":58,"rows":65},"University of Pittsburgh",[4,6],"University of Pittsburgh Medical Center",1401,false,237,50,10872265,6,1146,[15,18,21,24,27,29,32,34],{"name":16,"count":17},"Depression",74,{"name":19,"count":20},"Obesity",48,{"name":22,"count":23},"Cardiovascular Diseases",22,{"name":25,"count":26},"Cancer",20,{"name":28,"count":26},"Anxiety",{"name":30,"count":31},"Sleep",19,{"name":33,"count":31},"Schizophrenia",{"name":35,"count":36},"Diabetes",17,[38,43,48,53],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT04084080","Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)","2026-05-31","Red Blood Cell",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT06474286","Prucalopride for Cognitive Functioning in Schizophrenia","2026-12-31","Prucalopride 1 MG",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT05450978","Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding","2027-04-01","Lamotrigine",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT03333200","Longitudinal Study of Neurodegenerative Disorders","2030-01","Hematopoetic Stem Cell Transplantation",[59,60,61,62,63,64],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[66,90,137,158,206,224,242,322,369,417,456,489,519,546,579,609,638,676,711,739,765,783,807,832,856,880,904,922,946,971,989,1016,1034,1057,1081,1106,1130,1156,1174,1197,1221,1244,1268,1294,1312,1336,1354,1372,1390,1416,1440,1462,1491,1509,1533,1556,1580,1603,1627,1649,1673,1691,1714,1738,1761,1779,1803,1825,1848,1870,1908,1942,1966,1992,2010,2033,2056,2081,2104,2128,2152,2174,2197,2223,2246,2270,2293,2320,2338,2356,2385,2403,2421,2491,2549,2584,2622,2669,2698,2734,2766,2788,2813,2850,2872,2896,2919,2937,2962,2980,3003,3024,3047,3072,3090,3111,3136,3154,3172,3190,3208,3226,3247,3271,3289,3315,3339,3366,3390,3408,3433,3456,3477,3503,3526,3547,3565,3587,3609,3627,3651,3673,3696,3721,3744,3762,3785,3809,3827,3845,3863,3896,3922,3951,3981,4011,4033,4055,4080,4115,4149,4171,4189,4211,4236,4259,4281,4299,4322,4340,4358,4376,4394,4412,4430,4448,4466,4489,4511,4534,4552,4576,4597,4619,4642,4660,4678,4696,4717,4735,4753,4776,4799,4817,4839,4861,4879,4902,4920,4938,4956,4979,5002,5027,5049,5072,5095,5119,5144,5162,5183,5205,5228,5246,5271,5325,5367,5397,5438,5468,5498,5525,5556,5585,5610,5644,5666,5691,5718,5736,5754,5772,5794,5816,5840,5858,5882,5905,5928,5952,5974,5992,6016,6034,6056,6080,6101,6123,6147,6165,6187,6210,6232,6254,6277,6295,6319,6341,6371,6389,6416,6434,6456,6479,6501,6523,6546,6564,6587,6609,6627,6648,6666,6688,6714,6732,6750,6774,6797,6815,6838,6860,6885,6910,6928,6951],{"intervention":42,"totalTrials":67,"cells":68},1,{"EARLY_PHASE1":69,"PHASE1":72,"PHASE2":74,"PHASE3":76,"PHASE4":86,"NA":88},{"trials":70,"activeCount":71},[],0,{"trials":73,"activeCount":71},[],{"trials":75,"activeCount":71},[],{"trials":77,"activeCount":67,"soonestReadout":41},[78],{"nctId":39,"briefTitle":40,"status":79,"phases":80,"primaryCompletion":41,"completion":41,"start":81,"enrollment":82,"conditions":83,"interventions":85},"ACTIVE_NOT_RECRUITING",[62],"2020-02-26",173,[84],"Sickle Cell Disease",[42],{"trials":87,"activeCount":71},[],{"trials":89,"activeCount":71},[],{"intervention":91,"totalTrials":92,"cells":93},"lamotrigine",2,{"EARLY_PHASE1":94,"PHASE1":96,"PHASE2":98,"PHASE3":100,"PHASE4":102,"NA":124},{"trials":95,"activeCount":71},[],{"trials":97,"activeCount":71},[],{"trials":99,"activeCount":71},[],{"trials":101,"activeCount":71},[],{"trials":103,"activeCount":71},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"completion":109,"start":110,"enrollment":111,"conditions":112,"interventions":114},"NCT00177567","Treatment of Geriatric Bipolar Mood Disorders: A Pilot Study","COMPLETED",[63],"2004-01","2001-07",60,[113],"Bipolar Disorder",[115,116,117,118,119,120,91,121,122,123],"lithium carbonate","Depakote-ER","risperidone","olanzapine","paroxetine","bupropion","venlafaxine","tranylcypromine","mirtazapine",{"trials":125,"activeCount":67,"soonestReadout":51},[126],{"nctId":49,"briefTitle":50,"status":127,"phases":128,"primaryCompletion":51,"completion":129,"start":130,"enrollment":111,"conditions":131,"interventions":134},"RECRUITING",[],"2028-04-01","2022-07-20",[132,133],"Epilepsy","Pregnancy Related",[52,135,136],"Levetiracetam","Oxcarbazepine",{"intervention":47,"totalTrials":67,"cells":138},{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":149},{"trials":140,"activeCount":71},[],{"trials":142,"activeCount":71},[],{"trials":144,"activeCount":71},[],{"trials":146,"activeCount":71},[],{"trials":148,"activeCount":71},[],{"trials":150,"activeCount":67,"soonestReadout":46},[151],{"nctId":44,"briefTitle":45,"status":152,"phases":153,"primaryCompletion":46,"completion":46,"start":154,"enrollment":155,"conditions":156,"interventions":157},"NOT_YET_RECRUITING",[64],"2026-07-31",34,[33],[47],{"intervention":57,"totalTrials":67,"cells":159},{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":170},{"trials":161,"activeCount":71},[],{"trials":163,"activeCount":71},[],{"trials":165,"activeCount":71},[],{"trials":167,"activeCount":71},[],{"trials":169,"activeCount":71},[],{"trials":171,"activeCount":67,"soonestReadout":56},[172],{"nctId":54,"briefTitle":55,"status":127,"phases":173,"primaryCompletion":56,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":205},[],"2035-01","2012-01-11",1500,[178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,198,199,200,201,202,203,204],"MLD","Krabbe Disease","ALD","MPS I","MPS II","MPS III","Vanishing White Matter Disease","GM3 Gangliosidosis","PKAN","Tay-Sachs Disease","NP Deficiency","Osteopetrosis","Alpha-Mannosidosis","Sandhoff Disease","Niemann-Pick Diseases","MPS IV","Gaucher Disease","GAN","GM1 Gangliosidoses","Morquio Disease","S-Adenosylhomocysteine Hydrolase Deficiency","Batten Disease","Pelizaeus-Merzbacher Disease","Leukodystrophy","Lysosomal Storage Diseases","Purine Nucleoside Phosphorylase Deficiency","Multiple Sulfatase Deficiency Disease",[57],{"intervention":135,"totalTrials":67,"cells":207},{"EARLY_PHASE1":208,"PHASE1":210,"PHASE2":212,"PHASE3":214,"PHASE4":216,"NA":218},{"trials":209,"activeCount":71},[],{"trials":211,"activeCount":71},[],{"trials":213,"activeCount":71},[],{"trials":215,"activeCount":71},[],{"trials":217,"activeCount":71},[],{"trials":219,"activeCount":67,"soonestReadout":51},[220],{"nctId":49,"briefTitle":50,"status":127,"phases":221,"primaryCompletion":51,"completion":129,"start":130,"enrollment":111,"conditions":222,"interventions":223},[],[132,133],[52,135,136],{"intervention":136,"totalTrials":67,"cells":225},{"EARLY_PHASE1":226,"PHASE1":228,"PHASE2":230,"PHASE3":232,"PHASE4":234,"NA":236},{"trials":227,"activeCount":71},[],{"trials":229,"activeCount":71},[],{"trials":231,"activeCount":71},[],{"trials":233,"activeCount":71},[],{"trials":235,"activeCount":71},[],{"trials":237,"activeCount":67,"soonestReadout":51},[238],{"nctId":49,"briefTitle":50,"status":127,"phases":239,"primaryCompletion":51,"completion":129,"start":130,"enrollment":111,"conditions":240,"interventions":241},[],[132,133],[52,135,136],{"intervention":243,"totalTrials":12,"cells":244},"Escitalopram",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":320},{"trials":246,"activeCount":71},[],{"trials":248,"activeCount":71},[],{"trials":250,"activeCount":71},[],{"trials":252,"activeCount":71},[],{"trials":254,"activeCount":71},[255,266,275,288,299,308],{"nctId":256,"briefTitle":257,"status":107,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":264},"NCT00177216","Characteristics of Sleep Patterns in Young Adults With and Without Insomnia",[63],"2008-05","2002-02",69,[263],"Sleep Disorders",[265,243],"Zolpidem",{"nctId":267,"briefTitle":268,"status":107,"phases":269,"primaryCompletion":270,"completion":270,"start":271,"enrollment":272,"conditions":273,"interventions":274},"NCT00073697","Treatment of Depression in Adults",[63],"2007-10","2003-05",290,[16],[243],{"nctId":276,"briefTitle":277,"status":107,"phases":278,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT00177671","Antidepressant Medication Plus Donepezil for Treating Late-life Depression",[63],"2009-09","2003-12",220,[16,283],"Dementia",[243,285,286,287],"Donepezil","Venlafaxine","Duloxetine",{"nctId":289,"briefTitle":290,"status":107,"phases":291,"completion":292,"start":293,"enrollment":294,"conditions":295,"interventions":297},"NCT00222820","Depression: The Search for Treatment-Relevant Phenotypes-Pilot Study",[63],"2004-09","2002-04",35,[296],"Major Depression",[298],"escitalopram",{"nctId":300,"briefTitle":301,"status":107,"phases":302,"primaryCompletion":303,"completion":303,"start":304,"enrollment":305,"conditions":306,"interventions":307},"NCT00177294","Augmenting Antidepressant Treatment With Interpersonal Psychotherapy for Treating Late-life Depression",[63],"2009-08","2004-04",319,[16],[243],{"nctId":309,"briefTitle":310,"status":107,"phases":311,"primaryCompletion":312,"completion":313,"start":314,"enrollment":315,"conditions":316,"interventions":319},"NCT00105586","Drug Therapy for Generalized Anxiety Disorder Among the Elderly",[63],"2008-01","2008-04","2004-12",177,[317,318],"Anxiety Disorders","Generalized Anxiety Disorder",[243],{"trials":321,"activeCount":71},[],{"intervention":119,"totalTrials":323,"cells":324},4,{"EARLY_PHASE1":325,"PHASE1":327,"PHASE2":329,"PHASE3":331,"PHASE4":333,"NA":367},{"trials":326,"activeCount":71},[],{"trials":328,"activeCount":71},[],{"trials":330,"activeCount":71},[],{"trials":332,"activeCount":71},[],{"trials":334,"activeCount":71},[335,345,354,363],{"nctId":336,"briefTitle":337,"status":107,"phases":338,"completion":339,"start":340,"enrollment":341,"conditions":342,"interventions":344},"NCT00178100","Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression",[63],"2005-08","1999-03",225,[343],"Unipolar Depression",[119],{"nctId":346,"briefTitle":347,"status":107,"phases":348,"completion":349,"start":350,"enrollment":351,"conditions":352,"interventions":353},"NCT00178035","Sleep Deprivation Plus Paroxetine for Treating Major Depression in Elderly Individuals",[63],"2003-08","1999-12",158,[16],[119],{"nctId":355,"briefTitle":356,"status":107,"phases":357,"completion":280,"start":358,"enrollment":359,"conditions":360,"interventions":362},"NCT00178048","Paroxetine in the Treatment of Chronic Primary Insomnia",[63],"1998-09",66,[361,16],"Primary Insomnia",[119],{"nctId":105,"briefTitle":106,"status":107,"phases":364,"completion":109,"start":110,"enrollment":111,"conditions":365,"interventions":366},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":368,"activeCount":71},[],{"intervention":370,"totalTrials":371,"cells":372},"Hydroxychloroquine",3,{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":397,"PHASE3":399,"PHASE4":401,"NA":415},{"trials":374,"activeCount":71},[],{"trials":376,"activeCount":71},[377,386],{"nctId":378,"briefTitle":379,"status":107,"phases":380,"primaryCompletion":381,"completion":381,"start":382,"enrollment":155,"conditions":383,"interventions":385},"NCT02124681","Rediscovering Hydroxychloroquine as a Novel Insulin Sensitizer",[60],"2016-08","2014-04",[384],"Insulin Resistance",[370],{"nctId":387,"briefTitle":388,"status":389,"phases":390,"primaryCompletion":391,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":396},"NCT01144169","Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma","TERMINATED",[60],"2016-09","2010-10",7,[395],"Renal Cell Carcinoma",[370],{"trials":398,"activeCount":71},[],{"trials":400,"activeCount":71},[],{"trials":402,"activeCount":71},[403],{"nctId":404,"briefTitle":405,"status":107,"phases":406,"primaryCompletion":407,"completion":408,"start":409,"enrollment":410,"conditions":411,"interventions":413},"NCT01326533","Reducing Risk of Type 2 Diabetes: Hydroxychloroquine Use in Pre-Diabetes",[63],"2013-03","2014-12","2011-03",32,[412],"Pre-diabetes",[414],"hydroxychloroquine",{"trials":416,"activeCount":71},[],{"intervention":418,"totalTrials":371,"cells":419},"Mirtazapine",{"EARLY_PHASE1":420,"PHASE1":422,"PHASE2":424,"PHASE3":446,"PHASE4":448,"NA":454},{"trials":421,"activeCount":71},[],{"trials":423,"activeCount":71},[],{"trials":425,"activeCount":71},[426,437],{"nctId":427,"briefTitle":428,"status":107,"phases":429,"primaryCompletion":430,"completion":430,"start":431,"enrollment":432,"conditions":433,"interventions":436},"NCT02646449","Treatment of Young Adults With Comorbid AUD\u002FMDD: A Pilot Medication Trial",[61],"2016-12","2015-06",11,[434,435],"Major Depressive Disorder","Alcohol Use Disorder",[418],{"nctId":438,"briefTitle":439,"status":107,"phases":440,"primaryCompletion":441,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":445},"NCT02185131","Double-blind Pilot Trial of Mirtazapine for the Treatment of Co-occurring AD\u002FMDD.",[61],"2016-07","2013-09",16,[434,435],[418],{"trials":447,"activeCount":71},[],{"trials":449,"activeCount":71},[450],{"nctId":105,"briefTitle":106,"status":107,"phases":451,"completion":109,"start":110,"enrollment":111,"conditions":452,"interventions":453},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":455,"activeCount":71},[],{"intervention":286,"totalTrials":371,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":477,"NA":487},{"trials":459,"activeCount":71},[],{"trials":461,"activeCount":71},[],{"trials":463,"activeCount":71},[],{"trials":465,"activeCount":71},[466],{"nctId":467,"briefTitle":468,"status":107,"phases":469,"primaryCompletion":470,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":474},"NCT00018902","Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)",[61,62],"2007-03","2001-01",334,[16],[475,286,476],"Fluoxetine","Citalopram",{"trials":478,"activeCount":71},[479,483],{"nctId":276,"briefTitle":277,"status":107,"phases":480,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":481,"interventions":482},[63],[16,283],[243,285,286,287],{"nctId":105,"briefTitle":106,"status":107,"phases":484,"completion":109,"start":110,"enrollment":111,"conditions":485,"interventions":486},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":488,"activeCount":71},[],{"intervention":490,"totalTrials":92,"cells":491},"Bupropion",{"EARLY_PHASE1":492,"PHASE1":494,"PHASE2":496,"PHASE3":498,"PHASE4":500,"NA":517},{"trials":493,"activeCount":71},[],{"trials":495,"activeCount":71},[],{"trials":497,"activeCount":71},[],{"trials":499,"activeCount":71},[],{"trials":501,"activeCount":71},[502,513],{"nctId":503,"briefTitle":504,"status":107,"phases":505,"primaryCompletion":506,"completion":507,"start":508,"enrollment":509,"conditions":510,"interventions":512},"NCT00006170","Bupropion and Weight Control for Smoking Cessation - 1",[63],"2009-12","2010-09","2000-09",349,[511],"Tobacco Use Disorder",[490],{"nctId":105,"briefTitle":106,"status":107,"phases":514,"completion":109,"start":110,"enrollment":111,"conditions":515,"interventions":516},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":518,"activeCount":71},[],{"intervention":520,"totalTrials":92,"cells":521},"Lithium carbonate",{"EARLY_PHASE1":522,"PHASE1":524,"PHASE2":526,"PHASE3":528,"PHASE4":538,"NA":544},{"trials":523,"activeCount":71},[],{"trials":525,"activeCount":71},[],{"trials":527,"activeCount":71},[],{"trials":529,"activeCount":71},[530],{"nctId":531,"briefTitle":532,"status":107,"phases":533,"completion":534,"start":535,"conditions":536,"interventions":537},"NCT00000369","Maintenance Therapies in Bipolar Disorders",[62],"2002-12","1997-06",[113],[520],{"trials":539,"activeCount":71},[540],{"nctId":105,"briefTitle":106,"status":107,"phases":541,"completion":109,"start":110,"enrollment":111,"conditions":542,"interventions":543},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":545,"activeCount":71},[],{"intervention":547,"totalTrials":92,"cells":548},"Sertraline",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":565,"NA":577},{"trials":550,"activeCount":71},[],{"trials":552,"activeCount":71},[],{"trials":554,"activeCount":71},[],{"trials":556,"activeCount":71},[557],{"nctId":558,"briefTitle":559,"status":107,"phases":560,"primaryCompletion":561,"completion":561,"start":280,"enrollment":562,"conditions":563,"interventions":564},"NCT00276900","Sertraline for the Prevention of Recurrent Postpartum Depression",[62],"2006-08",300,[16],[547],{"trials":566,"activeCount":71},[567],{"nctId":568,"briefTitle":569,"status":389,"phases":570,"primaryCompletion":270,"completion":270,"start":571,"enrollment":572,"conditions":573,"interventions":575},"NCT00177424","Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes",[63],"2004-07",154,[574,16],"Cerebrovascular Accident",[576],"sertraline",{"trials":578,"activeCount":71},[],{"intervention":287,"totalTrials":92,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":589,"NA":607},{"trials":582,"activeCount":71},[],{"trials":584,"activeCount":71},[],{"trials":586,"activeCount":71},[],{"trials":588,"activeCount":71},[],{"trials":590,"activeCount":71},[591,603],{"nctId":592,"briefTitle":593,"status":107,"phases":594,"primaryCompletion":595,"completion":596,"start":597,"enrollment":598,"conditions":599,"interventions":602},"NCT00696293","Duloxetine Treatment of Major Depression and Chronic Low Back Pain For Older Adults",[63],"2010-03","2010-04","2007-05",30,[434,600,601],"Back Pain","Aged",[287],{"nctId":276,"briefTitle":277,"status":107,"phases":604,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":605,"interventions":606},[63],[16,283],[243,285,286,287],{"trials":608,"activeCount":71},[],{"intervention":285,"totalTrials":92,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":617,"PHASE4":619,"NA":636},{"trials":612,"activeCount":71},[],{"trials":614,"activeCount":71},[],{"trials":616,"activeCount":71},[],{"trials":618,"activeCount":71},[],{"trials":620,"activeCount":71},[621,625],{"nctId":276,"briefTitle":277,"status":107,"phases":622,"primaryCompletion":279,"completion":279,"start":280,"enrollment":281,"conditions":623,"interventions":624},[63],[16,283],[243,285,286,287],{"nctId":626,"briefTitle":627,"status":107,"phases":628,"primaryCompletion":629,"completion":630,"start":631,"enrollment":632,"conditions":633,"interventions":634},"NCT00227994","Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke",[63],"2005-01","2005-03","2003-04",40,[574],[635,285],"Galantamine",{"trials":637,"activeCount":71},[],{"intervention":639,"totalTrials":92,"cells":640},"Midazolam",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":658,"PHASE3":660,"PHASE4":662,"NA":674},{"trials":642,"activeCount":71},[],{"trials":644,"activeCount":71},[645],{"nctId":646,"briefTitle":647,"status":107,"phases":648,"primaryCompletion":649,"completion":649,"start":650,"enrollment":410,"conditions":651,"interventions":655},"NCT02515890","Memory Modulation by Pain During Anesthesia",[60],"2018-12-12","2015-11-19",[652,653,654],"Amnesia","Pain","Anesthesia",[656,639,657],"Dexmedetomidine","Ketamine",{"trials":659,"activeCount":71},[],{"trials":661,"activeCount":71},[],{"trials":663,"activeCount":71},[664],{"nctId":665,"briefTitle":666,"status":107,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":632,"conditions":671,"interventions":673},"NCT02168439","Intranasal Dexmedetomidine vs Intranasal Midazolam as Anxiolysis Prior to Pediatric Laceration Repair",[63],"2015-04","2016-06","2014-06",[672,28],"Laceration",[656,639],{"trials":675,"activeCount":71},[],{"intervention":677,"totalTrials":92,"cells":678},"Atomoxetine",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":696,"PHASE4":698,"NA":709},{"trials":680,"activeCount":71},[],{"trials":682,"activeCount":71},[],{"trials":684,"activeCount":71},[685],{"nctId":686,"briefTitle":687,"status":107,"phases":688,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":695},"NCT00029614","Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD",[61],"2007-07","2006-05",24,[693,694],"Substance Use Disorders","Attention Deficit Hyperactivity Disorder",[677],{"trials":697,"activeCount":71},[],{"trials":699,"activeCount":71},[700],{"nctId":701,"briefTitle":702,"status":107,"phases":703,"completion":704,"start":705,"enrollment":359,"conditions":706,"interventions":708},"NCT00222794","A Clinical Trial to Examine Effects of Atomoxetine in the Treatment of Negative Symptoms in Patients With Schizophrenia",[63],"2006-07","2003-11",[33,707],"Schizoaffective Disorder",[677],{"trials":710,"activeCount":71},[],{"intervention":712,"totalTrials":92,"cells":713},"Risperidone",{"EARLY_PHASE1":714,"PHASE1":716,"PHASE2":718,"PHASE3":729,"PHASE4":731,"NA":737},{"trials":715,"activeCount":71},[],{"trials":717,"activeCount":71},[],{"trials":719,"activeCount":71},[720],{"nctId":721,"briefTitle":722,"status":107,"phases":723,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":727,"interventions":728},"NCT00073658","Treating Behavioral Disturbances in Individuals With Dementia",[61],"2005-06","2000-01",137,[283],[476,712],{"trials":730,"activeCount":71},[],{"trials":732,"activeCount":71},[733],{"nctId":105,"briefTitle":106,"status":107,"phases":734,"completion":109,"start":110,"enrollment":111,"conditions":735,"interventions":736},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":738,"activeCount":71},[],{"intervention":740,"totalTrials":67,"cells":741},"Tranexamic acid",{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":750,"NA":763},{"trials":743,"activeCount":71},[],{"trials":745,"activeCount":71},[],{"trials":747,"activeCount":71},[],{"trials":749,"activeCount":71},[],{"trials":751,"activeCount":71},[752],{"nctId":753,"briefTitle":754,"status":389,"phases":755,"primaryCompletion":756,"completion":756,"start":757,"enrollment":26,"conditions":758,"interventions":761},"NCT00722436","Tranexamic Acid for Craniofacial Surgery",[63],"2012-06","2008-07",[759,760],"Craniosynostosis","Bleeding",[740,762],"saline",{"trials":764,"activeCount":71},[],{"intervention":762,"totalTrials":67,"cells":766},{"EARLY_PHASE1":767,"PHASE1":769,"PHASE2":771,"PHASE3":773,"PHASE4":775,"NA":781},{"trials":768,"activeCount":71},[],{"trials":770,"activeCount":71},[],{"trials":772,"activeCount":71},[],{"trials":774,"activeCount":71},[],{"trials":776,"activeCount":71},[777],{"nctId":753,"briefTitle":754,"status":389,"phases":778,"primaryCompletion":756,"completion":756,"start":757,"enrollment":26,"conditions":779,"interventions":780},[63],[759,760],[740,762],{"trials":782,"activeCount":71},[],{"intervention":784,"totalTrials":67,"cells":785},"Doxycycline",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":794,"NA":805},{"trials":787,"activeCount":71},[],{"trials":789,"activeCount":71},[],{"trials":791,"activeCount":71},[],{"trials":793,"activeCount":71},[],{"trials":795,"activeCount":71},[796],{"nctId":797,"briefTitle":798,"status":107,"phases":799,"primaryCompletion":690,"completion":690,"start":800,"enrollment":632,"conditions":801,"interventions":804},"NCT00177333","Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens",[63],"2005-09",[802,803],"Abortion, Induced","Vomiting",[784],{"trials":806,"activeCount":71},[],{"intervention":808,"totalTrials":67,"cells":809},"amoxicillin-clavulanate",{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":818,"NA":830},{"trials":811,"activeCount":71},[],{"trials":813,"activeCount":71},[],{"trials":815,"activeCount":71},[],{"trials":817,"activeCount":71},[],{"trials":819,"activeCount":71},[820],{"nctId":821,"briefTitle":822,"status":107,"phases":823,"primaryCompletion":824,"completion":824,"start":825,"enrollment":826,"conditions":827,"interventions":829},"NCT00377260","Acute Otitis Media (AOM) Therapy Trial in Young Children",[63],"2009-04","2006-11",291,[828],"Acute Otitis Media",[808],{"trials":831,"activeCount":71},[],{"intervention":833,"totalTrials":67,"cells":834},"Higher-dose venlafaxine",{"EARLY_PHASE1":835,"PHASE1":837,"PHASE2":839,"PHASE3":841,"PHASE4":843,"NA":854},{"trials":836,"activeCount":71},[],{"trials":838,"activeCount":71},[],{"trials":840,"activeCount":71},[],{"trials":842,"activeCount":71},[],{"trials":844,"activeCount":71},[845],{"nctId":846,"briefTitle":847,"status":107,"phases":848,"primaryCompletion":849,"completion":849,"start":850,"enrollment":851,"conditions":852,"interventions":853},"NCT01124188","ADAPT: Addressing Depression and Pain Together",[63],"2016-02","2010-05",263,[16,600],[833],{"trials":855,"activeCount":71},[],{"intervention":857,"totalTrials":67,"cells":858},"intravenous immunoglobulin G",{"EARLY_PHASE1":859,"PHASE1":861,"PHASE2":863,"PHASE3":865,"PHASE4":867,"NA":878},{"trials":860,"activeCount":71},[],{"trials":862,"activeCount":71},[],{"trials":864,"activeCount":71},[],{"trials":866,"activeCount":71},[],{"trials":868,"activeCount":71},[869],{"nctId":870,"briefTitle":871,"status":389,"phases":872,"primaryCompletion":313,"completion":313,"start":873,"enrollment":874,"conditions":875,"interventions":877},"NCT00177970","IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff",[63],"2003-10",14,[876],"Clostridium Difficile-associated Diarrhea (CDAD)",[857],{"trials":879,"activeCount":71},[],{"intervention":881,"totalTrials":67,"cells":882},"venlafaxine XR plus aripiprazole",{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":889,"PHASE4":891,"NA":902},{"trials":884,"activeCount":71},[],{"trials":886,"activeCount":71},[],{"trials":888,"activeCount":71},[],{"trials":890,"activeCount":71},[],{"trials":892,"activeCount":71},[893],{"nctId":894,"briefTitle":895,"status":107,"phases":896,"primaryCompletion":897,"completion":897,"start":303,"enrollment":898,"conditions":899,"interventions":900},"NCT00892047","Incomplete Response in Late Life Depression: Getting to Remission (IRL GREY)",[63],"2014-09",468,[16],[881,901],"venlafaxine plus placebo",{"trials":903,"activeCount":71},[],{"intervention":901,"totalTrials":67,"cells":905},{"EARLY_PHASE1":906,"PHASE1":908,"PHASE2":910,"PHASE3":912,"PHASE4":914,"NA":920},{"trials":907,"activeCount":71},[],{"trials":909,"activeCount":71},[],{"trials":911,"activeCount":71},[],{"trials":913,"activeCount":71},[],{"trials":915,"activeCount":71},[916],{"nctId":894,"briefTitle":895,"status":107,"phases":917,"primaryCompletion":897,"completion":897,"start":303,"enrollment":898,"conditions":918,"interventions":919},[63],[16],[881,901],{"trials":921,"activeCount":71},[],{"intervention":923,"totalTrials":67,"cells":924},"Experimental: Valacyclovir treatment",{"EARLY_PHASE1":925,"PHASE1":927,"PHASE2":929,"PHASE3":931,"PHASE4":933,"NA":944},{"trials":926,"activeCount":71},[],{"trials":928,"activeCount":71},[],{"trials":930,"activeCount":71},[],{"trials":932,"activeCount":71},[],{"trials":934,"activeCount":71},[935],{"nctId":936,"briefTitle":937,"status":107,"phases":938,"primaryCompletion":391,"completion":391,"start":939,"enrollment":940,"conditions":941,"interventions":943},"NCT01794897","Valacyclovir Augmentation for Cognitive and Functional Remediation in Schizophrenia",[63],"2013-02",134,[942,33,707],"Herpes Simplex",[923],{"trials":945,"activeCount":71},[],{"intervention":947,"totalTrials":67,"cells":948},"High Dose Inactivated Influenza Vaccine",{"EARLY_PHASE1":949,"PHASE1":951,"PHASE2":953,"PHASE3":955,"PHASE4":957,"NA":969},{"trials":950,"activeCount":71},[],{"trials":952,"activeCount":71},[],{"trials":954,"activeCount":71},[],{"trials":956,"activeCount":71},[],{"trials":958,"activeCount":71},[959],{"nctId":960,"briefTitle":961,"status":107,"phases":962,"primaryCompletion":670,"completion":670,"start":963,"enrollment":964,"conditions":965,"interventions":967},"NCT01654224","Randomized Trial of High Dose Influenza Vaccine in Long Term Care Setting",[63],"2011-11",205,[966],"Influenza",[947,968],"Standard Dose Inactivated Influenza Vaccine",{"trials":970,"activeCount":71},[],{"intervention":968,"totalTrials":67,"cells":972},{"EARLY_PHASE1":973,"PHASE1":975,"PHASE2":977,"PHASE3":979,"PHASE4":981,"NA":987},{"trials":974,"activeCount":71},[],{"trials":976,"activeCount":71},[],{"trials":978,"activeCount":71},[],{"trials":980,"activeCount":71},[],{"trials":982,"activeCount":71},[983],{"nctId":960,"briefTitle":961,"status":107,"phases":984,"primaryCompletion":670,"completion":670,"start":963,"enrollment":964,"conditions":985,"interventions":986},[63],[966],[947,968],{"trials":988,"activeCount":71},[],{"intervention":990,"totalTrials":67,"cells":991},"Aprepitant plus Ondansetron",{"EARLY_PHASE1":992,"PHASE1":994,"PHASE2":996,"PHASE3":998,"PHASE4":1000,"NA":1014},{"trials":993,"activeCount":71},[],{"trials":995,"activeCount":71},[],{"trials":997,"activeCount":71},[],{"trials":999,"activeCount":71},[],{"trials":1001,"activeCount":71},[1002],{"nctId":1003,"briefTitle":1004,"status":107,"phases":1005,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1012},"NCT00659945","Aprepitant for PONV Prophylaxis in Outpatient Plastic Surgery",[63],"2009-11","2010-06","2008-06",150,[1011],"Postoperative Nausea and Vomiting",[990,1013],"Ondansetron plus placebo",{"trials":1015,"activeCount":71},[],{"intervention":1013,"totalTrials":67,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1024,"PHASE4":1026,"NA":1032},{"trials":1019,"activeCount":71},[],{"trials":1021,"activeCount":71},[],{"trials":1023,"activeCount":71},[],{"trials":1025,"activeCount":71},[],{"trials":1027,"activeCount":71},[1028],{"nctId":1003,"briefTitle":1004,"status":107,"phases":1029,"primaryCompletion":1006,"completion":1007,"start":1008,"enrollment":1009,"conditions":1030,"interventions":1031},[63],[1011],[990,1013],{"trials":1033,"activeCount":71},[],{"intervention":1035,"totalTrials":67,"cells":1036},"Celebrex",{"EARLY_PHASE1":1037,"PHASE1":1039,"PHASE2":1041,"PHASE3":1043,"PHASE4":1045,"NA":1055},{"trials":1038,"activeCount":71},[],{"trials":1040,"activeCount":71},[],{"trials":1042,"activeCount":71},[],{"trials":1044,"activeCount":71},[],{"trials":1046,"activeCount":71},[1047],{"nctId":1048,"briefTitle":1049,"status":389,"phases":1050,"primaryCompletion":1007,"completion":1007,"start":280,"enrollment":1051,"conditions":1052,"interventions":1054},"NCT00177866","Safety of Celecoxib in Patients With Crohn's Disease",[63],28,[1053],"Crohn's Disease",[1035],{"trials":1056,"activeCount":71},[],{"intervention":1058,"totalTrials":67,"cells":1059},"Imipramine",{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1066,"PHASE4":1068,"NA":1079},{"trials":1061,"activeCount":71},[],{"trials":1063,"activeCount":71},[],{"trials":1065,"activeCount":71},[],{"trials":1067,"activeCount":71},[],{"trials":1069,"activeCount":71},[1070],{"nctId":1071,"briefTitle":1072,"status":107,"phases":1073,"completion":1074,"start":1075,"enrollment":1076,"conditions":1077,"interventions":1078},"NCT00227955","Comparing Various Treatments for Achieving and Maintaining Remission of Depression",[63],"1993-12","1987-12",200,[16],[1058],{"trials":1080,"activeCount":71},[],{"intervention":1082,"totalTrials":67,"cells":1083},"Exubera",{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1092,"NA":1104},{"trials":1085,"activeCount":71},[],{"trials":1087,"activeCount":71},[],{"trials":1089,"activeCount":71},[],{"trials":1091,"activeCount":71},[],{"trials":1093,"activeCount":71},[1094],{"nctId":1095,"briefTitle":1096,"status":107,"phases":1097,"completion":1098,"start":1099,"enrollment":1100,"conditions":1101,"interventions":1103},"NCT00315952","Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes",[63],"2006-12","2006-04",12,[1102],"Type 1 Diabetes Mellitus",[1082],{"trials":1105,"activeCount":71},[],{"intervention":1107,"totalTrials":67,"cells":1108},"mifepristone and misoprostol",{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1115,"PHASE4":1117,"NA":1128},{"trials":1110,"activeCount":71},[],{"trials":1112,"activeCount":71},[],{"trials":1114,"activeCount":71},[],{"trials":1116,"activeCount":71},[],{"trials":1118,"activeCount":71},[1119],{"nctId":1120,"briefTitle":1121,"status":107,"phases":1122,"primaryCompletion":1099,"completion":1099,"start":1123,"enrollment":1124,"conditions":1125,"interventions":1127},"NCT00269568","Mifepristone at Same Time Multicenter Study",[63],"2004-06",1128,[1126],"Abortion Seekers",[1107],{"trials":1129,"activeCount":71},[],{"intervention":1131,"totalTrials":67,"cells":1132},"Doxycycline pre-operatively",{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1154},{"trials":1134,"activeCount":71},[],{"trials":1136,"activeCount":71},[],{"trials":1138,"activeCount":71},[],{"trials":1140,"activeCount":71},[],{"trials":1142,"activeCount":71},[1143],{"nctId":1144,"briefTitle":1145,"status":107,"phases":1146,"primaryCompletion":1147,"completion":1147,"start":1148,"enrollment":1149,"conditions":1150,"interventions":1152},"NCT00547170","Doxycycline Prophylaxis at Vacuum Aspiration Trial",[63],"2008-03","2007-01",1000,[1151],"Endometritis",[1131,1153],"Doxycycline post-operatively",{"trials":1155,"activeCount":71},[],{"intervention":1153,"totalTrials":67,"cells":1157},{"EARLY_PHASE1":1158,"PHASE1":1160,"PHASE2":1162,"PHASE3":1164,"PHASE4":1166,"NA":1172},{"trials":1159,"activeCount":71},[],{"trials":1161,"activeCount":71},[],{"trials":1163,"activeCount":71},[],{"trials":1165,"activeCount":71},[],{"trials":1167,"activeCount":71},[1168],{"nctId":1144,"briefTitle":1145,"status":107,"phases":1169,"primaryCompletion":1147,"completion":1147,"start":1148,"enrollment":1149,"conditions":1170,"interventions":1171},[63],[1151],[1131,1153],{"trials":1173,"activeCount":71},[],{"intervention":1175,"totalTrials":67,"cells":1176},"IV acetaminophen",{"EARLY_PHASE1":1177,"PHASE1":1179,"PHASE2":1181,"PHASE3":1183,"PHASE4":1185,"NA":1195},{"trials":1178,"activeCount":71},[],{"trials":1180,"activeCount":71},[],{"trials":1182,"activeCount":71},[],{"trials":1184,"activeCount":71},[],{"trials":1186,"activeCount":71},[1187],{"nctId":1188,"briefTitle":1189,"status":107,"phases":1190,"primaryCompletion":391,"completion":391,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1194},"NCT02400580","IV Acetaminophen for Postoperative Pain Analgesia After Laparoscopic Hysterectomy",[63],"2015-02",183,[653],[1175],{"trials":1196,"activeCount":71},[],{"intervention":1198,"totalTrials":67,"cells":1199},"Roflumilast",{"EARLY_PHASE1":1200,"PHASE1":1202,"PHASE2":1204,"PHASE3":1206,"PHASE4":1208,"NA":1219},{"trials":1201,"activeCount":71},[],{"trials":1203,"activeCount":71},[],{"trials":1205,"activeCount":71},[],{"trials":1207,"activeCount":71},[],{"trials":1209,"activeCount":71},[1210],{"nctId":1211,"briefTitle":1212,"status":107,"phases":1213,"primaryCompletion":669,"completion":1214,"start":939,"enrollment":1215,"conditions":1216,"interventions":1218},"NCT01745848","Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD",[63],"2016-06-30",26,[1217],"Chronic Obstructive Pulmonary Disease",[1198],{"trials":1220,"activeCount":71},[],{"intervention":1222,"totalTrials":67,"cells":1223},"infliximab",{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1230,"PHASE4":1232,"NA":1242},{"trials":1225,"activeCount":71},[],{"trials":1227,"activeCount":71},[],{"trials":1229,"activeCount":71},[],{"trials":1231,"activeCount":71},[],{"trials":1233,"activeCount":71},[1234],{"nctId":1235,"briefTitle":1236,"status":107,"phases":1237,"primaryCompletion":1238,"completion":1239,"start":629,"enrollment":691,"conditions":1240,"interventions":1241},"NCT00688636","Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery",[63],"2008-08","2009-01",[1053],[1222],{"trials":1243,"activeCount":71},[],{"intervention":1245,"totalTrials":67,"cells":1246},"Taclonex Topical Suspension",{"EARLY_PHASE1":1247,"PHASE1":1249,"PHASE2":1251,"PHASE3":1253,"PHASE4":1255,"NA":1266},{"trials":1248,"activeCount":71},[],{"trials":1250,"activeCount":71},[],{"trials":1252,"activeCount":71},[],{"trials":1254,"activeCount":71},[],{"trials":1256,"activeCount":71},[1257],{"nctId":1258,"briefTitle":1259,"status":107,"phases":1260,"primaryCompletion":897,"completion":897,"start":1261,"enrollment":1262,"conditions":1263,"interventions":1265},"NCT01761019","A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy",[63],"2013-01",8,[1264],"Psoriasis",[1245],{"trials":1267,"activeCount":71},[],{"intervention":1269,"totalTrials":67,"cells":1270},"start cozaar",{"EARLY_PHASE1":1271,"PHASE1":1273,"PHASE2":1275,"PHASE3":1277,"PHASE4":1279,"NA":1292},{"trials":1272,"activeCount":71},[],{"trials":1274,"activeCount":71},[],{"trials":1276,"activeCount":71},[],{"trials":1278,"activeCount":71},[],{"trials":1280,"activeCount":71},[1281],{"nctId":1282,"briefTitle":1283,"status":389,"phases":1284,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1288,"interventions":1290},"NCT01233635","Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)",[63],"2007-11","2005-11",228,[1289],"Atrial Fibrillation",[1269,1291],"continue cozaar",{"trials":1293,"activeCount":71},[],{"intervention":1291,"totalTrials":67,"cells":1295},{"EARLY_PHASE1":1296,"PHASE1":1298,"PHASE2":1300,"PHASE3":1302,"PHASE4":1304,"NA":1310},{"trials":1297,"activeCount":71},[],{"trials":1299,"activeCount":71},[],{"trials":1301,"activeCount":71},[],{"trials":1303,"activeCount":71},[],{"trials":1305,"activeCount":71},[1306],{"nctId":1282,"briefTitle":1283,"status":389,"phases":1307,"primaryCompletion":1285,"completion":1285,"start":1286,"enrollment":1287,"conditions":1308,"interventions":1309},[63],[1289],[1269,1291],{"trials":1311,"activeCount":71},[],{"intervention":1313,"totalTrials":67,"cells":1314},"Etanercept",{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1321,"PHASE4":1323,"NA":1334},{"trials":1316,"activeCount":71},[],{"trials":1318,"activeCount":71},[],{"trials":1320,"activeCount":71},[],{"trials":1322,"activeCount":71},[],{"trials":1324,"activeCount":71},[1325],{"nctId":1326,"briefTitle":1327,"status":1328,"phases":1329,"primaryCompletion":1330,"completion":1330,"start":1006,"enrollment":71,"conditions":1331,"interventions":1333},"NCT01009879","Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants","WITHDRAWN",[63],"2012-02",[1332],"Rheumatoid Arthritis",[1313],{"trials":1335,"activeCount":71},[],{"intervention":116,"totalTrials":67,"cells":1337},{"EARLY_PHASE1":1338,"PHASE1":1340,"PHASE2":1342,"PHASE3":1344,"PHASE4":1346,"NA":1352},{"trials":1339,"activeCount":71},[],{"trials":1341,"activeCount":71},[],{"trials":1343,"activeCount":71},[],{"trials":1345,"activeCount":71},[],{"trials":1347,"activeCount":71},[1348],{"nctId":105,"briefTitle":106,"status":107,"phases":1349,"completion":109,"start":110,"enrollment":111,"conditions":1350,"interventions":1351},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":1353,"activeCount":71},[],{"intervention":118,"totalTrials":67,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1370},{"trials":1357,"activeCount":71},[],{"trials":1359,"activeCount":71},[],{"trials":1361,"activeCount":71},[],{"trials":1363,"activeCount":71},[],{"trials":1365,"activeCount":71},[1366],{"nctId":105,"briefTitle":106,"status":107,"phases":1367,"completion":109,"start":110,"enrollment":111,"conditions":1368,"interventions":1369},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":1371,"activeCount":71},[],{"intervention":122,"totalTrials":67,"cells":1373},{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1380,"PHASE4":1382,"NA":1388},{"trials":1375,"activeCount":71},[],{"trials":1377,"activeCount":71},[],{"trials":1379,"activeCount":71},[],{"trials":1381,"activeCount":71},[],{"trials":1383,"activeCount":71},[1384],{"nctId":105,"briefTitle":106,"status":107,"phases":1385,"completion":109,"start":110,"enrollment":111,"conditions":1386,"interventions":1387},[63],[113],[115,116,117,118,119,120,91,121,122,123],{"trials":1389,"activeCount":71},[],{"intervention":1391,"totalTrials":67,"cells":1392},"Sodium Valproate treatment",{"EARLY_PHASE1":1393,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1401,"NA":1414},{"trials":1394,"activeCount":71},[],{"trials":1396,"activeCount":71},[],{"trials":1398,"activeCount":71},[],{"trials":1400,"activeCount":71},[],{"trials":1402,"activeCount":71},[1403],{"nctId":1404,"briefTitle":1405,"status":107,"phases":1406,"primaryCompletion":1407,"completion":1408,"start":1409,"enrollment":1410,"conditions":1411,"interventions":1413},"NCT02011750","Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia",[63],"2017-10-30","2017-12-31","2013-04-01",109,[1412,33],"Toxoplasmosis",[1391],{"trials":1415,"activeCount":71},[],{"intervention":1417,"totalTrials":67,"cells":1418},"Glargine insulin vs regular insulin",{"EARLY_PHASE1":1419,"PHASE1":1421,"PHASE2":1423,"PHASE3":1425,"PHASE4":1427,"NA":1438},{"trials":1420,"activeCount":71},[],{"trials":1422,"activeCount":71},[],{"trials":1424,"activeCount":71},[],{"trials":1426,"activeCount":71},[],{"trials":1428,"activeCount":71},[1429],{"nctId":1430,"briefTitle":1431,"status":107,"phases":1432,"completion":561,"start":1433,"enrollment":10,"conditions":1434,"interventions":1437},"NCT00177398","Effect of Glargine Insulin on Glucose Control in Hospitalized Patients Who Receive Tube Feedings",[63],"2005-02",[1435,1436],"Type 2 Diabetes","Hyperglycemia",[1417],{"trials":1439,"activeCount":71},[],{"intervention":1441,"totalTrials":67,"cells":1442},"Glyburide",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1460},{"trials":1444,"activeCount":71},[],{"trials":1446,"activeCount":71},[],{"trials":1448,"activeCount":71},[],{"trials":1450,"activeCount":71},[],{"trials":1452,"activeCount":71},[1453],{"nctId":1454,"briefTitle":1455,"status":1328,"phases":1456,"primaryCompletion":897,"completion":897,"start":442,"enrollment":71,"conditions":1457,"interventions":1459},"NCT01947699","Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide",[63],[1458],"Gestational Diabetes",[1441],{"trials":1461,"activeCount":71},[],{"intervention":1463,"totalTrials":67,"cells":1464},"Anidulafungin",{"EARLY_PHASE1":1465,"PHASE1":1467,"PHASE2":1469,"PHASE3":1471,"PHASE4":1473,"NA":1489},{"trials":1466,"activeCount":71},[],{"trials":1468,"activeCount":71},[],{"trials":1470,"activeCount":71},[],{"trials":1472,"activeCount":71},[],{"trials":1474,"activeCount":71},[1475],{"nctId":1476,"briefTitle":1477,"status":107,"phases":1478,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1076,"conditions":1482,"interventions":1487},"NCT00841971","Anidulafungin Versus Fluconazole for the Prevention of Fungal Infections in Liver Transplant Recipients",[63],"2013-07","2014-05","2010-02",[1483,1484,1485,1486],"Mycoses","Fungemia","Central Nervous System Fungal Infections","Lung Diseases, Fungal",[1463,1488],"Fluconazole",{"trials":1490,"activeCount":71},[],{"intervention":1488,"totalTrials":67,"cells":1492},{"EARLY_PHASE1":1493,"PHASE1":1495,"PHASE2":1497,"PHASE3":1499,"PHASE4":1501,"NA":1507},{"trials":1494,"activeCount":71},[],{"trials":1496,"activeCount":71},[],{"trials":1498,"activeCount":71},[],{"trials":1500,"activeCount":71},[],{"trials":1502,"activeCount":71},[1503],{"nctId":1476,"briefTitle":1477,"status":107,"phases":1504,"primaryCompletion":1479,"completion":1480,"start":1481,"enrollment":1076,"conditions":1505,"interventions":1506},[63],[1483,1484,1485,1486],[1463,1488],{"trials":1508,"activeCount":71},[],{"intervention":1510,"totalTrials":67,"cells":1511},"venlafaxine-XR",{"EARLY_PHASE1":1512,"PHASE1":1514,"PHASE2":1516,"PHASE3":1518,"PHASE4":1520,"NA":1531},{"trials":1513,"activeCount":71},[],{"trials":1515,"activeCount":71},[],{"trials":1517,"activeCount":71},[],{"trials":1519,"activeCount":71},[],{"trials":1521,"activeCount":71},[1522],{"nctId":1523,"briefTitle":1524,"status":107,"phases":1525,"primaryCompletion":1526,"start":1527,"enrollment":1528,"conditions":1529,"interventions":1530},"NCT00177528","Safety and Efficacy of Venlafaxine XR in Elderly Patients With Major Depression",[63],"2004-11","2000-10",70,[16],[1510],{"trials":1532,"activeCount":71},[],{"intervention":1534,"totalTrials":67,"cells":1535},"Pravastatin",{"EARLY_PHASE1":1536,"PHASE1":1538,"PHASE2":1540,"PHASE3":1542,"PHASE4":1544,"NA":1554},{"trials":1537,"activeCount":71},[],{"trials":1539,"activeCount":71},[],{"trials":1541,"activeCount":71},[],{"trials":1543,"activeCount":71},[],{"trials":1545,"activeCount":71},[1546],{"nctId":1547,"briefTitle":1548,"status":107,"phases":1549,"primaryCompletion":1148,"completion":689,"start":1550,"enrollment":1551,"conditions":1552,"interventions":1553},"NCT00177580","Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin",[63],"2003-07",72,[33,707],[1534],{"trials":1555,"activeCount":71},[],{"intervention":1557,"totalTrials":67,"cells":1558},"eletriptan",{"EARLY_PHASE1":1559,"PHASE1":1561,"PHASE2":1563,"PHASE3":1565,"PHASE4":1567,"NA":1578},{"trials":1560,"activeCount":71},[],{"trials":1562,"activeCount":71},[],{"trials":1564,"activeCount":71},[],{"trials":1566,"activeCount":71},[],{"trials":1568,"activeCount":71},[1569],{"nctId":1570,"briefTitle":1571,"status":107,"phases":1572,"primaryCompletion":1238,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1577},"NCT00259649","Prospective Survey of Menstrual Migraine & Prevention With Eletriptan",[63],"2004-08",71,[1576],"Migraine",[1557],{"trials":1579,"activeCount":71},[],{"intervention":1581,"totalTrials":67,"cells":1582},"Metronidazole",{"EARLY_PHASE1":1583,"PHASE1":1585,"PHASE2":1587,"PHASE3":1589,"PHASE4":1591,"NA":1601},{"trials":1584,"activeCount":71},[],{"trials":1586,"activeCount":71},[],{"trials":1588,"activeCount":71},[],{"trials":1590,"activeCount":71},[],{"trials":1592,"activeCount":71},[1593],{"nctId":1594,"briefTitle":1595,"status":107,"phases":1596,"primaryCompletion":595,"completion":595,"start":1597,"enrollment":1100,"conditions":1598,"interventions":1600},"NCT00464542","Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV\u002FHSV-2) Shedding Study",[63],"2007-12",[1599],"Bacterial Vaginosis",[1581],{"trials":1602,"activeCount":71},[],{"intervention":1604,"totalTrials":67,"cells":1605},"Acitretin",{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1610,"PHASE3":1612,"PHASE4":1614,"NA":1625},{"trials":1607,"activeCount":71},[],{"trials":1609,"activeCount":71},[],{"trials":1611,"activeCount":71},[],{"trials":1613,"activeCount":71},[],{"trials":1615,"activeCount":71},[1616],{"nctId":1617,"briefTitle":1618,"status":1328,"phases":1619,"primaryCompletion":1620,"completion":1620,"start":1621,"enrollment":71,"conditions":1622,"interventions":1624},"NCT01299220","Study of Acitretin to Treat Skin Rash Caused by Erlotinib (a Chemotherapy Drug)",[63],"2011-09","2010-11",[1623],"Skin Rash",[1604],{"trials":1626,"activeCount":71},[],{"intervention":1628,"totalTrials":67,"cells":1629},"methylphenidate HCl",{"EARLY_PHASE1":1630,"PHASE1":1632,"PHASE2":1634,"PHASE3":1636,"PHASE4":1638,"NA":1647},{"trials":1631,"activeCount":71},[],{"trials":1633,"activeCount":71},[],{"trials":1635,"activeCount":71},[],{"trials":1637,"activeCount":71},[],{"trials":1639,"activeCount":71},[1640],{"nctId":1641,"briefTitle":1642,"status":1328,"phases":1643,"primaryCompletion":596,"completion":596,"start":596,"enrollment":71,"conditions":1644,"interventions":1646},"NCT00931398","Treatment of College Students With Attention-Deficit\u002FHyperactivity Disorder (ADHD) Using OROS Methylphenidate",[63],[1645],"Attention-Deficit\u002FHyperactivity Disorder (ADHD)",[1628],{"trials":1648,"activeCount":71},[],{"intervention":1650,"totalTrials":67,"cells":1651},"ethinyl estradiol\u002Fetonogestrel vaginal ring",{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1656,"PHASE3":1658,"PHASE4":1660,"NA":1671},{"trials":1653,"activeCount":71},[],{"trials":1655,"activeCount":71},[],{"trials":1657,"activeCount":71},[],{"trials":1659,"activeCount":71},[],{"trials":1661,"activeCount":71},[1662],{"nctId":1663,"briefTitle":1664,"status":107,"phases":1665,"primaryCompletion":1098,"completion":1098,"start":724,"enrollment":1666,"conditions":1667,"interventions":1669},"NCT00269620","PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra",[63],500,[1668],"Contraception",[1650,1670],"ethinyl estradiol\u002Fnorelgestromin transdermal contraceptive",{"trials":1672,"activeCount":71},[],{"intervention":1670,"totalTrials":67,"cells":1674},{"EARLY_PHASE1":1675,"PHASE1":1677,"PHASE2":1679,"PHASE3":1681,"PHASE4":1683,"NA":1689},{"trials":1676,"activeCount":71},[],{"trials":1678,"activeCount":71},[],{"trials":1680,"activeCount":71},[],{"trials":1682,"activeCount":71},[],{"trials":1684,"activeCount":71},[1685],{"nctId":1663,"briefTitle":1664,"status":107,"phases":1686,"primaryCompletion":1098,"completion":1098,"start":724,"enrollment":1666,"conditions":1687,"interventions":1688},[63],[1668],[1650,1670],{"trials":1690,"activeCount":71},[],{"intervention":1692,"totalTrials":67,"cells":1693},"Levonorgestrel IUD",{"EARLY_PHASE1":1694,"PHASE1":1696,"PHASE2":1698,"PHASE3":1700,"PHASE4":1702,"NA":1712},{"trials":1695,"activeCount":71},[],{"trials":1697,"activeCount":71},[],{"trials":1699,"activeCount":71},[],{"trials":1701,"activeCount":71},[],{"trials":1703,"activeCount":71},[1704],{"nctId":1705,"briefTitle":1706,"status":107,"phases":1707,"primaryCompletion":1006,"completion":1006,"start":470,"enrollment":1708,"conditions":1709,"interventions":1711},"NCT00475228","'Levonorgestrel IUD Insertion After D&E Procedure",[63],93,[1710],"Contraceptive Usage",[1692],{"trials":1713,"activeCount":71},[],{"intervention":1715,"totalTrials":67,"cells":1716},"mifepristone\u002Fmisoprostol",{"EARLY_PHASE1":1717,"PHASE1":1719,"PHASE2":1721,"PHASE3":1723,"PHASE4":1725,"NA":1736},{"trials":1718,"activeCount":71},[],{"trials":1720,"activeCount":71},[],{"trials":1722,"activeCount":71},[],{"trials":1724,"activeCount":71},[],{"trials":1726,"activeCount":71},[1727],{"nctId":1728,"briefTitle":1729,"status":107,"phases":1730,"primaryCompletion":800,"completion":800,"start":629,"enrollment":598,"conditions":1731,"interventions":1735},"NCT00177372","Mifepristone and Misoprostol for Fetal Demise",[63],[1732,1733,1734],"Anembryonic Pregnancy","Gestation Abnormality","Intrauterine Fetal Demise Term",[1715],{"trials":1737,"activeCount":71},[],{"intervention":1739,"totalTrials":67,"cells":1740},"Posaconazole",{"EARLY_PHASE1":1741,"PHASE1":1743,"PHASE2":1745,"PHASE3":1747,"PHASE4":1749,"NA":1759},{"trials":1742,"activeCount":71},[],{"trials":1744,"activeCount":71},[],{"trials":1746,"activeCount":71},[],{"trials":1748,"activeCount":71},[],{"trials":1750,"activeCount":71},[1751],{"nctId":1752,"briefTitle":1753,"status":389,"phases":1754,"completion":825,"start":1573,"enrollment":1755,"conditions":1756,"interventions":1758},"NCT00177749","Limited Access Protocol of Posaconazole in Invasive Fungal Infections Study PO2095",[63],10,[1757],"Fungal Infection",[1739],{"trials":1760,"activeCount":71},[],{"intervention":635,"totalTrials":67,"cells":1762},{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1769,"PHASE4":1771,"NA":1777},{"trials":1764,"activeCount":71},[],{"trials":1766,"activeCount":71},[],{"trials":1768,"activeCount":71},[],{"trials":1770,"activeCount":71},[],{"trials":1772,"activeCount":71},[1773],{"nctId":626,"briefTitle":627,"status":107,"phases":1774,"primaryCompletion":629,"completion":630,"start":631,"enrollment":632,"conditions":1775,"interventions":1776},[63],[574],[635,285],{"trials":1778,"activeCount":71},[],{"intervention":1780,"totalTrials":67,"cells":1781},"Etonogestrel",{"EARLY_PHASE1":1782,"PHASE1":1784,"PHASE2":1786,"PHASE3":1788,"PHASE4":1790,"NA":1801},{"trials":1783,"activeCount":71},[],{"trials":1785,"activeCount":71},[],{"trials":1787,"activeCount":71},[],{"trials":1789,"activeCount":71},[],{"trials":1791,"activeCount":71},[1792],{"nctId":1793,"briefTitle":1794,"status":107,"phases":1795,"primaryCompletion":1796,"completion":1796,"start":1797,"enrollment":111,"conditions":1798,"interventions":1800},"NCT02082652","A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy",[63],"2016-03","2014-10",[1799,1668],"HIV",[1780],{"trials":1802,"activeCount":71},[],{"intervention":1804,"totalTrials":67,"cells":1805},"zonisamide",{"EARLY_PHASE1":1806,"PHASE1":1808,"PHASE2":1810,"PHASE3":1812,"PHASE4":1814,"NA":1823},{"trials":1807,"activeCount":71},[],{"trials":1809,"activeCount":71},[],{"trials":1811,"activeCount":71},[],{"trials":1813,"activeCount":71},[],{"trials":1815,"activeCount":71},[1816],{"nctId":1817,"briefTitle":1818,"status":1328,"phases":1819,"primaryCompletion":312,"completion":312,"start":1573,"enrollment":71,"conditions":1820,"interventions":1822},"NCT00259636","Zonisamide for Fibromyalgia & Migraine",[63],[1821,1576],"Fibromyalgia",[1804],{"trials":1824,"activeCount":71},[],{"intervention":1826,"totalTrials":67,"cells":1827},"Nimodipine",{"EARLY_PHASE1":1828,"PHASE1":1830,"PHASE2":1832,"PHASE3":1834,"PHASE4":1836,"NA":1846},{"trials":1829,"activeCount":71},[],{"trials":1831,"activeCount":71},[],{"trials":1833,"activeCount":71},[],{"trials":1835,"activeCount":71},[],{"trials":1837,"activeCount":71},[1838],{"nctId":1839,"briefTitle":1840,"status":389,"phases":1841,"primaryCompletion":1842,"completion":1842,"start":1238,"enrollment":1843,"conditions":1844,"interventions":1845},"NCT00781326","Effectiveness of Nimodipine Plus Antidepressant Medication in Treating Vascular Depression",[63],"2009-02",9,[16],[1826],{"trials":1847,"activeCount":71},[],{"intervention":1849,"totalTrials":67,"cells":1850},"sertraline hydrochloride",{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1855,"PHASE3":1857,"PHASE4":1859,"NA":1868},{"trials":1852,"activeCount":71},[],{"trials":1854,"activeCount":71},[],{"trials":1856,"activeCount":71},[],{"trials":1858,"activeCount":71},[],{"trials":1860,"activeCount":71},[1861],{"nctId":1862,"briefTitle":1863,"status":107,"phases":1864,"primaryCompletion":1148,"completion":1148,"start":1865,"enrollment":598,"conditions":1866,"interventions":1867},"NCT00177996","Pharmacotherapy in Depression With Panic Spectrum",[63],"2001-10",[296],[1849],{"trials":1869,"activeCount":71},[],{"intervention":1871,"totalTrials":371,"cells":1872},"Amphotericin B",{"EARLY_PHASE1":1873,"PHASE1":1875,"PHASE2":1877,"PHASE3":1879,"PHASE4":1904,"NA":1906},{"trials":1874,"activeCount":71},[],{"trials":1876,"activeCount":71},[],{"trials":1878,"activeCount":71},[],{"trials":1880,"activeCount":71},[1881,1890,1898],{"nctId":1882,"briefTitle":1883,"status":389,"phases":1884,"completion":1099,"start":1885,"enrollment":1100,"conditions":1886,"interventions":1889},"NCT00235651","Abelcet Radiotagging Protocol: Inhaled Lipid Complex Abelcet® in Lung Transplant Recipients",[62],"2005-10",[1887,1888],"Lung Transplantation","Lung Diseases",[1871],{"nctId":1891,"briefTitle":1892,"status":107,"phases":1893,"completion":1597,"start":1894,"enrollment":20,"conditions":1895,"interventions":1897},"NCT00177710","Pharmacokinetic Profile of Inhaled Liposomal Amphotericin B in Lung Transplant Recipients - Ambisome Study",[62],"2006-01",[1887,1896],"Fungal Infections",[1871],{"nctId":1899,"briefTitle":1900,"status":107,"phases":1901,"completion":800,"start":292,"enrollment":20,"conditions":1902,"interventions":1903},"NCT00177684","Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®)",[62],[1887,1896],[1871],{"trials":1905,"activeCount":71},[],{"trials":1907,"activeCount":71},[],{"intervention":1909,"totalTrials":92,"cells":1910},"Cisplatin",{"EARLY_PHASE1":1911,"PHASE1":1913,"PHASE2":1915,"PHASE3":1926,"PHASE4":1938,"NA":1940},{"trials":1912,"activeCount":71},[],{"trials":1914,"activeCount":71},[],{"trials":1916,"activeCount":71},[1917],{"nctId":1918,"briefTitle":1919,"status":107,"phases":1920,"primaryCompletion":1479,"completion":1479,"start":1885,"enrollment":1921,"conditions":1922,"interventions":1923},"NCT00226239","Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer",[61],39,[25],[1924,1909,1925],"Docetaxel","Cetuximab",{"trials":1927,"activeCount":71},[1928],{"nctId":1929,"briefTitle":1930,"status":107,"phases":1931,"primaryCompletion":1932,"completion":1932,"start":1433,"enrollment":1933,"conditions":1934,"interventions":1936},"NCT00109954","Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery",[62],"2005-12",120,[1935],"Liver Cancer",[1937],"cisplatin",{"trials":1939,"activeCount":71},[],{"trials":1941,"activeCount":71},[],{"intervention":1943,"totalTrials":67,"cells":1944},"rF.VIII",{"EARLY_PHASE1":1945,"PHASE1":1947,"PHASE2":1949,"PHASE3":1951,"PHASE4":1962,"NA":1964},{"trials":1946,"activeCount":71},[],{"trials":1948,"activeCount":71},[],{"trials":1950,"activeCount":71},[],{"trials":1952,"activeCount":71},[1953],{"nctId":1954,"briefTitle":1955,"status":389,"phases":1956,"primaryCompletion":1957,"completion":1957,"start":1958,"enrollment":323,"conditions":1959,"interventions":1961},"NCT01405742","Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A",[62],"2013-11","2012-07",[1960],"Severe Hemophilia A",[1943],{"trials":1963,"activeCount":71},[],{"trials":1965,"activeCount":71},[],{"intervention":1967,"totalTrials":67,"cells":1968},"CDB-2914",{"EARLY_PHASE1":1969,"PHASE1":1971,"PHASE2":1973,"PHASE3":1975,"PHASE4":1988,"NA":1990},{"trials":1970,"activeCount":71},[],{"trials":1972,"activeCount":71},[],{"trials":1974,"activeCount":71},[],{"trials":1976,"activeCount":71},[1977],{"nctId":1978,"briefTitle":1979,"status":107,"phases":1980,"completion":1981,"start":1982,"enrollment":1983,"conditions":1984,"interventions":1986},"NCT00271583","Efficacy Trial of CDB 2914 for Emergency Contraception",[61,62],"2001-09","1999-09",1672,[1985],"Emergency Contraception",[1967,1987],"levonorgestrel",{"trials":1989,"activeCount":71},[],{"trials":1991,"activeCount":71},[],{"intervention":1987,"totalTrials":67,"cells":1993},{"EARLY_PHASE1":1994,"PHASE1":1996,"PHASE2":1998,"PHASE3":2000,"PHASE4":2006,"NA":2008},{"trials":1995,"activeCount":71},[],{"trials":1997,"activeCount":71},[],{"trials":1999,"activeCount":71},[],{"trials":2001,"activeCount":71},[2002],{"nctId":1978,"briefTitle":1979,"status":107,"phases":2003,"completion":1981,"start":1982,"enrollment":1983,"conditions":2004,"interventions":2005},[61,62],[1985],[1967,1987],{"trials":2007,"activeCount":71},[],{"trials":2009,"activeCount":71},[],{"intervention":2011,"totalTrials":67,"cells":2012},"MucoMilk product",{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2017,"PHASE3":2019,"PHASE4":2029,"NA":2031},{"trials":2014,"activeCount":71},[],{"trials":2016,"activeCount":71},[],{"trials":2018,"activeCount":71},[],{"trials":2020,"activeCount":71},[2021],{"nctId":2022,"briefTitle":2023,"status":389,"phases":2024,"completion":339,"start":2025,"enrollment":111,"conditions":2026,"interventions":2028},"NCT00177775","Whey Protein Concentrate 40% Made of Milk of Immunized Cows to Aid in the Prevention of Relapse of Clostridium Difficile-Diarrhea",[61,62],"2005-04",[2027],"Positive C-Diff Culture",[2011],{"trials":2030,"activeCount":71},[],{"trials":2032,"activeCount":71},[],{"intervention":2034,"totalTrials":67,"cells":2035},"Sirolimus",{"EARLY_PHASE1":2036,"PHASE1":2038,"PHASE2":2040,"PHASE3":2042,"PHASE4":2052,"NA":2054},{"trials":2037,"activeCount":71},[],{"trials":2039,"activeCount":71},[],{"trials":2041,"activeCount":71},[],{"trials":2043,"activeCount":71},[2044],{"nctId":2045,"briefTitle":2046,"status":389,"phases":2047,"primaryCompletion":2048,"completion":2048,"start":1932,"enrollment":371,"conditions":2049,"interventions":2051},"NCT01709136","Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity",[61,62],"2010-01",[2050],"Hypertension",[2034],{"trials":2053,"activeCount":71},[],{"trials":2055,"activeCount":71},[],{"intervention":2057,"totalTrials":67,"cells":2058},"Indomethacin",{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2065,"PHASE4":2077,"NA":2079},{"trials":2060,"activeCount":71},[],{"trials":2062,"activeCount":71},[],{"trials":2064,"activeCount":71},[],{"trials":2066,"activeCount":71},[2067],{"nctId":2068,"briefTitle":2069,"status":107,"phases":2070,"primaryCompletion":2071,"completion":2072,"start":1479,"enrollment":2073,"conditions":2074,"interventions":2076},"NCT02692391","A Randomized Controlled Pilot Trial of Indomethacin in Acute Pancreatitis",[62],"2019-07-19","2019-12-30",42,[2075],"Acute Pancreatitis",[2057],{"trials":2078,"activeCount":71},[],{"trials":2080,"activeCount":71},[],{"intervention":2082,"totalTrials":67,"cells":2083},"Seroquel",{"EARLY_PHASE1":2084,"PHASE1":2086,"PHASE2":2088,"PHASE3":2090,"PHASE4":2100,"NA":2102},{"trials":2085,"activeCount":71},[],{"trials":2087,"activeCount":71},[],{"trials":2089,"activeCount":71},[],{"trials":2091,"activeCount":71},[2092],{"nctId":2093,"briefTitle":2094,"status":107,"phases":2095,"primaryCompletion":507,"completion":507,"start":1098,"enrollment":2096,"conditions":2097,"interventions":2099},"NCT00411463","Psychotherapy for Bipolar II Depression, Pilot Study, Phase II",[61,62],25,[2098],"Bipolar II Disorder",[2082],{"trials":2101,"activeCount":71},[],{"trials":2103,"activeCount":71},[],{"intervention":2105,"totalTrials":67,"cells":2106},"N-acetylcysteine",{"EARLY_PHASE1":2107,"PHASE1":2109,"PHASE2":2111,"PHASE3":2113,"PHASE4":2124,"NA":2126},{"trials":2108,"activeCount":71},[],{"trials":2110,"activeCount":71},[],{"trials":2112,"activeCount":71},[],{"trials":2114,"activeCount":71},[2115],{"nctId":2116,"briefTitle":2117,"status":107,"phases":2118,"primaryCompletion":279,"completion":392,"start":725,"enrollment":2119,"conditions":2120,"interventions":2123},"NCT00248625","N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure",[62],184,[2121,2122],"Acute Liver Failure","Hepatic Encephalopathy",[2105],{"trials":2125,"activeCount":71},[],{"trials":2127,"activeCount":71},[],{"intervention":2129,"totalTrials":67,"cells":2130},"Valganciclovir",{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2137,"PHASE4":2148,"NA":2150},{"trials":2132,"activeCount":71},[],{"trials":2134,"activeCount":71},[],{"trials":2136,"activeCount":71},[],{"trials":2138,"activeCount":71},[2139],{"nctId":2140,"briefTitle":2141,"status":389,"phases":2142,"completion":1099,"start":2143,"enrollment":2144,"conditions":2145,"interventions":2147},"NCT00275314","WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients",[62],"2006-02",5,[2146],"Kidney Transplant",[2129],{"trials":2149,"activeCount":71},[],{"trials":2151,"activeCount":71},[],{"intervention":2153,"totalTrials":67,"cells":2154},"Injectable Risperidone (Consta) or oral antipsychotic",{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2161,"PHASE4":2170,"NA":2172},{"trials":2156,"activeCount":71},[],{"trials":2158,"activeCount":71},[],{"trials":2160,"activeCount":71},[],{"trials":2162,"activeCount":71},[2163],{"nctId":2164,"briefTitle":2165,"status":107,"phases":2166,"primaryCompletion":1147,"completion":506,"start":705,"enrollment":10,"conditions":2167,"interventions":2169},"NCT00177164","Risperdal Consta for Bipolar Disorder",[62],[2168],"Bipolar I Disorder",[2153],{"trials":2171,"activeCount":71},[],{"trials":2173,"activeCount":71},[],{"intervention":2175,"totalTrials":67,"cells":2176},"Sensoril",{"EARLY_PHASE1":2177,"PHASE1":2179,"PHASE2":2181,"PHASE3":2183,"PHASE4":2193,"NA":2195},{"trials":2178,"activeCount":71},[],{"trials":2180,"activeCount":71},[],{"trials":2182,"activeCount":71},[],{"trials":2184,"activeCount":71},[2185],{"nctId":2186,"briefTitle":2187,"status":107,"phases":2188,"primaryCompletion":409,"completion":409,"start":2189,"enrollment":111,"conditions":2190,"interventions":2192},"NCT00761761","Sensoril(Ashwaganhda)for Bipolar Disorder",[62],"2008-10",[2168,2098,2191],"Bipolar Disorder NOS",[2175],{"trials":2194,"activeCount":71},[],{"trials":2196,"activeCount":71},[],{"intervention":2198,"totalTrials":67,"cells":2199},"Prolotherapy",{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2206,"PHASE4":2219,"NA":2221},{"trials":2201,"activeCount":71},[],{"trials":2203,"activeCount":71},[],{"trials":2205,"activeCount":71},[],{"trials":2207,"activeCount":71},[2208],{"nctId":2209,"briefTitle":2210,"status":107,"phases":2211,"primaryCompletion":392,"completion":2212,"start":2213,"enrollment":2214,"conditions":2215,"interventions":2218},"NCT00674622","Prolotherapy for the Treatment of Chronic Lateral Epicondylitis",[61,62],"2011-10","2007-09",67,[2216,2217],"Lateral Epicondylitis","Tennis Elbow",[2198],{"trials":2220,"activeCount":71},[],{"trials":2222,"activeCount":71},[],{"intervention":2224,"totalTrials":67,"cells":2225},"Alendronate",{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2242,"NA":2244},{"trials":2227,"activeCount":71},[],{"trials":2229,"activeCount":71},[],{"trials":2231,"activeCount":71},[],{"trials":2233,"activeCount":71},[2234],{"nctId":2235,"briefTitle":2236,"status":107,"phases":2237,"primaryCompletion":1932,"completion":1932,"start":2238,"enrollment":1933,"conditions":2239,"interventions":2241},"NCT00177619","Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)",[62],"2002-05",[2240],"Prostatic Neoplasms",[2224],{"trials":2243,"activeCount":71},[],{"trials":2245,"activeCount":71},[],{"intervention":2247,"totalTrials":67,"cells":2248},"Proton Pump Inhibitors; active control",{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2253,"PHASE3":2255,"PHASE4":2266,"NA":2268},{"trials":2250,"activeCount":71},[],{"trials":2252,"activeCount":71},[],{"trials":2254,"activeCount":71},[],{"trials":2256,"activeCount":71},[2257],{"nctId":2258,"briefTitle":2259,"status":389,"phases":2260,"primaryCompletion":2261,"completion":2261,"start":2262,"enrollment":111,"conditions":2263,"interventions":2265},"NCT00857597","Endoscopic Fundoplication Versus Proton Pump Inhibitors for GERD Treatment",[62],"2011-12","2009-03",[2264],"Gastroesophageal Reflux Disease (GERD)",[2247],{"trials":2267,"activeCount":71},[],{"trials":2269,"activeCount":71},[],{"intervention":2271,"totalTrials":67,"cells":2272},"haloperidol",{"EARLY_PHASE1":2273,"PHASE1":2275,"PHASE2":2277,"PHASE3":2279,"PHASE4":2289,"NA":2291},{"trials":2274,"activeCount":71},[],{"trials":2276,"activeCount":71},[],{"trials":2278,"activeCount":71},[],{"trials":2280,"activeCount":71},[2281],{"nctId":2282,"briefTitle":2283,"status":389,"phases":2284,"primaryCompletion":2212,"completion":2212,"start":2285,"enrollment":632,"conditions":2286,"interventions":2288},"NCT00300391","ORIC-I: Optimizing Recovery From Intensive Care: Mechanical Ventilation and Delirium",[62],"2006-03",[2287],"Delirium",[2271],{"trials":2290,"activeCount":71},[],{"trials":2292,"activeCount":71},[],{"intervention":2294,"totalTrials":67,"cells":2295},"Lithium",{"EARLY_PHASE1":2296,"PHASE1":2298,"PHASE2":2300,"PHASE3":2302,"PHASE4":2316,"NA":2318},{"trials":2297,"activeCount":71},[],{"trials":2299,"activeCount":71},[],{"trials":2301,"activeCount":71},[],{"trials":2303,"activeCount":71},[2304],{"nctId":2305,"briefTitle":2306,"status":107,"phases":2307,"completion":2308,"start":2309,"enrollment":2310,"conditions":2311,"interventions":2313},"NCT00518947","Pharmacotherapy of Treatment-Resistant Mania",[62],"1999-06","1994-11",45,[2312],"Mania",[2294,2314,2315],"verapamil","verapamil plus lithium",{"trials":2317,"activeCount":71},[],{"trials":2319,"activeCount":71},[],{"intervention":2314,"totalTrials":67,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2326,"PHASE3":2328,"PHASE4":2334,"NA":2336},{"trials":2323,"activeCount":71},[],{"trials":2325,"activeCount":71},[],{"trials":2327,"activeCount":71},[],{"trials":2329,"activeCount":71},[2330],{"nctId":2305,"briefTitle":2306,"status":107,"phases":2331,"completion":2308,"start":2309,"enrollment":2310,"conditions":2332,"interventions":2333},[62],[2312],[2294,2314,2315],{"trials":2335,"activeCount":71},[],{"trials":2337,"activeCount":71},[],{"intervention":2315,"totalTrials":67,"cells":2339},{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2346,"PHASE4":2352,"NA":2354},{"trials":2341,"activeCount":71},[],{"trials":2343,"activeCount":71},[],{"trials":2345,"activeCount":71},[],{"trials":2347,"activeCount":71},[2348],{"nctId":2305,"briefTitle":2306,"status":107,"phases":2349,"completion":2308,"start":2309,"enrollment":2310,"conditions":2350,"interventions":2351},[62],[2312],[2294,2314,2315],{"trials":2353,"activeCount":71},[],{"trials":2355,"activeCount":71},[],{"intervention":2357,"totalTrials":67,"cells":2358},"Biguanides, thiazolidinediones",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2365,"PHASE4":2381,"NA":2383},{"trials":2360,"activeCount":71},[],{"trials":2362,"activeCount":71},[],{"trials":2364,"activeCount":71},[],{"trials":2366,"activeCount":71},[2367],{"nctId":2368,"briefTitle":2369,"status":107,"phases":2370,"primaryCompletion":2371,"completion":2262,"start":508,"enrollment":2372,"conditions":2373,"interventions":2378},"NCT00006305","Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes",[62],"2008-11",2368,[2374,22,2375,384,2376,2377],"Coronary Disease","Heart Diseases","Diabetes Mellitus","Diabetes Mellitus, Non-Insulin-Dependent",[2357,2379,2380],"Insulin, sulfonylurea","ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers",{"trials":2382,"activeCount":71},[],{"trials":2384,"activeCount":71},[],{"intervention":2379,"totalTrials":67,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2393,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":71},[],{"trials":2390,"activeCount":71},[],{"trials":2392,"activeCount":71},[],{"trials":2394,"activeCount":71},[2395],{"nctId":2368,"briefTitle":2369,"status":107,"phases":2396,"primaryCompletion":2371,"completion":2262,"start":508,"enrollment":2372,"conditions":2397,"interventions":2398},[62],[2374,22,2375,384,2376,2377],[2357,2379,2380],{"trials":2400,"activeCount":71},[],{"trials":2402,"activeCount":71},[],{"intervention":2380,"totalTrials":67,"cells":2404},{"EARLY_PHASE1":2405,"PHASE1":2407,"PHASE2":2409,"PHASE3":2411,"PHASE4":2417,"NA":2419},{"trials":2406,"activeCount":71},[],{"trials":2408,"activeCount":71},[],{"trials":2410,"activeCount":71},[],{"trials":2412,"activeCount":71},[2413],{"nctId":2368,"briefTitle":2369,"status":107,"phases":2414,"primaryCompletion":2371,"completion":2262,"start":508,"enrollment":2372,"conditions":2415,"interventions":2416},[62],[2374,22,2375,384,2376,2377],[2357,2379,2380],{"trials":2418,"activeCount":71},[],{"trials":2420,"activeCount":71},[],{"intervention":2422,"totalTrials":12,"cells":2423},"Bevacizumab",{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2485,"PHASE4":2487,"NA":2489},{"trials":2425,"activeCount":71},[],{"trials":2427,"activeCount":71},[],{"trials":2429,"activeCount":71},[2430,2438,2445,2456,2464,2476],{"nctId":2431,"briefTitle":2432,"status":107,"phases":2433,"primaryCompletion":2434,"completion":2434,"start":1286,"enrollment":2073,"conditions":2435,"interventions":2436},"NCT00222729","Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer",[61],"2013-10",[25],[2437,2422],"Pemetrexed",{"nctId":2439,"briefTitle":2440,"status":107,"phases":2441,"primaryCompletion":897,"completion":897,"start":2189,"enrollment":2442,"conditions":2443,"interventions":2444},"NCT00703976","Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer",[61],80,[25],[2422,1925,2437],{"nctId":2446,"briefTitle":2447,"status":389,"phases":2448,"primaryCompletion":1261,"completion":1261,"start":507,"enrollment":371,"conditions":2449,"interventions":2452},"NCT00932152","Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer",[61],[2450,2451],"Non-small Cell Lung Cancer","Postmenopausal Women",[2453,2454,2422,2455],"fulvestrant","anastrozole","Best supportive care",{"nctId":2457,"briefTitle":2458,"status":107,"phases":2459,"primaryCompletion":1330,"completion":1330,"start":629,"enrollment":632,"conditions":2460,"interventions":2461},"NCT00177307","Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer",[61],[25],[2422,2462,2463],"Capecitabine","Oxaliplatin",{"nctId":2465,"briefTitle":2466,"status":107,"phases":2467,"primaryCompletion":2468,"completion":408,"start":507,"enrollment":10,"conditions":2469,"interventions":2473},"NCT01031381","Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer",[61],"2014-01",[2470,2471,2472],"Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Carcinoma",[2474,2475],"RAD001","bevacizumab",{"nctId":2477,"briefTitle":2478,"status":1328,"phases":2479,"primaryCompletion":2480,"completion":2480,"start":2481,"enrollment":71,"conditions":2482,"interventions":2484},"NCT01262859","Pilot Study for Locally Advanced Head and Neck Cancer",[61],"2011-07","2010-12",[2483],"Head and Neck Neoplasms",[2475],{"trials":2486,"activeCount":71},[],{"trials":2488,"activeCount":71},[],{"trials":2490,"activeCount":71},[],{"intervention":1925,"totalTrials":12,"cells":2492},{"EARLY_PHASE1":2493,"PHASE1":2495,"PHASE2":2515,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2494,"activeCount":71},[],{"trials":2496,"activeCount":71},[2497,2508],{"nctId":2498,"briefTitle":2499,"status":107,"phases":2500,"primaryCompletion":2501,"completion":939,"start":2502,"enrollment":2503,"conditions":2504,"interventions":2506},"NCT00388427","Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies",[60],"2009-07","2007-06",31,[2505],"Malignant Solid Tumour",[2507,1925],"Dasatinib",{"nctId":2509,"briefTitle":2510,"status":107,"phases":2511,"primaryCompletion":1147,"completion":1239,"start":2285,"enrollment":632,"conditions":2512,"interventions":2514},"NCT00291707","Trial of Cetuximab and Pemetrexed With Radiation in Head and Neck Cancer",[60],[2513],"Head and Neck Cancer",[1925,2437],{"trials":2516,"activeCount":71},[2517,2521,2525,2536],{"nctId":1918,"briefTitle":1919,"status":107,"phases":2518,"primaryCompletion":1479,"completion":1479,"start":1885,"enrollment":1921,"conditions":2519,"interventions":2520},[61],[25],[1924,1909,1925],{"nctId":2439,"briefTitle":2440,"status":107,"phases":2522,"primaryCompletion":897,"completion":897,"start":2189,"enrollment":2442,"conditions":2523,"interventions":2524},[61],[25],[2422,1925,2437],{"nctId":2526,"briefTitle":2527,"status":107,"phases":2528,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":294,"conditions":2531,"interventions":2534},"NCT00336856","Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy",[61],"2011-06","2006-06",[2532,2533],"Colon Cancer","Rectum Cancer",[1925,2535],"Irinotecan",{"nctId":2537,"briefTitle":2538,"status":107,"phases":2539,"primaryCompletion":1330,"completion":1330,"start":2530,"enrollment":632,"conditions":2540,"interventions":2542},"NCT00492206","Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC",[61],[2541],"Non Small Cell Lung Cancer (NSCLC)",[1925],{"trials":2544,"activeCount":71},[],{"trials":2546,"activeCount":71},[],{"trials":2548,"activeCount":71},[],{"intervention":2437,"totalTrials":323,"cells":2550},{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2568,"PHASE3":2578,"PHASE4":2580,"NA":2582},{"trials":2552,"activeCount":71},[],{"trials":2554,"activeCount":71},[2555,2564],{"nctId":2556,"briefTitle":2557,"status":389,"phases":2558,"primaryCompletion":2559,"completion":2559,"start":2501,"enrollment":1100,"conditions":2560,"interventions":2562},"NCT00907179","Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer",[60],"2015-07",[2561],"Non-Small Cell Lung Cancer",[2563,2437],"LBH 589",{"nctId":2509,"briefTitle":2510,"status":107,"phases":2565,"primaryCompletion":1147,"completion":1239,"start":2285,"enrollment":632,"conditions":2566,"interventions":2567},[60],[2513],[1925,2437],{"trials":2569,"activeCount":71},[2570,2574],{"nctId":2431,"briefTitle":2432,"status":107,"phases":2571,"primaryCompletion":2434,"completion":2434,"start":1286,"enrollment":2073,"conditions":2572,"interventions":2573},[61],[25],[2437,2422],{"nctId":2439,"briefTitle":2440,"status":107,"phases":2575,"primaryCompletion":897,"completion":897,"start":2189,"enrollment":2442,"conditions":2576,"interventions":2577},[61],[25],[2422,1925,2437],{"trials":2579,"activeCount":71},[],{"trials":2581,"activeCount":71},[],{"trials":2583,"activeCount":71},[],{"intervention":1924,"totalTrials":371,"cells":2585},{"EARLY_PHASE1":2586,"PHASE1":2588,"PHASE2":2603,"PHASE3":2616,"PHASE4":2618,"NA":2620},{"trials":2587,"activeCount":71},[],{"trials":2589,"activeCount":71},[2590],{"nctId":2591,"briefTitle":2592,"status":107,"phases":2593,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2096,"conditions":2596,"interventions":2598},"NCT00008125","Combination Chemotherapy With or Without Filgrastim in Treating Patients With Advanced Solid Tumors",[60],"2004-02","1998-03",[2597],"Unspecified Adult Solid Tumor, Protocol Specific",[2599,2600,2601,2602],"filgrastim","carboplatin","docetaxel","gemcitabine hydrochloride",{"trials":2604,"activeCount":71},[2605,2609],{"nctId":1918,"briefTitle":1919,"status":107,"phases":2606,"primaryCompletion":1479,"completion":1479,"start":1885,"enrollment":1921,"conditions":2607,"interventions":2608},[61],[25],[1924,1909,1925],{"nctId":2610,"briefTitle":2611,"status":389,"phases":2612,"primaryCompletion":2613,"completion":2613,"start":2025,"enrollment":632,"conditions":2614,"interventions":2615},"NCT00177255","A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers",[61],"2008-12",[25],[1924,2462],{"trials":2617,"activeCount":71},[],{"trials":2619,"activeCount":71},[],{"trials":2621,"activeCount":71},[],{"intervention":2623,"totalTrials":371,"cells":2624},"Parathyroid Hormone",{"EARLY_PHASE1":2625,"PHASE1":2637,"PHASE2":2651,"PHASE3":2663,"PHASE4":2665,"NA":2667},{"trials":2626,"activeCount":71},[2627],{"nctId":2628,"briefTitle":2629,"status":107,"phases":2630,"primaryCompletion":1597,"completion":1597,"start":2631,"enrollment":432,"conditions":2632,"interventions":2636},"NCT00377312","7 Day Continuous Parathyroid Hormone IV Infusion",[59],"2006-09",[2633,2634,2635],"Osteoporosis","Bone Diseases, Endocrine","Hyperparathyroidism",[2623],{"trials":2638,"activeCount":71},[2639],{"nctId":2640,"briefTitle":2641,"status":1328,"phases":2642,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":71,"conditions":2645,"interventions":2647},"NCT01333267","One Week Comparison Study of PTH and PTHrP Infusions",[60],"2017-07","2015-01",[2633,2646,2635,2634],"Hypercalcemia of Malignancy",[2648,2649,2650],"Parathyroid Hormone-related Protein","parathyroid hormone","PTH",{"trials":2652,"activeCount":71},[2653],{"nctId":2654,"briefTitle":2655,"status":107,"phases":2656,"primaryCompletion":1330,"completion":756,"start":2657,"enrollment":2658,"conditions":2659,"interventions":2660},"NCT00853723","Comparison Study of PTHrP and PTH to Treat Osteoporosis",[61],"2009-05",105,[2633],[2661,2661,2662],"Parathyroid hormone related protein","Parathyroid hormone",{"trials":2664,"activeCount":71},[],{"trials":2666,"activeCount":71},[],{"trials":2668,"activeCount":71},[],{"intervention":2670,"totalTrials":92,"cells":2671},"irinotecan",{"EARLY_PHASE1":2672,"PHASE1":2674,"PHASE2":2686,"PHASE3":2692,"PHASE4":2694,"NA":2696},{"trials":2673,"activeCount":71},[],{"trials":2675,"activeCount":71},[2676],{"nctId":2677,"briefTitle":2678,"status":389,"phases":2679,"primaryCompletion":1098,"completion":2680,"start":1098,"enrollment":2681,"conditions":2682,"interventions":2684},"NCT00177853","Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer",[60],"2010-07",23,[2683],"Pancreatic Cancer",[2685,2670],"celecoxib",{"trials":2687,"activeCount":71},[2688],{"nctId":2526,"briefTitle":2527,"status":107,"phases":2689,"primaryCompletion":2529,"completion":2529,"start":2530,"enrollment":294,"conditions":2690,"interventions":2691},[61],[2532,2533],[1925,2535],{"trials":2693,"activeCount":71},[],{"trials":2695,"activeCount":71},[],{"trials":2697,"activeCount":71},[],{"intervention":2699,"totalTrials":92,"cells":2700},"Nivolumab",{"EARLY_PHASE1":2701,"PHASE1":2703,"PHASE2":2715,"PHASE3":2728,"PHASE4":2730,"NA":2732},{"trials":2702,"activeCount":71},[],{"trials":2704,"activeCount":71},[2705],{"nctId":2706,"briefTitle":2707,"status":1328,"phases":2708,"primaryCompletion":2709,"completion":2709,"start":2709,"enrollment":71,"conditions":2710,"interventions":2712},"NCT02357732","Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and\u002For Trametinib",[60],"2015-08",[2711],"Metastatic Melanoma",[2699,2713,2714],"Trametinib","Dabrafenib",{"trials":2716,"activeCount":71},[2717],{"nctId":2718,"briefTitle":2719,"status":1328,"phases":2720,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":71,"conditions":2724,"interventions":2726},"NCT06767956","Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy",[60,61],"2027-04-30","2028-04-30","2025-06-30",[2725],"Non Hodgkin Lymphoma",[2727,2699],"GOLCADOMIDE",{"trials":2729,"activeCount":71},[],{"trials":2731,"activeCount":71},[],{"trials":2733,"activeCount":71},[],{"intervention":2735,"totalTrials":92,"cells":2736},"Doxil",{"EARLY_PHASE1":2737,"PHASE1":2739,"PHASE2":2741,"PHASE3":2760,"PHASE4":2762,"NA":2764},{"trials":2738,"activeCount":71},[],{"trials":2740,"activeCount":71},[],{"trials":2742,"activeCount":71},[2743,2751],{"nctId":2744,"briefTitle":2745,"status":107,"phases":2746,"primaryCompletion":279,"completion":279,"start":292,"enrollment":2144,"conditions":2747,"interventions":2749},"NCT00630409","Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma",[61],[2748],"Metastatic Renal Cell Carcinoma",[2750,2735],"Gemcitabine",{"nctId":2752,"briefTitle":2753,"status":107,"phases":2754,"primaryCompletion":2755,"completion":2755,"start":2285,"enrollment":632,"conditions":2756,"interventions":2758},"NCT00307294","Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC)",[61],"2012-01",[2757],"Prostate Cancer",[2759,2735],"Thalidomide",{"trials":2761,"activeCount":71},[],{"trials":2763,"activeCount":71},[],{"trials":2765,"activeCount":71},[],{"intervention":2462,"totalTrials":92,"cells":2767},{"EARLY_PHASE1":2768,"PHASE1":2770,"PHASE2":2772,"PHASE3":2782,"PHASE4":2784,"NA":2786},{"trials":2769,"activeCount":71},[],{"trials":2771,"activeCount":71},[],{"trials":2773,"activeCount":71},[2774,2778],{"nctId":2457,"briefTitle":2458,"status":107,"phases":2775,"primaryCompletion":1330,"completion":1330,"start":629,"enrollment":632,"conditions":2776,"interventions":2777},[61],[25],[2422,2462,2463],{"nctId":2610,"briefTitle":2611,"status":389,"phases":2779,"primaryCompletion":2613,"completion":2613,"start":2025,"enrollment":632,"conditions":2780,"interventions":2781},[61],[25],[1924,2462],{"trials":2783,"activeCount":71},[],{"trials":2785,"activeCount":71},[],{"trials":2787,"activeCount":71},[],{"intervention":2463,"totalTrials":92,"cells":2789},{"EARLY_PHASE1":2790,"PHASE1":2792,"PHASE2":2794,"PHASE3":2807,"PHASE4":2809,"NA":2811},{"trials":2791,"activeCount":71},[],{"trials":2793,"activeCount":71},[],{"trials":2795,"activeCount":71},[2796,2800],{"nctId":2457,"briefTitle":2458,"status":107,"phases":2797,"primaryCompletion":1330,"completion":1330,"start":629,"enrollment":632,"conditions":2798,"interventions":2799},[61],[25],[2422,2462,2463],{"nctId":2801,"briefTitle":2802,"status":107,"phases":2803,"primaryCompletion":2213,"completion":2213,"start":1526,"enrollment":155,"conditions":2804,"interventions":2805},"NCT00260611","Study of Oxaliplatin and Taxotere in Prostate Cancer",[61],[2757],[2463,2806],"Taxotere",{"trials":2808,"activeCount":71},[],{"trials":2810,"activeCount":71},[],{"trials":2812,"activeCount":71},[],{"intervention":2814,"totalTrials":92,"cells":2815},"Rituximab",{"EARLY_PHASE1":2816,"PHASE1":2818,"PHASE2":2820,"PHASE3":2844,"PHASE4":2846,"NA":2848},{"trials":2817,"activeCount":71},[],{"trials":2819,"activeCount":71},[],{"trials":2821,"activeCount":71},[2822,2833],{"nctId":2823,"briefTitle":2824,"status":107,"phases":2825,"primaryCompletion":1481,"completion":2826,"start":2285,"enrollment":1076,"conditions":2827,"interventions":2832},"NCT00106184","Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)",[61],"2010-08",[2828,2829,2830,2831],"Myositis","Dermatomyositis","Polymyositis","Juvenile Dermatomyositis",[2814],{"nctId":2834,"briefTitle":2835,"status":107,"phases":2836,"primaryCompletion":2837,"completion":1261,"start":1123,"enrollment":2838,"conditions":2839,"interventions":2841},"NCT00280241","Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia",[61],"2008-02",65,[2840],"Chronic Lymphocytic Leukemia",[2842,2843,2814],"Fludarabine","Cyclophosphamide",{"trials":2845,"activeCount":71},[],{"trials":2847,"activeCount":71},[],{"trials":2849,"activeCount":71},[],{"intervention":2851,"totalTrials":67,"cells":2852},"Chemotherapy and Radioimmunotherapy",{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2854,"activeCount":71},[],{"trials":2856,"activeCount":71},[],{"trials":2858,"activeCount":71},[2859],{"nctId":2860,"briefTitle":2861,"status":107,"phases":2862,"primaryCompletion":597,"completion":597,"start":705,"enrollment":111,"conditions":2863,"interventions":2865},"NCT00177554","Phase II Trial of CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma",[61],[2864],"Non-Hodgkin Lymphoma",[2851],{"trials":2867,"activeCount":71},[],{"trials":2869,"activeCount":71},[],{"trials":2871,"activeCount":71},[],{"intervention":2873,"totalTrials":67,"cells":2874},"LC Bead loaded with doxorubicin",{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2890,"PHASE4":2892,"NA":2894},{"trials":2876,"activeCount":71},[],{"trials":2878,"activeCount":71},[],{"trials":2880,"activeCount":71},[2881],{"nctId":2882,"briefTitle":2883,"status":107,"phases":2884,"primaryCompletion":2885,"completion":2886,"start":2371,"enrollment":92,"conditions":2887,"interventions":2889},"NCT00877071","LC Drug Eluting Bead for Treatment of Liver Cancer Which Cannot be Surgically Removed",[61],"2011-05","2012-04",[2888],"Hepatocellular Carcinoma",[2873],{"trials":2891,"activeCount":71},[],{"trials":2893,"activeCount":71},[],{"trials":2895,"activeCount":71},[],{"intervention":2897,"totalTrials":67,"cells":2898},"Sorafenib",{"EARLY_PHASE1":2899,"PHASE1":2901,"PHASE2":2903,"PHASE3":2913,"PHASE4":2915,"NA":2917},{"trials":2900,"activeCount":71},[],{"trials":2902,"activeCount":71},[],{"trials":2904,"activeCount":71},[2905],{"nctId":2906,"briefTitle":2907,"status":389,"phases":2908,"primaryCompletion":595,"completion":596,"start":312,"enrollment":31,"conditions":2909,"interventions":2911},"NCT00576056","Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC",[61],[2910],"Carcinoma, Hepatocellular",[2897,2912],"TACE",{"trials":2914,"activeCount":71},[],{"trials":2916,"activeCount":71},[],{"trials":2918,"activeCount":71},[],{"intervention":2912,"totalTrials":67,"cells":2920},{"EARLY_PHASE1":2921,"PHASE1":2923,"PHASE2":2925,"PHASE3":2931,"PHASE4":2933,"NA":2935},{"trials":2922,"activeCount":71},[],{"trials":2924,"activeCount":71},[],{"trials":2926,"activeCount":71},[2927],{"nctId":2906,"briefTitle":2907,"status":389,"phases":2928,"primaryCompletion":595,"completion":596,"start":312,"enrollment":31,"conditions":2929,"interventions":2930},[61],[2910],[2897,2912],{"trials":2932,"activeCount":71},[],{"trials":2934,"activeCount":71},[],{"trials":2936,"activeCount":71},[],{"intervention":2938,"totalTrials":67,"cells":2939},"Nivolumab - Arm A",{"EARLY_PHASE1":2940,"PHASE1":2942,"PHASE2":2944,"PHASE3":2956,"PHASE4":2958,"NA":2960},{"trials":2941,"activeCount":71},[],{"trials":2943,"activeCount":71},[],{"trials":2945,"activeCount":71},[2946],{"nctId":2947,"briefTitle":2948,"status":1328,"phases":2949,"primaryCompletion":2950,"completion":2950,"start":2951,"enrollment":71,"conditions":2952,"interventions":2954},"NCT02736123","Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone",[60,61],"2017-02-09","2016-10",[2953],"Melanoma",[2938,2955],"Nivolumab + Ipilimumab - Arm B",{"trials":2957,"activeCount":71},[],{"trials":2959,"activeCount":71},[],{"trials":2961,"activeCount":71},[],{"intervention":2955,"totalTrials":67,"cells":2963},{"EARLY_PHASE1":2964,"PHASE1":2966,"PHASE2":2968,"PHASE3":2974,"PHASE4":2976,"NA":2978},{"trials":2965,"activeCount":71},[],{"trials":2967,"activeCount":71},[],{"trials":2969,"activeCount":71},[2970],{"nctId":2947,"briefTitle":2948,"status":1328,"phases":2971,"primaryCompletion":2950,"completion":2950,"start":2951,"enrollment":71,"conditions":2972,"interventions":2973},[60,61],[2953],[2938,2955],{"trials":2975,"activeCount":71},[],{"trials":2977,"activeCount":71},[],{"trials":2979,"activeCount":71},[],{"intervention":2981,"totalTrials":67,"cells":2982},"PEG-Intron",{"EARLY_PHASE1":2983,"PHASE1":2985,"PHASE2":2987,"PHASE3":2997,"PHASE4":2999,"NA":3001},{"trials":2984,"activeCount":71},[],{"trials":2986,"activeCount":71},[],{"trials":2988,"activeCount":71},[2989],{"nctId":2990,"briefTitle":2991,"status":107,"phases":2992,"primaryCompletion":382,"completion":382,"start":1098,"enrollment":2993,"conditions":2994,"interventions":2996},"NCT00396019","Study of PEG-Intron for Plexiform Neurofibromas",[61],86,[2995],"Plexiform Neurofibroma",[2981],{"trials":2998,"activeCount":71},[],{"trials":3000,"activeCount":71},[],{"trials":3002,"activeCount":71},[],{"intervention":3004,"totalTrials":67,"cells":3005},"Merck L-830982",{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3010,"PHASE3":3018,"PHASE4":3020,"NA":3022},{"trials":3007,"activeCount":71},[],{"trials":3009,"activeCount":71},[],{"trials":3011,"activeCount":71},[3012],{"nctId":3013,"briefTitle":3014,"status":107,"phases":3015,"primaryCompletion":312,"completion":312,"start":339,"enrollment":443,"conditions":3016,"interventions":3017},"NCT00129441","Gamma-Amino Butyric Acid (GABA)-A Alpha2\u002F3 Study",[61],[33],[3004],{"trials":3019,"activeCount":71},[],{"trials":3021,"activeCount":71},[],{"trials":3023,"activeCount":71},[],{"intervention":3025,"totalTrials":67,"cells":3026},"Neumega",{"EARLY_PHASE1":3027,"PHASE1":3029,"PHASE2":3031,"PHASE3":3041,"PHASE4":3043,"NA":3045},{"trials":3028,"activeCount":71},[],{"trials":3030,"activeCount":71},[],{"trials":3032,"activeCount":71},[3033],{"nctId":3034,"briefTitle":3035,"status":107,"phases":3036,"primaryCompletion":2886,"completion":2886,"start":2048,"enrollment":1843,"conditions":3037,"interventions":3040},"NCT00994929","Efficacy and Safety of IL-11 in DDAVP Unresponsive",[61],[3038,3039],"Hemophilia A","Von Willebrand Disease",[3025],{"trials":3042,"activeCount":71},[],{"trials":3044,"activeCount":71},[],{"trials":3046,"activeCount":71},[],{"intervention":3048,"totalTrials":67,"cells":3049},"Fondaparinux Sodium",{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3054,"PHASE3":3066,"PHASE4":3068,"NA":3070},{"trials":3051,"activeCount":71},[],{"trials":3053,"activeCount":71},[],{"trials":3055,"activeCount":71},[3056],{"nctId":3057,"briefTitle":3058,"status":107,"phases":3059,"completion":1597,"start":3060,"enrollment":3061,"conditions":3062,"interventions":3065},"NCT00436787","Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers",[61],"2007-02",21,[3063,3064],"Venous Thrombosis","Pulmonary Embolism",[3048],{"trials":3067,"activeCount":71},[],{"trials":3069,"activeCount":71},[],{"trials":3071,"activeCount":71},[],{"intervention":2727,"totalTrials":67,"cells":3073},{"EARLY_PHASE1":3074,"PHASE1":3076,"PHASE2":3078,"PHASE3":3084,"PHASE4":3086,"NA":3088},{"trials":3075,"activeCount":71},[],{"trials":3077,"activeCount":71},[],{"trials":3079,"activeCount":71},[3080],{"nctId":2718,"briefTitle":2719,"status":1328,"phases":3081,"primaryCompletion":2721,"completion":2722,"start":2723,"enrollment":71,"conditions":3082,"interventions":3083},[60,61],[2725],[2727,2699],{"trials":3085,"activeCount":71},[],{"trials":3087,"activeCount":71},[],{"trials":3089,"activeCount":71},[],{"intervention":3091,"totalTrials":67,"cells":3092},"recombinant interleukin-11",{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3105,"PHASE4":3107,"NA":3109},{"trials":3094,"activeCount":71},[],{"trials":3096,"activeCount":71},[],{"trials":3098,"activeCount":71},[3099],{"nctId":3100,"briefTitle":3101,"status":107,"phases":3102,"primaryCompletion":1597,"completion":1597,"start":571,"enrollment":1100,"conditions":3103,"interventions":3104},"NCT00151125","Phase II Study of IL-11 (Neumega) in Von Willebrand Disease",[61],[3039],[3091,3091,3091],{"trials":3106,"activeCount":71},[],{"trials":3108,"activeCount":71},[],{"trials":3110,"activeCount":71},[],{"intervention":3112,"totalTrials":67,"cells":3113},"SOM230",{"EARLY_PHASE1":3114,"PHASE1":3116,"PHASE2":3118,"PHASE3":3130,"PHASE4":3132,"NA":3134},{"trials":3115,"activeCount":71},[],{"trials":3117,"activeCount":71},[],{"trials":3119,"activeCount":71},[3120],{"nctId":3121,"briefTitle":3122,"status":1328,"phases":3123,"primaryCompletion":1330,"completion":1330,"start":2261,"enrollment":71,"conditions":3124,"interventions":3127},"NCT01329289","SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma",[61],[3125,3126],"Multiple Myeloma in Relapse","Multiple Myeloma",[3112,3128,3129],"Bortezomib","Dexamethasone",{"trials":3131,"activeCount":71},[],{"trials":3133,"activeCount":71},[],{"trials":3135,"activeCount":71},[],{"intervention":3128,"totalTrials":67,"cells":3137},{"EARLY_PHASE1":3138,"PHASE1":3140,"PHASE2":3142,"PHASE3":3148,"PHASE4":3150,"NA":3152},{"trials":3139,"activeCount":71},[],{"trials":3141,"activeCount":71},[],{"trials":3143,"activeCount":71},[3144],{"nctId":3121,"briefTitle":3122,"status":1328,"phases":3145,"primaryCompletion":1330,"completion":1330,"start":2261,"enrollment":71,"conditions":3146,"interventions":3147},[61],[3125,3126],[3112,3128,3129],{"trials":3149,"activeCount":71},[],{"trials":3151,"activeCount":71},[],{"trials":3153,"activeCount":71},[],{"intervention":2453,"totalTrials":67,"cells":3155},{"EARLY_PHASE1":3156,"PHASE1":3158,"PHASE2":3160,"PHASE3":3166,"PHASE4":3168,"NA":3170},{"trials":3157,"activeCount":71},[],{"trials":3159,"activeCount":71},[],{"trials":3161,"activeCount":71},[3162],{"nctId":2446,"briefTitle":2447,"status":389,"phases":3163,"primaryCompletion":1261,"completion":1261,"start":507,"enrollment":371,"conditions":3164,"interventions":3165},[61],[2450,2451],[2453,2454,2422,2455],{"trials":3167,"activeCount":71},[],{"trials":3169,"activeCount":71},[],{"trials":3171,"activeCount":71},[],{"intervention":2454,"totalTrials":67,"cells":3173},{"EARLY_PHASE1":3174,"PHASE1":3176,"PHASE2":3178,"PHASE3":3184,"PHASE4":3186,"NA":3188},{"trials":3175,"activeCount":71},[],{"trials":3177,"activeCount":71},[],{"trials":3179,"activeCount":71},[3180],{"nctId":2446,"briefTitle":2447,"status":389,"phases":3181,"primaryCompletion":1261,"completion":1261,"start":507,"enrollment":371,"conditions":3182,"interventions":3183},[61],[2450,2451],[2453,2454,2422,2455],{"trials":3185,"activeCount":71},[],{"trials":3187,"activeCount":71},[],{"trials":3189,"activeCount":71},[],{"intervention":2455,"totalTrials":67,"cells":3191},{"EARLY_PHASE1":3192,"PHASE1":3194,"PHASE2":3196,"PHASE3":3202,"PHASE4":3204,"NA":3206},{"trials":3193,"activeCount":71},[],{"trials":3195,"activeCount":71},[],{"trials":3197,"activeCount":71},[3198],{"nctId":2446,"briefTitle":2447,"status":389,"phases":3199,"primaryCompletion":1261,"completion":1261,"start":507,"enrollment":371,"conditions":3200,"interventions":3201},[61],[2450,2451],[2453,2454,2422,2455],{"trials":3203,"activeCount":71},[],{"trials":3205,"activeCount":71},[],{"trials":3207,"activeCount":71},[],{"intervention":2750,"totalTrials":67,"cells":3209},{"EARLY_PHASE1":3210,"PHASE1":3212,"PHASE2":3214,"PHASE3":3220,"PHASE4":3222,"NA":3224},{"trials":3211,"activeCount":71},[],{"trials":3213,"activeCount":71},[],{"trials":3215,"activeCount":71},[3216],{"nctId":2744,"briefTitle":2745,"status":107,"phases":3217,"primaryCompletion":279,"completion":279,"start":292,"enrollment":2144,"conditions":3218,"interventions":3219},[61],[2748],[2750,2735],{"trials":3221,"activeCount":71},[],{"trials":3223,"activeCount":71},[],{"trials":3225,"activeCount":71},[],{"intervention":3227,"totalTrials":67,"cells":3228},"arsenic trioxide",{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3233,"PHASE3":3241,"PHASE4":3243,"NA":3245},{"trials":3230,"activeCount":71},[],{"trials":3232,"activeCount":71},[],{"trials":3234,"activeCount":71},[3235],{"nctId":3236,"briefTitle":3237,"status":107,"phases":3238,"primaryCompletion":1932,"start":1123,"enrollment":2096,"conditions":3239,"interventions":3240},"NCT00128596","Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery",[61],[1935],[3227],{"trials":3242,"activeCount":71},[],{"trials":3244,"activeCount":71},[],{"trials":3246,"activeCount":71},[],{"intervention":3248,"totalTrials":67,"cells":3249},"Clofarabine",{"EARLY_PHASE1":3250,"PHASE1":3252,"PHASE2":3254,"PHASE3":3265,"PHASE4":3267,"NA":3269},{"trials":3251,"activeCount":71},[],{"trials":3253,"activeCount":71},[],{"trials":3255,"activeCount":71},[3256],{"nctId":3257,"briefTitle":3258,"status":389,"phases":3259,"primaryCompletion":3260,"completion":3260,"start":2434,"enrollment":92,"conditions":3261,"interventions":3263},"NCT01960387","Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia",[61],"2015-03",[3262],"Acute Myeloid Leukemia",[3248,3264],"Cytarabine",{"trials":3266,"activeCount":71},[],{"trials":3268,"activeCount":71},[],{"trials":3270,"activeCount":71},[],{"intervention":3264,"totalTrials":67,"cells":3272},{"EARLY_PHASE1":3273,"PHASE1":3275,"PHASE2":3277,"PHASE3":3283,"PHASE4":3285,"NA":3287},{"trials":3274,"activeCount":71},[],{"trials":3276,"activeCount":71},[],{"trials":3278,"activeCount":71},[3279],{"nctId":3257,"briefTitle":3258,"status":389,"phases":3280,"primaryCompletion":3260,"completion":3260,"start":2434,"enrollment":92,"conditions":3281,"interventions":3282},[61],[3262],[3248,3264],{"trials":3284,"activeCount":71},[],{"trials":3286,"activeCount":71},[],{"trials":3288,"activeCount":71},[],{"intervention":3290,"totalTrials":67,"cells":3291},"Panitumumab",{"EARLY_PHASE1":3292,"PHASE1":3294,"PHASE2":3296,"PHASE3":3309,"PHASE4":3311,"NA":3313},{"trials":3293,"activeCount":71},[],{"trials":3295,"activeCount":71},[],{"trials":3297,"activeCount":71},[3298],{"nctId":3299,"briefTitle":3300,"status":1328,"phases":3301,"primaryCompletion":3302,"completion":3302,"start":3302,"enrollment":71,"conditions":3303,"interventions":3308},"NCT00984217","Trial of Radiotherapy and Panitumumab in Salivary Gland Malignancies",[61],"2011-08",[3304,3305,3306,3307],"Adenoma, Pleomorphic","Mixed Salivary Gland Tumor","Salivary Gland Tumor, Mixed","Syringoma, Chondroid",[3290],{"trials":3310,"activeCount":71},[],{"trials":3312,"activeCount":71},[],{"trials":3314,"activeCount":71},[],{"intervention":3316,"totalTrials":67,"cells":3317},"17-OHPC",{"EARLY_PHASE1":3318,"PHASE1":3320,"PHASE2":3322,"PHASE3":3333,"PHASE4":3335,"NA":3337},{"trials":3319,"activeCount":71},[],{"trials":3321,"activeCount":71},[],{"trials":3323,"activeCount":71},[3324],{"nctId":3325,"briefTitle":3326,"status":107,"phases":3327,"primaryCompletion":313,"completion":3328,"start":2285,"enrollment":3329,"conditions":3330,"interventions":3332},"NCT00409825","Study of Pharmacology of 17-OHPC in Pregnancy",[61],"2014-02",61,[3331],"Pregnancy",[3316],{"trials":3334,"activeCount":71},[],{"trials":3336,"activeCount":71},[],{"trials":3338,"activeCount":71},[],{"intervention":3340,"totalTrials":67,"cells":3341},"ICX-RHY-013",{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3360,"PHASE4":3362,"NA":3364},{"trials":3343,"activeCount":71},[],{"trials":3345,"activeCount":71},[],{"trials":3347,"activeCount":71},[3348],{"nctId":3349,"briefTitle":3350,"status":389,"phases":3351,"primaryCompletion":3328,"completion":3328,"start":3352,"enrollment":3353,"conditions":3354,"interventions":3359},"NCT01564407","A Clinical Study of Allogeneic Human Dermal Fibroblasts for Remodeling Scar Contractures",[60,61],"2011-01",15,[3355,3356,3357,3358],"Restrictive Scar Contracture","Restrictive Hypertrophic Scar","Burn Scar Contractures","Burn Scar",[3340],{"trials":3361,"activeCount":71},[],{"trials":3363,"activeCount":71},[],{"trials":3365,"activeCount":71},[],{"intervention":3367,"totalTrials":67,"cells":3368},"Standard Steroid Treatment",{"EARLY_PHASE1":3369,"PHASE1":3371,"PHASE2":3373,"PHASE3":3384,"PHASE4":3386,"NA":3388},{"trials":3370,"activeCount":71},[],{"trials":3372,"activeCount":71},[],{"trials":3374,"activeCount":71},[3375],{"nctId":3376,"briefTitle":3377,"status":1328,"phases":3378,"primaryCompletion":669,"completion":669,"start":3379,"enrollment":71,"conditions":3380,"interventions":3382},"NCT01524068","A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations",[61],"2012-09",[3381],"Idiopathic Pulmonary Fibrosis",[3367,3383],"The Standard Steroid Treatment, Plasma Exchange and rituximab",{"trials":3385,"activeCount":71},[],{"trials":3387,"activeCount":71},[],{"trials":3389,"activeCount":71},[],{"intervention":3383,"totalTrials":67,"cells":3391},{"EARLY_PHASE1":3392,"PHASE1":3394,"PHASE2":3396,"PHASE3":3402,"PHASE4":3404,"NA":3406},{"trials":3393,"activeCount":71},[],{"trials":3395,"activeCount":71},[],{"trials":3397,"activeCount":71},[3398],{"nctId":3376,"briefTitle":3377,"status":1328,"phases":3399,"primaryCompletion":669,"completion":669,"start":3379,"enrollment":71,"conditions":3400,"interventions":3401},[61],[3381],[3367,3383],{"trials":3403,"activeCount":71},[],{"trials":3405,"activeCount":71},[],{"trials":3407,"activeCount":71},[],{"intervention":3409,"totalTrials":67,"cells":3410},"Aspirin",{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3427,"PHASE4":3429,"NA":3431},{"trials":3412,"activeCount":71},[],{"trials":3414,"activeCount":71},[],{"trials":3416,"activeCount":71},[3417],{"nctId":3418,"briefTitle":3419,"status":107,"phases":3420,"primaryCompletion":3421,"completion":3421,"start":668,"enrollment":3422,"conditions":3423,"interventions":3426},"NCT02401269","Cardiovascular Risk in HIV Patients on Antiretroviral Therapy Therapy: The MHEART Study",[60,61],"2016-01",91,[3424,3425],"Cardiovascular Disease Risk in HIV Patients","Endothelial Function",[3409],{"trials":3428,"activeCount":71},[],{"trials":3430,"activeCount":71},[],{"trials":3432,"activeCount":71},[],{"intervention":3434,"totalTrials":67,"cells":3435},"Simethicone",{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3440,"PHASE3":3450,"PHASE4":3452,"NA":3454},{"trials":3437,"activeCount":71},[],{"trials":3439,"activeCount":71},[],{"trials":3441,"activeCount":71},[3442],{"nctId":3443,"briefTitle":3444,"status":107,"phases":3445,"primaryCompletion":3446,"completion":3446,"start":409,"enrollment":2096,"conditions":3447,"interventions":3449},"NCT01312038","Effect of Simethicone on Eustachian Tube Dysfunction",[61],"2014-07",[3448],"Otitis Media",[3434],{"trials":3451,"activeCount":71},[],{"trials":3453,"activeCount":71},[],{"trials":3455,"activeCount":71},[],{"intervention":3457,"totalTrials":67,"cells":3458},"mifepristone, misoprostol",{"EARLY_PHASE1":3459,"PHASE1":3461,"PHASE2":3463,"PHASE3":3471,"PHASE4":3473,"NA":3475},{"trials":3460,"activeCount":71},[],{"trials":3462,"activeCount":71},[],{"trials":3464,"activeCount":71},[3465],{"nctId":3466,"briefTitle":3467,"status":107,"phases":3468,"completion":561,"start":2285,"enrollment":1933,"conditions":3469,"interventions":3470},"NCT00330993","Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation",[61],[802],[3457],{"trials":3472,"activeCount":71},[],{"trials":3474,"activeCount":71},[],{"trials":3476,"activeCount":71},[],{"intervention":3478,"totalTrials":67,"cells":3479},"Alemtuzumab",{"EARLY_PHASE1":3480,"PHASE1":3482,"PHASE2":3484,"PHASE3":3497,"PHASE4":3499,"NA":3501},{"trials":3481,"activeCount":71},[],{"trials":3483,"activeCount":71},[],{"trials":3485,"activeCount":71},[3486],{"nctId":3487,"briefTitle":3488,"status":107,"phases":3489,"primaryCompletion":3490,"completion":3490,"start":3491,"enrollment":2681,"conditions":3492,"interventions":3496},"NCT01208337","Safety and Efficacy of Alemtuzumab in Pediatric Intestinal Transplantation",[61],"2014-11","2007-04",[3493,3494,3495],"Evidence of Liver Transplantation","Rejection","ALEMTUZUMAB",[3478],{"trials":3498,"activeCount":71},[],{"trials":3500,"activeCount":71},[],{"trials":3502,"activeCount":71},[],{"intervention":3504,"totalTrials":67,"cells":3505},"Donepezil HCl",{"EARLY_PHASE1":3506,"PHASE1":3508,"PHASE2":3510,"PHASE3":3520,"PHASE4":3522,"NA":3524},{"trials":3507,"activeCount":71},[],{"trials":3509,"activeCount":71},[],{"trials":3511,"activeCount":71},[3512],{"nctId":3513,"briefTitle":3514,"status":107,"phases":3515,"primaryCompletion":561,"completion":561,"start":3516,"enrollment":155,"conditions":3517,"interventions":3519},"NCT00047697","Donepezil HCl & Cognitive Deficits in Autism",[61],"2002-10",[3518],"Autistic Disorder",[3504],{"trials":3521,"activeCount":71},[],{"trials":3523,"activeCount":71},[],{"trials":3525,"activeCount":71},[],{"intervention":3527,"totalTrials":67,"cells":3528},"Gefitinib",{"EARLY_PHASE1":3529,"PHASE1":3531,"PHASE2":3533,"PHASE3":3541,"PHASE4":3543,"NA":3545},{"trials":3530,"activeCount":71},[],{"trials":3532,"activeCount":71},[],{"trials":3534,"activeCount":71},[3535],{"nctId":3536,"briefTitle":3537,"status":107,"phases":3538,"completion":1098,"start":292,"enrollment":2310,"conditions":3539,"interventions":3540},"NCT00177242","Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma",[61],[25],[3527],{"trials":3542,"activeCount":71},[],{"trials":3544,"activeCount":71},[],{"trials":3546,"activeCount":71},[],{"intervention":2759,"totalTrials":67,"cells":3548},{"EARLY_PHASE1":3549,"PHASE1":3551,"PHASE2":3553,"PHASE3":3559,"PHASE4":3561,"NA":3563},{"trials":3550,"activeCount":71},[],{"trials":3552,"activeCount":71},[],{"trials":3554,"activeCount":71},[3555],{"nctId":2752,"briefTitle":2753,"status":107,"phases":3556,"primaryCompletion":2755,"completion":2755,"start":2285,"enrollment":632,"conditions":3557,"interventions":3558},[61],[2757],[2759,2735],{"trials":3560,"activeCount":71},[],{"trials":3562,"activeCount":71},[],{"trials":3564,"activeCount":71},[],{"intervention":3566,"totalTrials":67,"cells":3567},"Calcitriol",{"EARLY_PHASE1":3568,"PHASE1":3570,"PHASE2":3572,"PHASE3":3581,"PHASE4":3583,"NA":3585},{"trials":3569,"activeCount":71},[],{"trials":3571,"activeCount":71},[],{"trials":3573,"activeCount":71},[3574],{"nctId":3575,"briefTitle":3576,"status":107,"phases":3577,"primaryCompletion":2213,"completion":2657,"start":1981,"enrollment":410,"conditions":3578,"interventions":3580},"NCT00030069","Calcitriol and Dexamethasone in Patients With Myelodysplastic Syndromes",[61],[3579],"Myelodysplastic Syndromes",[3566,3129],{"trials":3582,"activeCount":71},[],{"trials":3584,"activeCount":71},[],{"trials":3586,"activeCount":71},[],{"intervention":3588,"totalTrials":67,"cells":3589},"doxorubicin and bortezomib",{"EARLY_PHASE1":3590,"PHASE1":3592,"PHASE2":3594,"PHASE3":3603,"PHASE4":3605,"NA":3607},{"trials":3591,"activeCount":71},[],{"trials":3593,"activeCount":71},[],{"trials":3595,"activeCount":71},[3596],{"nctId":3597,"briefTitle":3598,"status":107,"phases":3599,"primaryCompletion":2529,"completion":2529,"start":1285,"enrollment":1755,"conditions":3600,"interventions":3602},"NCT00581360","Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck",[61],[3601],"Adenoid Cystic Carcinoma",[3588],{"trials":3604,"activeCount":71},[],{"trials":3606,"activeCount":71},[],{"trials":3608,"activeCount":71},[],{"intervention":2474,"totalTrials":67,"cells":3610},{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3621,"PHASE4":3623,"NA":3625},{"trials":3612,"activeCount":71},[],{"trials":3614,"activeCount":71},[],{"trials":3616,"activeCount":71},[3617],{"nctId":2465,"briefTitle":2466,"status":107,"phases":3618,"primaryCompletion":2468,"completion":408,"start":507,"enrollment":10,"conditions":3619,"interventions":3620},[61],[2470,2471,2472],[2474,2475],{"trials":3622,"activeCount":71},[],{"trials":3624,"activeCount":71},[],{"trials":3626,"activeCount":71},[],{"intervention":3628,"totalTrials":67,"cells":3629},"Eicosapentaenoic acid",{"EARLY_PHASE1":3630,"PHASE1":3632,"PHASE2":3634,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3631,"activeCount":71},[],{"trials":3633,"activeCount":71},[],{"trials":3635,"activeCount":71},[3636],{"nctId":3637,"briefTitle":3638,"status":107,"phases":3639,"primaryCompletion":3640,"completion":3640,"start":800,"enrollment":3641,"conditions":3642,"interventions":3644},"NCT00167310","Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation",[61],"2015-12",57,[33,707,296,113,3643],"Coronary Artery Disease",[3628],{"trials":3646,"activeCount":71},[],{"trials":3648,"activeCount":71},[],{"trials":3650,"activeCount":71},[],{"intervention":3652,"totalTrials":67,"cells":3653},"amlodipine",{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3658,"PHASE3":3667,"PHASE4":3669,"NA":3671},{"trials":3655,"activeCount":71},[],{"trials":3657,"activeCount":71},[],{"trials":3659,"activeCount":71},[3660],{"nctId":3661,"briefTitle":3662,"status":107,"phases":3663,"completion":1932,"start":339,"enrollment":1262,"conditions":3664,"interventions":3666},"NCT00156403","A Pilot Study of Use of Calcium Channel Blocker to Decrease Inflammation and Pain in Hereditary Pancreatitis",[60,61],[3665],"Pancreatitis",[3652],{"trials":3668,"activeCount":71},[],{"trials":3670,"activeCount":71},[],{"trials":3672,"activeCount":71},[],{"intervention":3674,"totalTrials":67,"cells":3675},"Autologous Dendritic Cell Vaccine",{"EARLY_PHASE1":3676,"PHASE1":3678,"PHASE2":3680,"PHASE3":3690,"PHASE4":3692,"NA":3694},{"trials":3677,"activeCount":71},[],{"trials":3679,"activeCount":71},[],{"trials":3681,"activeCount":71},[3682],{"nctId":3683,"briefTitle":3684,"status":107,"phases":3685,"completion":2213,"start":292,"enrollment":36,"conditions":3686,"interventions":3689},"NCT00099593","Immunization Against Tumor Cells in Sezary Syndrome",[61],[3687,3688],"Cutaneous T-cell Lymphoma","Sezary Syndrome",[3674],{"trials":3691,"activeCount":71},[],{"trials":3693,"activeCount":71},[],{"trials":3695,"activeCount":71},[],{"intervention":3697,"totalTrials":67,"cells":3698},"Sodium Nitrite",{"EARLY_PHASE1":3699,"PHASE1":3701,"PHASE2":3703,"PHASE3":3715,"PHASE4":3717,"NA":3719},{"trials":3700,"activeCount":71},[],{"trials":3702,"activeCount":71},[],{"trials":3704,"activeCount":71},[3705],{"nctId":3706,"briefTitle":3707,"status":107,"phases":3708,"primaryCompletion":3709,"completion":3709,"start":1407,"enrollment":3710,"conditions":3711,"interventions":3714},"NCT03015402","Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction",[61],"2023-01-25",33,[3712,3713],"Pulmonary Hypertension Secondary","Heart Failure",[3697],{"trials":3716,"activeCount":71},[],{"trials":3718,"activeCount":71},[],{"trials":3720,"activeCount":71},[],{"intervention":3722,"totalTrials":67,"cells":3723},"Mycophenolate mofetil",{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3728,"PHASE3":3738,"PHASE4":3740,"NA":3742},{"trials":3725,"activeCount":71},[],{"trials":3727,"activeCount":71},[],{"trials":3729,"activeCount":71},[3730],{"nctId":3731,"briefTitle":3732,"status":107,"phases":3733,"primaryCompletion":408,"completion":3421,"start":1007,"enrollment":31,"conditions":3734,"interventions":3737},"NCT01487577","Pharmacokinetics-based Mycophenolate Mofetil Dosing for GVHD Prevention",[61],[3735,3736],"Allogeneic Blood and Marrow Transplantation (BMT)","Graft Versus Host Disease",[3722],{"trials":3739,"activeCount":71},[],{"trials":3741,"activeCount":71},[],{"trials":3743,"activeCount":71},[],{"intervention":2661,"totalTrials":67,"cells":3745},{"EARLY_PHASE1":3746,"PHASE1":3748,"PHASE2":3750,"PHASE3":3756,"PHASE4":3758,"NA":3760},{"trials":3747,"activeCount":71},[],{"trials":3749,"activeCount":71},[],{"trials":3751,"activeCount":71},[3752],{"nctId":2654,"briefTitle":2655,"status":107,"phases":3753,"primaryCompletion":1330,"completion":756,"start":2657,"enrollment":2658,"conditions":3754,"interventions":3755},[61],[2633],[2661,2661,2662],{"trials":3757,"activeCount":71},[],{"trials":3759,"activeCount":71},[],{"trials":3761,"activeCount":71},[],{"intervention":3763,"totalTrials":67,"cells":3764},"Probenecid and N-acetyl cysteine",{"EARLY_PHASE1":3765,"PHASE1":3767,"PHASE2":3769,"PHASE3":3779,"PHASE4":3781,"NA":3783},{"trials":3766,"activeCount":71},[],{"trials":3768,"activeCount":71},[],{"trials":3770,"activeCount":71},[3771],{"nctId":3772,"briefTitle":3773,"status":107,"phases":3774,"primaryCompletion":3775,"completion":3260,"start":409,"enrollment":874,"conditions":3776,"interventions":3778},"NCT01322009","Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury",[60,61],"2013-12",[3777],"Pediatric Traumatic Brain Injury",[3763],{"trials":3780,"activeCount":71},[],{"trials":3782,"activeCount":71},[],{"trials":3784,"activeCount":71},[],{"intervention":3786,"totalTrials":67,"cells":3787},"5-azacytidine (5-aza) maintenance therapy after transplant",{"EARLY_PHASE1":3788,"PHASE1":3790,"PHASE2":3792,"PHASE3":3803,"PHASE4":3805,"NA":3807},{"trials":3789,"activeCount":71},[],{"trials":3791,"activeCount":71},[],{"trials":3793,"activeCount":71},[3794],{"nctId":3795,"briefTitle":3796,"status":1328,"phases":3797,"primaryCompletion":668,"completion":3798,"start":668,"enrollment":71,"conditions":3799,"interventions":3802},"NCT02204020","Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS",[61],"2016-05-04",[3800,3801],"Acute Myeloid Leukemia (AML)","Myelodysplastic Syndrome (MDS)",[3786],{"trials":3804,"activeCount":71},[],{"trials":3806,"activeCount":71},[],{"trials":3808,"activeCount":71},[],{"intervention":2806,"totalTrials":67,"cells":3810},{"EARLY_PHASE1":3811,"PHASE1":3813,"PHASE2":3815,"PHASE3":3821,"PHASE4":3823,"NA":3825},{"trials":3812,"activeCount":71},[],{"trials":3814,"activeCount":71},[],{"trials":3816,"activeCount":71},[3817],{"nctId":2801,"briefTitle":2802,"status":107,"phases":3818,"primaryCompletion":2213,"completion":2213,"start":1526,"enrollment":155,"conditions":3819,"interventions":3820},[61],[2757],[2463,2806],{"trials":3822,"activeCount":71},[],{"trials":3824,"activeCount":71},[],{"trials":3826,"activeCount":71},[],{"intervention":2842,"totalTrials":67,"cells":3828},{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3833,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3830,"activeCount":71},[],{"trials":3832,"activeCount":71},[],{"trials":3834,"activeCount":71},[3835],{"nctId":2834,"briefTitle":2835,"status":107,"phases":3836,"primaryCompletion":2837,"completion":1261,"start":1123,"enrollment":2838,"conditions":3837,"interventions":3838},[61],[2840],[2842,2843,2814],{"trials":3840,"activeCount":71},[],{"trials":3842,"activeCount":71},[],{"trials":3844,"activeCount":71},[],{"intervention":2843,"totalTrials":67,"cells":3846},{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3851,"PHASE3":3857,"PHASE4":3859,"NA":3861},{"trials":3848,"activeCount":71},[],{"trials":3850,"activeCount":71},[],{"trials":3852,"activeCount":71},[3853],{"nctId":2834,"briefTitle":2835,"status":107,"phases":3854,"primaryCompletion":2837,"completion":1261,"start":1123,"enrollment":2838,"conditions":3855,"interventions":3856},[61],[2840],[2842,2843,2814],{"trials":3858,"activeCount":71},[],{"trials":3860,"activeCount":71},[],{"trials":3862,"activeCount":71},[],{"intervention":2648,"totalTrials":371,"cells":3864},{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3888,"PHASE3":3890,"PHASE4":3892,"NA":3894},{"trials":3866,"activeCount":71},[],{"trials":3868,"activeCount":71},[3869,3878,3882],{"nctId":3870,"briefTitle":3871,"status":107,"phases":3872,"primaryCompletion":3873,"completion":3873,"start":3874,"enrollment":3329,"conditions":3875,"interventions":3877},"NCT00222872","3-Week Parathyroid Hormone-related Protein (PTHrP) Dose Escalation Study in Post-Menopausal Women",[60],"2008-09","2005-07",[2633,3876],"Osteoporosis, Postmenopausal",[2648],{"nctId":2640,"briefTitle":2641,"status":1328,"phases":3879,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":71,"conditions":3880,"interventions":3881},[60],[2633,2646,2635,2634],[2648,2649,2650],{"nctId":3883,"briefTitle":3884,"status":1328,"phases":3885,"primaryCompletion":689,"completion":689,"start":3874,"enrollment":71,"conditions":3886,"interventions":3887},"NCT00177411","\"PTHrP(1-36) IV Dose Escalation Study\"",[60],[2633],[2648],{"trials":3889,"activeCount":71},[],{"trials":3891,"activeCount":71},[],{"trials":3893,"activeCount":71},[],{"trials":3895,"activeCount":71},[],{"intervention":2600,"totalTrials":92,"cells":3897},{"EARLY_PHASE1":3898,"PHASE1":3900,"PHASE2":3914,"PHASE3":3916,"PHASE4":3918,"NA":3920},{"trials":3899,"activeCount":71},[],{"trials":3901,"activeCount":71},[3902,3910],{"nctId":3903,"briefTitle":3904,"status":107,"phases":3905,"primaryCompletion":292,"completion":292,"start":3906,"conditions":3907,"interventions":3909},"NCT00008086","Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors",[60],"1996-01",[3908,2597],"Brain and Central Nervous System Tumors",[2600],{"nctId":2591,"briefTitle":2592,"status":107,"phases":3911,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2096,"conditions":3912,"interventions":3913},[60],[2597],[2599,2600,2601,2602],{"trials":3915,"activeCount":71},[],{"trials":3917,"activeCount":71},[],{"trials":3919,"activeCount":71},[],{"trials":3921,"activeCount":71},[],{"intervention":2507,"totalTrials":92,"cells":3923},{"EARLY_PHASE1":3924,"PHASE1":3926,"PHASE2":3943,"PHASE3":3945,"PHASE4":3947,"NA":3949},{"trials":3925,"activeCount":71},[],{"trials":3927,"activeCount":71},[3928,3932],{"nctId":2498,"briefTitle":2499,"status":107,"phases":3929,"primaryCompletion":2501,"completion":939,"start":2502,"enrollment":2503,"conditions":3930,"interventions":3931},[60],[2505],[2507,1925],{"nctId":3933,"briefTitle":3934,"status":107,"phases":3935,"primaryCompletion":3421,"completion":849,"start":3936,"enrollment":1843,"conditions":3937,"interventions":3940},"NCT00892190","Study of Dasatinib and All-Trans Retinoic Acid for Relapsed\u002FRefractory and\u002For Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome",[60],"2011-04",[3938,3939],"Acute Myelogenous Leukemia","Myelodysplastic Syndrome",[3941,3942],"dasatinib","all trans retinoic acid",{"trials":3944,"activeCount":71},[],{"trials":3946,"activeCount":71},[],{"trials":3948,"activeCount":71},[],{"trials":3950,"activeCount":71},[],{"intervention":3952,"totalTrials":92,"cells":3953},"paclitaxel",{"EARLY_PHASE1":3954,"PHASE1":3956,"PHASE2":3973,"PHASE3":3975,"PHASE4":3977,"NA":3979},{"trials":3955,"activeCount":71},[],{"trials":3957,"activeCount":71},[3958,3965],{"nctId":3959,"briefTitle":3960,"status":107,"phases":3961,"primaryCompletion":724,"completion":724,"start":3962,"enrollment":2310,"conditions":3963,"interventions":3964},"NCT00009802","Calcitriol Plus Paclitaxel in Treating Patients With Advanced Solid Tumors",[60],"1998-06",[2597],[3952],{"nctId":3966,"briefTitle":3967,"status":1328,"phases":3968,"start":350,"enrollment":71,"conditions":3969,"interventions":3970},"NCT00009828","Paclitaxel Combined With Fluorouracil-Uracil and Leucovorin in Treating Patients With Solid Tumors",[60],[2597],[3971,3952,3972],"leucovorin calcium","tegafur-uracil",{"trials":3974,"activeCount":71},[],{"trials":3976,"activeCount":71},[],{"trials":3978,"activeCount":71},[],{"trials":3980,"activeCount":71},[],{"intervention":3982,"totalTrials":92,"cells":3983},"etoposide",{"EARLY_PHASE1":3984,"PHASE1":3986,"PHASE2":4003,"PHASE3":4005,"PHASE4":4007,"NA":4009},{"trials":3985,"activeCount":71},[],{"trials":3987,"activeCount":71},[3988,3994],{"nctId":3989,"briefTitle":3990,"status":1328,"phases":3991,"start":350,"enrollment":71,"conditions":3992,"interventions":3993},"NCT00009815","Combination Chemotherapy in Treating Patients With Advanced Solid Tumors",[60],[2597],[3982,3971,3972],{"nctId":3995,"briefTitle":3996,"status":389,"phases":3997,"primaryCompletion":3936,"completion":3936,"start":3873,"enrollment":2144,"conditions":3998,"interventions":3999},"NCT00660036","Phase I\u002FII Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia",[60],[3262],[4000,4001,4002],"Gemtuzumab ozogamicin","Mitoxantrone","Etoposide",{"trials":4004,"activeCount":71},[],{"trials":4006,"activeCount":71},[],{"trials":4008,"activeCount":71},[],{"trials":4010,"activeCount":71},[],{"intervention":3971,"totalTrials":92,"cells":4012},{"EARLY_PHASE1":4013,"PHASE1":4015,"PHASE2":4025,"PHASE3":4027,"PHASE4":4029,"NA":4031},{"trials":4014,"activeCount":71},[],{"trials":4016,"activeCount":71},[4017,4021],{"nctId":3989,"briefTitle":3990,"status":1328,"phases":4018,"start":350,"enrollment":71,"conditions":4019,"interventions":4020},[60],[2597],[3982,3971,3972],{"nctId":3966,"briefTitle":3967,"status":1328,"phases":4022,"start":350,"enrollment":71,"conditions":4023,"interventions":4024},[60],[2597],[3971,3952,3972],{"trials":4026,"activeCount":71},[],{"trials":4028,"activeCount":71},[],{"trials":4030,"activeCount":71},[],{"trials":4032,"activeCount":71},[],{"intervention":3972,"totalTrials":92,"cells":4034},{"EARLY_PHASE1":4035,"PHASE1":4037,"PHASE2":4047,"PHASE3":4049,"PHASE4":4051,"NA":4053},{"trials":4036,"activeCount":71},[],{"trials":4038,"activeCount":71},[4039,4043],{"nctId":3989,"briefTitle":3990,"status":1328,"phases":4040,"start":350,"enrollment":71,"conditions":4041,"interventions":4042},[60],[2597],[3982,3971,3972],{"nctId":3966,"briefTitle":3967,"status":1328,"phases":4044,"start":350,"enrollment":71,"conditions":4045,"interventions":4046},[60],[2597],[3971,3952,3972],{"trials":4048,"activeCount":71},[],{"trials":4050,"activeCount":71},[],{"trials":4052,"activeCount":71},[],{"trials":4054,"activeCount":71},[],{"intervention":2602,"totalTrials":92,"cells":4056},{"EARLY_PHASE1":4057,"PHASE1":4059,"PHASE2":4072,"PHASE3":4074,"PHASE4":4076,"NA":4078},{"trials":4058,"activeCount":71},[],{"trials":4060,"activeCount":71},[4061,4068],{"nctId":4062,"briefTitle":4063,"status":1328,"phases":4064,"start":508,"enrollment":71,"conditions":4065,"interventions":4067},"NCT00014287","Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer",[60],[4066],"Bladder Cancer",[2602],{"nctId":2591,"briefTitle":2592,"status":107,"phases":4069,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2096,"conditions":4070,"interventions":4071},[60],[2597],[2599,2600,2601,2602],{"trials":4073,"activeCount":71},[],{"trials":4075,"activeCount":71},[],{"trials":4077,"activeCount":71},[],{"trials":4079,"activeCount":71},[],{"intervention":4081,"totalTrials":92,"cells":4082},"EGFR antisense DNA",{"EARLY_PHASE1":4083,"PHASE1":4085,"PHASE2":4107,"PHASE3":4109,"PHASE4":4111,"NA":4113},{"trials":4084,"activeCount":71},[],{"trials":4086,"activeCount":71},[4087,4097],{"nctId":4088,"briefTitle":4089,"status":107,"phases":4090,"primaryCompletion":4091,"completion":4091,"start":340,"enrollment":4092,"conditions":4093,"interventions":4094},"NCT00009841","Gene Therapy in Treating Patients With Advanced Head and Neck Cancer",[60],"2002-03",13,[2513],[4081,4095,4096],"growth factor antagonist therapy","DC-cholesterol liposome",{"nctId":4098,"briefTitle":4099,"status":389,"phases":4100,"primaryCompletion":3260,"completion":381,"start":2886,"enrollment":393,"conditions":4101,"interventions":4105},"NCT00903461","Safety and Efficacy of Radiation\u002FCetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma",[60],[4102,4103,4104],"Carcinoma, Squamous Cell of Head and Neck","Squamous Cell Carcinoma of the Head and Neck","Squamous Cell Carcinoma, Head And Neck",[4106],"EGFR Antisense DNA",{"trials":4108,"activeCount":71},[],{"trials":4110,"activeCount":71},[],{"trials":4112,"activeCount":71},[],{"trials":4114,"activeCount":71},[],{"intervention":4116,"totalTrials":92,"cells":4117},"Erlotinib",{"EARLY_PHASE1":4118,"PHASE1":4120,"PHASE2":4141,"PHASE3":4143,"PHASE4":4145,"NA":4147},{"trials":4119,"activeCount":71},[],{"trials":4121,"activeCount":71},[4122,4132],{"nctId":4123,"briefTitle":4124,"status":107,"phases":4125,"primaryCompletion":3328,"completion":3328,"start":1239,"enrollment":4126,"conditions":4127,"interventions":4129},"NCT00779389","Comparison of Biomarker Modulation by Inhibition of EGFR and\u002For SRC Family",[60],58,[2513,4128],"Non Small Cell Lung Cancer",[4116,4130,4131,4116],"Dasatinib + Placebo","Erlotinib plus Dasatinib",{"nctId":4133,"briefTitle":4134,"status":107,"phases":4135,"primaryCompletion":897,"completion":897,"start":1286,"enrollment":4136,"conditions":4137,"interventions":4139},"NCT01515137","Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma",[60],47,[4138],"Head and Neck Squamous Cell Carcinoma",[4116,4140],"Erlotinib plus sulindac",{"trials":4142,"activeCount":71},[],{"trials":4144,"activeCount":71},[],{"trials":4146,"activeCount":71},[],{"trials":4148,"activeCount":71},[],{"intervention":4150,"totalTrials":67,"cells":4151},"SSRI",{"EARLY_PHASE1":4152,"PHASE1":4154,"PHASE2":4163,"PHASE3":4165,"PHASE4":4167,"NA":4169},{"trials":4153,"activeCount":71},[],{"trials":4155,"activeCount":71},[4156],{"nctId":4157,"briefTitle":4158,"status":107,"phases":4159,"primaryCompletion":2480,"completion":2480,"start":1008,"enrollment":4160,"conditions":4161,"interventions":4162},"NCT00787501","Imaging Antidepressant vs. Cognitive Behavior Therapy Effects on Unipolar Depression",[60],98,[434],[4150],{"trials":4164,"activeCount":71},[],{"trials":4166,"activeCount":71},[],{"trials":4168,"activeCount":71},[],{"trials":4170,"activeCount":71},[],{"intervention":2685,"totalTrials":67,"cells":4172},{"EARLY_PHASE1":4173,"PHASE1":4175,"PHASE2":4181,"PHASE3":4183,"PHASE4":4185,"NA":4187},{"trials":4174,"activeCount":71},[],{"trials":4176,"activeCount":71},[4177],{"nctId":2677,"briefTitle":2678,"status":389,"phases":4178,"primaryCompletion":1098,"completion":2680,"start":1098,"enrollment":2681,"conditions":4179,"interventions":4180},[60],[2683],[2685,2670],{"trials":4182,"activeCount":71},[],{"trials":4184,"activeCount":71},[],{"trials":4186,"activeCount":71},[],{"trials":4188,"activeCount":71},[],{"intervention":4190,"totalTrials":67,"cells":4191},"Pre-operative cefazolin",{"EARLY_PHASE1":4192,"PHASE1":4194,"PHASE2":4203,"PHASE3":4205,"PHASE4":4207,"NA":4209},{"trials":4193,"activeCount":71},[],{"trials":4195,"activeCount":71},[4196],{"nctId":4197,"briefTitle":4198,"status":107,"phases":4199,"primaryCompletion":382,"completion":382,"start":4200,"enrollment":1215,"conditions":4201,"interventions":4202},"NCT01904500","Peri-operative Cefazolin Prophylaxis at Time of Cesarean Delivery in the Obese Gravida",[60],"2013-08",[19,3331],[4190],{"trials":4204,"activeCount":71},[],{"trials":4206,"activeCount":71},[],{"trials":4208,"activeCount":71},[],{"trials":4210,"activeCount":71},[],{"intervention":4212,"totalTrials":67,"cells":4213},"motexafin gadolinium",{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4228,"PHASE3":4230,"PHASE4":4232,"NA":4234},{"trials":4215,"activeCount":71},[],{"trials":4217,"activeCount":71},[4218],{"nctId":4219,"briefTitle":4220,"status":107,"phases":4221,"primaryCompletion":4222,"completion":4222,"start":4223,"conditions":4224,"interventions":4227},"NCT00003411","Radiation Therapy in Treating Patients With Bile Duct, Gallbladder, or Pancreatic Cancer",[60],"2002-06","1998-11",[4225,4226,2683],"Extrahepatic Bile Duct Cancer","Gallbladder Cancer",[4212],{"trials":4229,"activeCount":71},[],{"trials":4231,"activeCount":71},[],{"trials":4233,"activeCount":71},[],{"trials":4235,"activeCount":71},[],{"intervention":4237,"totalTrials":67,"cells":4238},"Ravicti",{"EARLY_PHASE1":4239,"PHASE1":4241,"PHASE2":4251,"PHASE3":4253,"PHASE4":4255,"NA":4257},{"trials":4240,"activeCount":71},[],{"trials":4242,"activeCount":71},[4243],{"nctId":4244,"briefTitle":4245,"status":107,"phases":4246,"primaryCompletion":849,"completion":849,"start":4247,"enrollment":323,"conditions":4248,"interventions":4250},"NCT01881984","Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation",[60],"2013-06",[4249],"Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency",[4237],{"trials":4252,"activeCount":71},[],{"trials":4254,"activeCount":71},[],{"trials":4256,"activeCount":71},[],{"trials":4258,"activeCount":71},[],{"intervention":4260,"totalTrials":67,"cells":4261},"doxorubicin hydrochloride",{"EARLY_PHASE1":4262,"PHASE1":4264,"PHASE2":4273,"PHASE3":4275,"PHASE4":4277,"NA":4279},{"trials":4263,"activeCount":71},[],{"trials":4265,"activeCount":71},[4266],{"nctId":4267,"briefTitle":4268,"status":107,"phases":4269,"primaryCompletion":2238,"completion":2238,"start":3906,"conditions":4270,"interventions":4271},"NCT00008073","Octreotide and Doxorubicin in Treating Patients With Advanced Cancer",[60],[2597],[4260,4272],"octreotide acetate",{"trials":4274,"activeCount":71},[],{"trials":4276,"activeCount":71},[],{"trials":4278,"activeCount":71},[],{"trials":4280,"activeCount":71},[],{"intervention":4272,"totalTrials":67,"cells":4282},{"EARLY_PHASE1":4283,"PHASE1":4285,"PHASE2":4291,"PHASE3":4293,"PHASE4":4295,"NA":4297},{"trials":4284,"activeCount":71},[],{"trials":4286,"activeCount":71},[4287],{"nctId":4267,"briefTitle":4268,"status":107,"phases":4288,"primaryCompletion":2238,"completion":2238,"start":3906,"conditions":4289,"interventions":4290},[60],[2597],[4260,4272],{"trials":4292,"activeCount":71},[],{"trials":4294,"activeCount":71},[],{"trials":4296,"activeCount":71},[],{"trials":4298,"activeCount":71},[],{"intervention":4300,"totalTrials":67,"cells":4301},"intravenous docetaxel with intraperitoneal oxaliplatin",{"EARLY_PHASE1":4302,"PHASE1":4304,"PHASE2":4314,"PHASE3":4316,"PHASE4":4318,"NA":4320},{"trials":4303,"activeCount":71},[],{"trials":4305,"activeCount":71},[4306],{"nctId":4307,"briefTitle":4308,"status":107,"phases":4309,"primaryCompletion":4247,"completion":2434,"start":2613,"enrollment":2096,"conditions":4310,"interventions":4312},"NCT00692900","Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer",[60],[2470,4311,2471],"Peritoneal Cancer",[4300,4313],"intravenous oxaliplatin with intraperitoneal docetaxel",{"trials":4315,"activeCount":71},[],{"trials":4317,"activeCount":71},[],{"trials":4319,"activeCount":71},[],{"trials":4321,"activeCount":71},[],{"intervention":4313,"totalTrials":67,"cells":4323},{"EARLY_PHASE1":4324,"PHASE1":4326,"PHASE2":4332,"PHASE3":4334,"PHASE4":4336,"NA":4338},{"trials":4325,"activeCount":71},[],{"trials":4327,"activeCount":71},[4328],{"nctId":4307,"briefTitle":4308,"status":107,"phases":4329,"primaryCompletion":4247,"completion":2434,"start":2613,"enrollment":2096,"conditions":4330,"interventions":4331},[60],[2470,4311,2471],[4300,4313],{"trials":4333,"activeCount":71},[],{"trials":4335,"activeCount":71},[],{"trials":4337,"activeCount":71},[],{"trials":4339,"activeCount":71},[],{"intervention":2563,"totalTrials":67,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4350,"PHASE3":4352,"PHASE4":4354,"NA":4356},{"trials":4343,"activeCount":71},[],{"trials":4345,"activeCount":71},[4346],{"nctId":2556,"briefTitle":2557,"status":389,"phases":4347,"primaryCompletion":2559,"completion":2559,"start":2501,"enrollment":1100,"conditions":4348,"interventions":4349},[60],[2561],[2563,2437],{"trials":4351,"activeCount":71},[],{"trials":4353,"activeCount":71},[],{"trials":4355,"activeCount":71},[],{"trials":4357,"activeCount":71},[],{"intervention":3942,"totalTrials":67,"cells":4359},{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4361,"activeCount":71},[],{"trials":4363,"activeCount":71},[4364],{"nctId":3933,"briefTitle":3934,"status":107,"phases":4365,"primaryCompletion":3421,"completion":849,"start":3936,"enrollment":1843,"conditions":4366,"interventions":4367},[60],[3938,3939],[3941,3942],{"trials":4369,"activeCount":71},[],{"trials":4371,"activeCount":71},[],{"trials":4373,"activeCount":71},[],{"trials":4375,"activeCount":71},[],{"intervention":2713,"totalTrials":67,"cells":4377},{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4386,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4379,"activeCount":71},[],{"trials":4381,"activeCount":71},[4382],{"nctId":2706,"briefTitle":2707,"status":1328,"phases":4383,"primaryCompletion":2709,"completion":2709,"start":2709,"enrollment":71,"conditions":4384,"interventions":4385},[60],[2711],[2699,2713,2714],{"trials":4387,"activeCount":71},[],{"trials":4389,"activeCount":71},[],{"trials":4391,"activeCount":71},[],{"trials":4393,"activeCount":71},[],{"intervention":2714,"totalTrials":67,"cells":4395},{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4404,"PHASE3":4406,"PHASE4":4408,"NA":4410},{"trials":4397,"activeCount":71},[],{"trials":4399,"activeCount":71},[4400],{"nctId":2706,"briefTitle":2707,"status":1328,"phases":4401,"primaryCompletion":2709,"completion":2709,"start":2709,"enrollment":71,"conditions":4402,"interventions":4403},[60],[2711],[2699,2713,2714],{"trials":4405,"activeCount":71},[],{"trials":4407,"activeCount":71},[],{"trials":4409,"activeCount":71},[],{"trials":4411,"activeCount":71},[],{"intervention":657,"totalTrials":67,"cells":4413},{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4422,"PHASE3":4424,"PHASE4":4426,"NA":4428},{"trials":4415,"activeCount":71},[],{"trials":4417,"activeCount":71},[4418],{"nctId":646,"briefTitle":647,"status":107,"phases":4419,"primaryCompletion":649,"completion":649,"start":650,"enrollment":410,"conditions":4420,"interventions":4421},[60],[652,653,654],[656,639,657],{"trials":4423,"activeCount":71},[],{"trials":4425,"activeCount":71},[],{"trials":4427,"activeCount":71},[],{"trials":4429,"activeCount":71},[],{"intervention":4095,"totalTrials":67,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4446},{"trials":4433,"activeCount":71},[],{"trials":4435,"activeCount":71},[4436],{"nctId":4088,"briefTitle":4089,"status":107,"phases":4437,"primaryCompletion":4091,"completion":4091,"start":340,"enrollment":4092,"conditions":4438,"interventions":4439},[60],[2513],[4081,4095,4096],{"trials":4441,"activeCount":71},[],{"trials":4443,"activeCount":71},[],{"trials":4445,"activeCount":71},[],{"trials":4447,"activeCount":71},[],{"intervention":4096,"totalTrials":67,"cells":4449},{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4451,"activeCount":71},[],{"trials":4453,"activeCount":71},[4454],{"nctId":4088,"briefTitle":4089,"status":107,"phases":4455,"primaryCompletion":4091,"completion":4091,"start":340,"enrollment":4092,"conditions":4456,"interventions":4457},[60],[2513],[4081,4095,4096],{"trials":4459,"activeCount":71},[],{"trials":4461,"activeCount":71},[],{"trials":4463,"activeCount":71},[],{"trials":4465,"activeCount":71},[],{"intervention":4467,"totalTrials":67,"cells":4468},"MUC1 antigen\u002FSB AS-2",{"EARLY_PHASE1":4469,"PHASE1":4471,"PHASE2":4481,"PHASE3":4483,"PHASE4":4485,"NA":4487},{"trials":4470,"activeCount":71},[],{"trials":4472,"activeCount":71},[4473],{"nctId":4474,"briefTitle":4475,"status":107,"phases":4476,"primaryCompletion":4477,"completion":2594,"start":4478,"enrollment":2096,"conditions":4479,"interventions":4480},"NCT00008099","Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer",[60],"2001-03","1998-05",[2683],[4467],{"trials":4482,"activeCount":71},[],{"trials":4484,"activeCount":71},[],{"trials":4486,"activeCount":71},[],{"trials":4488,"activeCount":71},[],{"intervention":4490,"totalTrials":67,"cells":4491},"autologous monocyte-derived dendritic cells (DC) transfected with DNA",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4503,"PHASE3":4505,"PHASE4":4507,"NA":4509},{"trials":4493,"activeCount":71},[],{"trials":4495,"activeCount":71},[4496],{"nctId":4497,"briefTitle":4498,"status":389,"phases":4499,"primaryCompletion":824,"completion":824,"start":824,"enrollment":2144,"conditions":4500,"interventions":4502},"NCT00377247","Active Immunization of Patients With Carcinoma of Oral Cavity or Oropharynx With Autologous Dendritic Cells Transfected With DNA From Autologous Tumor",[60],[4501,4103],"Primary Advanced Carcinoma of the Oral Cavity or Oropharynx",[4490],{"trials":4504,"activeCount":71},[],{"trials":4506,"activeCount":71},[],{"trials":4508,"activeCount":71},[],{"trials":4510,"activeCount":71},[],{"intervention":4512,"totalTrials":67,"cells":4513},"Antacids",{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4526,"PHASE3":4528,"PHASE4":4530,"NA":4532},{"trials":4515,"activeCount":71},[],{"trials":4517,"activeCount":71},[4518],{"nctId":4519,"briefTitle":4520,"status":107,"phases":4521,"primaryCompletion":2189,"completion":2189,"start":3491,"enrollment":1100,"conditions":4522,"interventions":4524},"NCT00446316","Effect of Antacids on Gleevec® in Healthy Volunteers",[60],[4523],"Healthy",[4512,4525],"Imatimib Mesylate",{"trials":4527,"activeCount":71},[],{"trials":4529,"activeCount":71},[],{"trials":4531,"activeCount":71},[],{"trials":4533,"activeCount":71},[],{"intervention":4525,"totalTrials":67,"cells":4535},{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4544,"PHASE3":4546,"PHASE4":4548,"NA":4550},{"trials":4537,"activeCount":71},[],{"trials":4539,"activeCount":71},[4540],{"nctId":4519,"briefTitle":4520,"status":107,"phases":4541,"primaryCompletion":2189,"completion":2189,"start":3491,"enrollment":1100,"conditions":4542,"interventions":4543},[60],[4523],[4512,4525],{"trials":4545,"activeCount":71},[],{"trials":4547,"activeCount":71},[],{"trials":4549,"activeCount":71},[],{"trials":4551,"activeCount":71},[],{"intervention":4553,"totalTrials":67,"cells":4554},"Minocycline",{"EARLY_PHASE1":4555,"PHASE1":4557,"PHASE2":4568,"PHASE3":4570,"PHASE4":4572,"NA":4574},{"trials":4556,"activeCount":71},[],{"trials":4558,"activeCount":71},[4559],{"nctId":4560,"briefTitle":4561,"status":389,"phases":4562,"primaryCompletion":4563,"completion":4563,"start":4564,"enrollment":67,"conditions":4565,"interventions":4567},"NCT02201563","Minocycline Therapy for Management of Adverse Radiation Effects",[60],"2018-05-31","2015-11",[4566],"Irradiation; Adverse Effect",[4553],{"trials":4569,"activeCount":71},[],{"trials":4571,"activeCount":71},[],{"trials":4573,"activeCount":71},[],{"trials":4575,"activeCount":71},[],{"intervention":4577,"totalTrials":67,"cells":4578},"Oseltamivir",{"EARLY_PHASE1":4579,"PHASE1":4581,"PHASE2":4589,"PHASE3":4591,"PHASE4":4593,"NA":4595},{"trials":4580,"activeCount":71},[],{"trials":4582,"activeCount":71},[4583],{"nctId":4584,"briefTitle":4585,"status":1328,"phases":4586,"primaryCompletion":507,"completion":507,"start":824,"enrollment":71,"conditions":4587,"interventions":4588},"NCT00873886","A Study of the Pharmacology of Oseltamivir (Tamiflu) in Pregnancy",[60],[3331,966],[4577],{"trials":4590,"activeCount":71},[],{"trials":4592,"activeCount":71},[],{"trials":4594,"activeCount":71},[],{"trials":4596,"activeCount":71},[],{"intervention":4598,"totalTrials":67,"cells":4599},"S CKD602",{"EARLY_PHASE1":4600,"PHASE1":4602,"PHASE2":4611,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4601,"activeCount":71},[],{"trials":4603,"activeCount":71},[4604],{"nctId":4605,"briefTitle":4606,"status":107,"phases":4607,"primaryCompletion":690,"completion":690,"start":4608,"enrollment":2310,"conditions":4609,"interventions":4610},"NCT00177281","Safety Study of S-CKD602 in Patients With Advanced Malignancies",[60],"2003-09",[25],[4598],{"trials":4612,"activeCount":71},[],{"trials":4614,"activeCount":71},[],{"trials":4616,"activeCount":71},[],{"trials":4618,"activeCount":71},[],{"intervention":4620,"totalTrials":67,"cells":4621},"- Lyc-O-Mato",{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4634,"PHASE3":4636,"PHASE4":4638,"NA":4640},{"trials":4623,"activeCount":71},[],{"trials":4625,"activeCount":71},[4626],{"nctId":4627,"briefTitle":4628,"status":107,"phases":4629,"completion":571,"start":1550,"enrollment":2442,"conditions":4630,"interventions":4632},"NCT00178113","A Pilot Study of Lycopene Supplementation in Prostatic Intraepithelial Neoplasia",[60],[4631],"Prostatic Intraepithelial Neoplasia",[4620,4633],"- Certagen",{"trials":4635,"activeCount":71},[],{"trials":4637,"activeCount":71},[],{"trials":4639,"activeCount":71},[],{"trials":4641,"activeCount":71},[],{"intervention":4633,"totalTrials":67,"cells":4643},{"EARLY_PHASE1":4644,"PHASE1":4646,"PHASE2":4652,"PHASE3":4654,"PHASE4":4656,"NA":4658},{"trials":4645,"activeCount":71},[],{"trials":4647,"activeCount":71},[4648],{"nctId":4627,"briefTitle":4628,"status":107,"phases":4649,"completion":571,"start":1550,"enrollment":2442,"conditions":4650,"interventions":4651},[60],[4631],[4620,4633],{"trials":4653,"activeCount":71},[],{"trials":4655,"activeCount":71},[],{"trials":4657,"activeCount":71},[],{"trials":4659,"activeCount":71},[],{"intervention":4000,"totalTrials":67,"cells":4661},{"EARLY_PHASE1":4662,"PHASE1":4664,"PHASE2":4670,"PHASE3":4672,"PHASE4":4674,"NA":4676},{"trials":4663,"activeCount":71},[],{"trials":4665,"activeCount":71},[4666],{"nctId":3995,"briefTitle":3996,"status":389,"phases":4667,"primaryCompletion":3936,"completion":3936,"start":3873,"enrollment":2144,"conditions":4668,"interventions":4669},[60],[3262],[4000,4001,4002],{"trials":4671,"activeCount":71},[],{"trials":4673,"activeCount":71},[],{"trials":4675,"activeCount":71},[],{"trials":4677,"activeCount":71},[],{"intervention":4001,"totalTrials":67,"cells":4679},{"EARLY_PHASE1":4680,"PHASE1":4682,"PHASE2":4688,"PHASE3":4690,"PHASE4":4692,"NA":4694},{"trials":4681,"activeCount":71},[],{"trials":4683,"activeCount":71},[4684],{"nctId":3995,"briefTitle":3996,"status":389,"phases":4685,"primaryCompletion":3936,"completion":3936,"start":3873,"enrollment":2144,"conditions":4686,"interventions":4687},[60],[3262],[4000,4001,4002],{"trials":4689,"activeCount":71},[],{"trials":4691,"activeCount":71},[],{"trials":4693,"activeCount":71},[],{"trials":4695,"activeCount":71},[],{"intervention":4697,"totalTrials":67,"cells":4698},"Cyclosporine",{"EARLY_PHASE1":4699,"PHASE1":4701,"PHASE2":4709,"PHASE3":4711,"PHASE4":4713,"NA":4715},{"trials":4700,"activeCount":71},[],{"trials":4702,"activeCount":71},[4703],{"nctId":4704,"briefTitle":4705,"status":107,"phases":4706,"primaryCompletion":279,"completion":279,"start":270,"enrollment":1262,"conditions":4707,"interventions":4708},"NCT00783107","Aerosol Cyclosporine in Chronic Obstructive Pulmonary Disease (COPD)",[60],[1217],[4697],{"trials":4710,"activeCount":71},[],{"trials":4712,"activeCount":71},[],{"trials":4714,"activeCount":71},[],{"trials":4716,"activeCount":71},[],{"intervention":4130,"totalTrials":67,"cells":4718},{"EARLY_PHASE1":4719,"PHASE1":4721,"PHASE2":4727,"PHASE3":4729,"PHASE4":4731,"NA":4733},{"trials":4720,"activeCount":71},[],{"trials":4722,"activeCount":71},[4723],{"nctId":4123,"briefTitle":4124,"status":107,"phases":4724,"primaryCompletion":3328,"completion":3328,"start":1239,"enrollment":4126,"conditions":4725,"interventions":4726},[60],[2513,4128],[4116,4130,4131,4116],{"trials":4728,"activeCount":71},[],{"trials":4730,"activeCount":71},[],{"trials":4732,"activeCount":71},[],{"trials":4734,"activeCount":71},[],{"intervention":4131,"totalTrials":67,"cells":4736},{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4745,"PHASE3":4747,"PHASE4":4749,"NA":4751},{"trials":4738,"activeCount":71},[],{"trials":4740,"activeCount":71},[4741],{"nctId":4123,"briefTitle":4124,"status":107,"phases":4742,"primaryCompletion":3328,"completion":3328,"start":1239,"enrollment":4126,"conditions":4743,"interventions":4744},[60],[2513,4128],[4116,4130,4131,4116],{"trials":4746,"activeCount":71},[],{"trials":4748,"activeCount":71},[],{"trials":4750,"activeCount":71},[],{"trials":4752,"activeCount":71},[],{"intervention":4754,"totalTrials":67,"cells":4755},"L-citrulline",{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4768,"PHASE3":4770,"PHASE4":4772,"NA":4774},{"trials":4757,"activeCount":71},[],{"trials":4759,"activeCount":71},[4760],{"nctId":4761,"briefTitle":4762,"status":107,"phases":4763,"primaryCompletion":4247,"completion":4247,"start":2048,"enrollment":4764,"conditions":4765,"interventions":4767},"NCT00743210","Oral L-Citrulline and ADMA in Pregnancy",[60],41,[4766],"Blood Pressure",[4754],{"trials":4769,"activeCount":71},[],{"trials":4771,"activeCount":71},[],{"trials":4773,"activeCount":71},[],{"trials":4775,"activeCount":71},[],{"intervention":4777,"totalTrials":67,"cells":4778},"inhaled hypertonic saline",{"EARLY_PHASE1":4779,"PHASE1":4781,"PHASE2":4791,"PHASE3":4793,"PHASE4":4795,"NA":4797},{"trials":4780,"activeCount":71},[],{"trials":4782,"activeCount":71},[4783],{"nctId":4784,"briefTitle":4785,"status":107,"phases":4786,"primaryCompletion":4787,"completion":4787,"start":670,"enrollment":1100,"conditions":4788,"interventions":4790},"NCT02141191","A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device",[60],"2015-10",[4789],"Cystic Fibrosis",[4777],{"trials":4792,"activeCount":71},[],{"trials":4794,"activeCount":71},[],{"trials":4796,"activeCount":71},[],{"trials":4798,"activeCount":71},[],{"intervention":2599,"totalTrials":67,"cells":4800},{"EARLY_PHASE1":4801,"PHASE1":4803,"PHASE2":4809,"PHASE3":4811,"PHASE4":4813,"NA":4815},{"trials":4802,"activeCount":71},[],{"trials":4804,"activeCount":71},[4805],{"nctId":2591,"briefTitle":2592,"status":107,"phases":4806,"primaryCompletion":2594,"completion":2594,"start":2595,"enrollment":2096,"conditions":4807,"interventions":4808},[60],[2597],[2599,2600,2601,2602],{"trials":4810,"activeCount":71},[],{"trials":4812,"activeCount":71},[],{"trials":4814,"activeCount":71},[],{"trials":4816,"activeCount":71},[],{"intervention":4818,"totalTrials":67,"cells":4819},"Administration of minocycline",{"EARLY_PHASE1":4820,"PHASE1":4822,"PHASE2":4831,"PHASE3":4833,"PHASE4":4835,"NA":4837},{"trials":4821,"activeCount":71},[],{"trials":4823,"activeCount":71},[4824],{"nctId":4825,"briefTitle":4826,"status":389,"phases":4827,"primaryCompletion":441,"completion":441,"start":3446,"enrollment":12,"conditions":4828,"interventions":4830},"NCT02178813","The Safety of High Dose Minocycline in the Patient Population Undergoing Carotid Revascularization",[60],[4829],"Stroke",[4818],{"trials":4832,"activeCount":71},[],{"trials":4834,"activeCount":71},[],{"trials":4836,"activeCount":71},[],{"trials":4838,"activeCount":71},[],{"intervention":4840,"totalTrials":67,"cells":4841},"Imatinib Mesylate",{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4853,"PHASE3":4855,"PHASE4":4857,"NA":4859},{"trials":4843,"activeCount":71},[],{"trials":4845,"activeCount":71},[4846],{"nctId":4847,"briefTitle":4848,"status":107,"phases":4849,"primaryCompletion":303,"completion":303,"start":3491,"enrollment":3353,"conditions":4850,"interventions":4851},"NCT00446004","Effect of a Proton Pump Inhibitor on Gleevec® in Healthy Volunteers",[60],[4523],[4840,4852],"Omeprazole",{"trials":4854,"activeCount":71},[],{"trials":4856,"activeCount":71},[],{"trials":4858,"activeCount":71},[],{"trials":4860,"activeCount":71},[],{"intervention":4852,"totalTrials":67,"cells":4862},{"EARLY_PHASE1":4863,"PHASE1":4865,"PHASE2":4871,"PHASE3":4873,"PHASE4":4875,"NA":4877},{"trials":4864,"activeCount":71},[],{"trials":4866,"activeCount":71},[4867],{"nctId":4847,"briefTitle":4848,"status":107,"phases":4868,"primaryCompletion":303,"completion":303,"start":3491,"enrollment":3353,"conditions":4869,"interventions":4870},[60],[4523],[4840,4852],{"trials":4872,"activeCount":71},[],{"trials":4874,"activeCount":71},[],{"trials":4876,"activeCount":71},[],{"trials":4878,"activeCount":71},[],{"intervention":4880,"totalTrials":67,"cells":4881},"Diabetes-suppressive dendritic cell vaccine",{"EARLY_PHASE1":4882,"PHASE1":4884,"PHASE2":4894,"PHASE3":4896,"PHASE4":4898,"NA":4900},{"trials":4883,"activeCount":71},[],{"trials":4885,"activeCount":71},[4886],{"nctId":4887,"briefTitle":4888,"status":107,"phases":4889,"primaryCompletion":2755,"completion":849,"start":470,"enrollment":1755,"conditions":4890,"interventions":4892},"NCT00445913","Autologous Dendritic Cell Therapy for Type 1 Diabetes Suppression: A Safety Study",[60],[4891],"Type 1 Diabetes",[4880,4893],"control dendritic cells",{"trials":4895,"activeCount":71},[],{"trials":4897,"activeCount":71},[],{"trials":4899,"activeCount":71},[],{"trials":4901,"activeCount":71},[],{"intervention":4893,"totalTrials":67,"cells":4903},{"EARLY_PHASE1":4904,"PHASE1":4906,"PHASE2":4912,"PHASE3":4914,"PHASE4":4916,"NA":4918},{"trials":4905,"activeCount":71},[],{"trials":4907,"activeCount":71},[4908],{"nctId":4887,"briefTitle":4888,"status":107,"phases":4909,"primaryCompletion":2755,"completion":849,"start":470,"enrollment":1755,"conditions":4910,"interventions":4911},[60],[4891],[4880,4893],{"trials":4913,"activeCount":71},[],{"trials":4915,"activeCount":71},[],{"trials":4917,"activeCount":71},[],{"trials":4919,"activeCount":71},[],{"intervention":2650,"totalTrials":67,"cells":4921},{"EARLY_PHASE1":4922,"PHASE1":4924,"PHASE2":4930,"PHASE3":4932,"PHASE4":4934,"NA":4936},{"trials":4923,"activeCount":71},[],{"trials":4925,"activeCount":71},[4926],{"nctId":2640,"briefTitle":2641,"status":1328,"phases":4927,"primaryCompletion":2643,"completion":2643,"start":2644,"enrollment":71,"conditions":4928,"interventions":4929},[60],[2633,2646,2635,2634],[2648,2649,2650],{"trials":4931,"activeCount":71},[],{"trials":4933,"activeCount":71},[],{"trials":4935,"activeCount":71},[],{"trials":4937,"activeCount":71},[],{"intervention":4140,"totalTrials":67,"cells":4939},{"EARLY_PHASE1":4940,"PHASE1":4942,"PHASE2":4948,"PHASE3":4950,"PHASE4":4952,"NA":4954},{"trials":4941,"activeCount":71},[],{"trials":4943,"activeCount":71},[4944],{"nctId":4133,"briefTitle":4134,"status":107,"phases":4945,"primaryCompletion":897,"completion":897,"start":1286,"enrollment":4136,"conditions":4946,"interventions":4947},[60],[4138],[4116,4140],{"trials":4949,"activeCount":71},[],{"trials":4951,"activeCount":71},[],{"trials":4953,"activeCount":71},[],{"trials":4955,"activeCount":71},[],{"intervention":4957,"totalTrials":67,"cells":4958},"hypertonic saline",{"EARLY_PHASE1":4959,"PHASE1":4961,"PHASE2":4971,"PHASE3":4973,"PHASE4":4975,"NA":4977},{"trials":4960,"activeCount":71},[],{"trials":4962,"activeCount":71},[4963],{"nctId":4964,"briefTitle":4965,"status":107,"phases":4966,"primaryCompletion":4967,"completion":4967,"start":507,"enrollment":26,"conditions":4968,"interventions":4969},"NCT01223183","Absorptive Clearance After Inhaled Osmotics in Cystic Fibrosis",[60],"2012-12",[4789],[4957,4970],"isotonic saline",{"trials":4972,"activeCount":71},[],{"trials":4974,"activeCount":71},[],{"trials":4976,"activeCount":71},[],{"trials":4978,"activeCount":71},[],{"intervention":4980,"totalTrials":67,"cells":4981},"Pittsburgh Compound B",{"EARLY_PHASE1":4982,"PHASE1":4992,"PHASE2":4994,"PHASE3":4996,"PHASE4":4998,"NA":5000},{"trials":4983,"activeCount":71},[4984],{"nctId":4985,"briefTitle":4986,"status":107,"phases":4987,"primaryCompletion":4988,"completion":4988,"start":4989,"enrollment":1921,"conditions":4990,"interventions":4991},"NCT03746366","[C-11]PiB PET Imaging in Alcohol Use Disorders",[59],"2020-07-01","2018-12-01",[435],[4980],{"trials":4993,"activeCount":71},[],{"trials":4995,"activeCount":71},[],{"trials":4997,"activeCount":71},[],{"trials":4999,"activeCount":71},[],{"trials":5001,"activeCount":71},[],{"intervention":5003,"totalTrials":67,"cells":5004},"NOP-1A",{"EARLY_PHASE1":5005,"PHASE1":5017,"PHASE2":5019,"PHASE3":5021,"PHASE4":5023,"NA":5025},{"trials":5006,"activeCount":71},[5007],{"nctId":5008,"briefTitle":5009,"status":107,"phases":5010,"primaryCompletion":5011,"completion":5011,"start":5012,"enrollment":5013,"conditions":5014,"interventions":5016},"NCT03348384","[11C]NOP-1A and Cocaine Use Disorders",[59],"2019-02-20","2014-10-30",49,[5015],"Cocaine Use Disorder",[5003],{"trials":5018,"activeCount":71},[],{"trials":5020,"activeCount":71},[],{"trials":5022,"activeCount":71},[],{"trials":5024,"activeCount":71},[],{"trials":5026,"activeCount":71},[],{"intervention":5028,"totalTrials":67,"cells":5029},"tinidazole",{"EARLY_PHASE1":5030,"PHASE1":5039,"PHASE2":5041,"PHASE3":5043,"PHASE4":5045,"NA":5047},{"trials":5031,"activeCount":71},[5032],{"nctId":5033,"briefTitle":5034,"status":107,"phases":5035,"primaryCompletion":279,"completion":279,"start":270,"enrollment":5036,"conditions":5037,"interventions":5038},"NCT00510614","Tinidazole for Recurrent Bacterial Vaginosis: A Pilot Study",[59],37,[1599],[5028],{"trials":5040,"activeCount":71},[],{"trials":5042,"activeCount":71},[],{"trials":5044,"activeCount":71},[],{"trials":5046,"activeCount":71},[],{"trials":5048,"activeCount":71},[],{"intervention":5050,"totalTrials":67,"cells":5051},"ruxolitinib",{"EARLY_PHASE1":5052,"PHASE1":5062,"PHASE2":5064,"PHASE3":5066,"PHASE4":5068,"NA":5070},{"trials":5053,"activeCount":71},[5054],{"nctId":5055,"briefTitle":5056,"status":1328,"phases":5057,"primaryCompletion":5058,"start":5059,"enrollment":71,"conditions":5060,"interventions":5061},"NCT02593929","Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck Cancer",[59],"2018-01","2017-01",[4138],[5050],{"trials":5063,"activeCount":71},[],{"trials":5065,"activeCount":71},[],{"trials":5067,"activeCount":71},[],{"trials":5069,"activeCount":71},[],{"trials":5071,"activeCount":71},[],{"intervention":5073,"totalTrials":67,"cells":5074},"Hydrocortisone",{"EARLY_PHASE1":5075,"PHASE1":5085,"PHASE2":5087,"PHASE3":5089,"PHASE4":5091,"NA":5093},{"trials":5076,"activeCount":71},[5077],{"nctId":5078,"briefTitle":5079,"status":107,"phases":5080,"primaryCompletion":5081,"completion":5081,"start":5082,"enrollment":31,"conditions":5083,"interventions":5084},"NCT03302416","CRF - Nociceptin Receptor Interactions",[59],"2019-06-01","2016-06-01",[4523],[5073],{"trials":5086,"activeCount":71},[],{"trials":5088,"activeCount":71},[],{"trials":5090,"activeCount":71},[],{"trials":5092,"activeCount":71},[],{"trials":5094,"activeCount":71},[],{"intervention":5096,"totalTrials":67,"cells":5097},"Indocyanine Green",{"EARLY_PHASE1":5098,"PHASE1":5109,"PHASE2":5111,"PHASE3":5113,"PHASE4":5115,"NA":5117},{"trials":5099,"activeCount":71},[5100],{"nctId":5101,"briefTitle":5102,"status":107,"phases":5103,"primaryCompletion":5104,"completion":5104,"start":5105,"enrollment":2096,"conditions":5106,"interventions":5108},"NCT02851368","Near Infrared Fluorescence Imaging With Indocyanine Green",[59],"2017-11","2016-11",[5107],"Solitary Pulmonary Nodules",[5096],{"trials":5110,"activeCount":71},[],{"trials":5112,"activeCount":71},[],{"trials":5114,"activeCount":71},[],{"trials":5116,"activeCount":71},[],{"trials":5118,"activeCount":71},[],{"intervention":5120,"totalTrials":67,"cells":5121},"Insulin",{"EARLY_PHASE1":5122,"PHASE1":5134,"PHASE2":5136,"PHASE3":5138,"PHASE4":5140,"NA":5142},{"trials":5123,"activeCount":71},[5124],{"nctId":5125,"briefTitle":5126,"status":1328,"phases":5127,"primaryCompletion":5128,"completion":5128,"start":5129,"enrollment":71,"conditions":5130,"interventions":5132},"NCT02982551","Insulin Modulation of fMRI Connectivity in Healthy Adults",[59],"2017-12","2016-01-01",[5131],"Healthy Volunteers",[5120,5133],"Dextrose",{"trials":5135,"activeCount":71},[],{"trials":5137,"activeCount":71},[],{"trials":5139,"activeCount":71},[],{"trials":5141,"activeCount":71},[],{"trials":5143,"activeCount":71},[],{"intervention":5133,"totalTrials":67,"cells":5145},{"EARLY_PHASE1":5146,"PHASE1":5152,"PHASE2":5154,"PHASE3":5156,"PHASE4":5158,"NA":5160},{"trials":5147,"activeCount":71},[5148],{"nctId":5125,"briefTitle":5126,"status":1328,"phases":5149,"primaryCompletion":5128,"completion":5128,"start":5129,"enrollment":71,"conditions":5150,"interventions":5151},[59],[5131],[5120,5133],{"trials":5153,"activeCount":71},[],{"trials":5155,"activeCount":71},[],{"trials":5157,"activeCount":71},[],{"trials":5159,"activeCount":71},[],{"trials":5161,"activeCount":71},[],{"intervention":5163,"totalTrials":67,"cells":5164},"STAT 3 DECOY",{"EARLY_PHASE1":5165,"PHASE1":5173,"PHASE2":5175,"PHASE3":5177,"PHASE4":5179,"NA":5181},{"trials":5166,"activeCount":71},[5167],{"nctId":5168,"briefTitle":5169,"status":107,"phases":5170,"primaryCompletion":3302,"completion":3302,"start":1238,"enrollment":410,"conditions":5171,"interventions":5172},"NCT00696176","STAT3 DECOY in Head and Neck Cancer",[59],[2513],[5163],{"trials":5174,"activeCount":71},[],{"trials":5176,"activeCount":71},[],{"trials":5178,"activeCount":71},[],{"trials":5180,"activeCount":71},[],{"trials":5182,"activeCount":71},[],{"intervention":5184,"totalTrials":67,"cells":5185},"PTHrP",{"EARLY_PHASE1":5186,"PHASE1":5195,"PHASE2":5197,"PHASE3":5199,"PHASE4":5201,"NA":5203},{"trials":5187,"activeCount":71},[5188],{"nctId":5189,"briefTitle":5190,"status":107,"phases":5191,"primaryCompletion":506,"completion":506,"start":312,"enrollment":874,"conditions":5192,"interventions":5194},"NCT00580788","One Week Parathyroid Hormone-related Protein (PTHrP) IV Dose Escalation Study",[59],[2633,5193,2635],"Humoral Hypercalcemia of Malignancy",[5184],{"trials":5196,"activeCount":71},[],{"trials":5198,"activeCount":71},[],{"trials":5200,"activeCount":71},[],{"trials":5202,"activeCount":71},[],{"trials":5204,"activeCount":71},[],{"intervention":5206,"totalTrials":67,"cells":5207},"IFNα2b",{"EARLY_PHASE1":5208,"PHASE1":5218,"PHASE2":5220,"PHASE3":5222,"PHASE4":5224,"NA":5226},{"trials":5209,"activeCount":71},[5210],{"nctId":5211,"briefTitle":5212,"status":389,"phases":5213,"primaryCompletion":5214,"completion":5214,"start":279,"enrollment":10,"conditions":5215,"interventions":5216},"NCT00871533","Pilot Study of IFN α2b for Melanoma Patients",[59],"2017-08",[2953],[5206,5206,5217,5217],"PEG- IFNα2b",{"trials":5219,"activeCount":71},[],{"trials":5221,"activeCount":71},[],{"trials":5223,"activeCount":71},[],{"trials":5225,"activeCount":71},[],{"trials":5227,"activeCount":71},[],{"intervention":5217,"totalTrials":67,"cells":5229},{"EARLY_PHASE1":5230,"PHASE1":5236,"PHASE2":5238,"PHASE3":5240,"PHASE4":5242,"NA":5244},{"trials":5231,"activeCount":71},[5232],{"nctId":5211,"briefTitle":5212,"status":389,"phases":5233,"primaryCompletion":5214,"completion":5214,"start":279,"enrollment":10,"conditions":5234,"interventions":5235},[59],[2953],[5206,5206,5217,5217],{"trials":5237,"activeCount":71},[],{"trials":5239,"activeCount":71},[],{"trials":5241,"activeCount":71},[],{"trials":5243,"activeCount":71},[],{"trials":5245,"activeCount":71},[],{"intervention":5247,"totalTrials":67,"cells":5248},"d-amphetamine",{"EARLY_PHASE1":5249,"PHASE1":5261,"PHASE2":5263,"PHASE3":5265,"PHASE4":5267,"NA":5269},{"trials":5250,"activeCount":71},[5251],{"nctId":5252,"briefTitle":5253,"status":107,"phases":5254,"primaryCompletion":5255,"completion":5256,"start":5257,"enrollment":598,"conditions":5258,"interventions":5260},"NCT03349606","Cocaine Use Disorder and Cortical Dopamine",[59],"2019-09-24","2020-06-01","2010-06-02",[5259],"Cocaine Dependence",[5247],{"trials":5262,"activeCount":71},[],{"trials":5264,"activeCount":71},[],{"trials":5266,"activeCount":71},[],{"trials":5268,"activeCount":71},[],{"trials":5270,"activeCount":71},[],{"intervention":475,"totalTrials":12,"cells":5272},{"EARLY_PHASE1":5273,"PHASE1":5275,"PHASE2":5277,"PHASE3":5295,"PHASE4":5307,"NA":5309},{"trials":5274,"activeCount":71},[],{"trials":5276,"activeCount":71},[],{"trials":5278,"activeCount":71},[5279,5287],{"nctId":5280,"briefTitle":5281,"status":107,"phases":5282,"primaryCompletion":2502,"completion":1008,"start":110,"enrollment":10,"conditions":5283,"interventions":5285},"NCT00027378","Pharmacological Intervention Project (Fluoxetine)",[61],[5284,16],"Alcoholism",[5286],"fluoxetine",{"nctId":5288,"briefTitle":5289,"status":107,"phases":5290,"primaryCompletion":303,"completion":4967,"start":292,"enrollment":1528,"conditions":5291,"interventions":5294},"NCT00149643","Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence",[61],[5292,5293],"Depressive Disorder, Major","Cannabis Abuse",[475],{"trials":5296,"activeCount":71},[5297,5303],{"nctId":5298,"briefTitle":5299,"status":107,"phases":5300,"primaryCompletion":271,"completion":271,"start":535,"conditions":5301,"interventions":5302},"NCT00000381","Fluoxetine for Anxious Children",[62],[317],[475],{"nctId":467,"briefTitle":468,"status":107,"phases":5304,"primaryCompletion":470,"completion":470,"start":471,"enrollment":472,"conditions":5305,"interventions":5306},[61,62],[16],[475,286,476],{"trials":5308,"activeCount":71},[],{"trials":5310,"activeCount":71},[5311,5318],{"nctId":5312,"briefTitle":5313,"status":107,"phases":5314,"completion":4477,"start":5315,"enrollment":1708,"conditions":5316,"interventions":5317},"NCT00227981","Maintenance Interpersonal Psychotherapy for Sustaining Remission of Depression",[64],"1995-03",[16],[475],{"nctId":5319,"briefTitle":5320,"status":107,"phases":5321,"primaryCompletion":2613,"completion":2613,"start":2502,"enrollment":2681,"conditions":5322,"interventions":5324},"NCT00603018","PET Imaging Study of Recovered Anorexics",[64],[5323],"Anorexia Nervosa",[475],{"intervention":3129,"totalTrials":323,"cells":5326},{"EARLY_PHASE1":5327,"PHASE1":5329,"PHASE2":5340,"PHASE3":5350,"PHASE4":5352,"NA":5354},{"trials":5328,"activeCount":71},[],{"trials":5330,"activeCount":71},[5331],{"nctId":5332,"briefTitle":5333,"status":107,"phases":5334,"primaryCompletion":5335,"completion":5336,"start":2308,"enrollment":23,"conditions":5337,"interventions":5338},"NCT00010231","Calcitriol Plus Dexamethasone in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy",[60],"2002-08","2002-11",[2757],[5339],"dexamethasone",{"trials":5341,"activeCount":71},[5342,5346],{"nctId":3121,"briefTitle":3122,"status":1328,"phases":5343,"primaryCompletion":1330,"completion":1330,"start":2261,"enrollment":71,"conditions":5344,"interventions":5345},[61],[3125,3126],[3112,3128,3129],{"nctId":3575,"briefTitle":3576,"status":107,"phases":5347,"primaryCompletion":2213,"completion":2657,"start":1981,"enrollment":410,"conditions":5348,"interventions":5349},[61],[3579],[3566,3129],{"trials":5351,"activeCount":71},[],{"trials":5353,"activeCount":71},[],{"trials":5355,"activeCount":71},[5356],{"nctId":5357,"briefTitle":5358,"status":1328,"phases":5359,"primaryCompletion":5360,"completion":5361,"start":5362,"enrollment":71,"conditions":5363,"interventions":5366},"NCT03328975","An Evaluation of Blood Glucose Levels and Insulin Requirement After Subacromial Corticosteroid Injection in Insulin Dependent Diabetics",[64],"2021-11-01","2022-11-01","2017-11-01",[5364,5365],"Shoulder Injury","Insulin-dependent Diabetics",[3129],{"intervention":476,"totalTrials":371,"cells":5368},{"EARLY_PHASE1":5369,"PHASE1":5371,"PHASE2":5373,"PHASE3":5379,"PHASE4":5385,"NA":5387},{"trials":5370,"activeCount":71},[],{"trials":5372,"activeCount":71},[],{"trials":5374,"activeCount":71},[5375],{"nctId":721,"briefTitle":722,"status":107,"phases":5376,"primaryCompletion":724,"completion":724,"start":725,"enrollment":726,"conditions":5377,"interventions":5378},[61],[283],[476,712],{"trials":5380,"activeCount":71},[5381],{"nctId":467,"briefTitle":468,"status":107,"phases":5382,"primaryCompletion":470,"completion":470,"start":471,"enrollment":472,"conditions":5383,"interventions":5384},[61,62],[16],[475,286,476],{"trials":5386,"activeCount":71},[],{"trials":5388,"activeCount":71},[5389],{"nctId":5390,"briefTitle":5391,"status":107,"phases":5392,"primaryCompletion":5393,"completion":5393,"start":4091,"conditions":5394,"interventions":5395},"NCT00217828","Effects of Citalopram on Hostility and CHD Risk",[64],"2003-02",[22,2375],[5396],"citalopram",{"intervention":5398,"totalTrials":371,"cells":5399},"Buprenorphine",{"EARLY_PHASE1":5400,"PHASE1":5402,"PHASE2":5404,"PHASE3":5413,"PHASE4":5422,"NA":5424},{"trials":5401,"activeCount":71},[],{"trials":5403,"activeCount":71},[],{"trials":5405,"activeCount":71},[5406],{"nctId":5407,"briefTitle":5408,"status":107,"phases":5409,"primaryCompletion":5410,"completion":5410,"start":850,"enrollment":3353,"conditions":5411,"interventions":5412},"NCT01071538","Buprenorphine for Late-Life Treatment Resistant Depression",[61],"2012-05",[16],[5398],{"trials":5414,"activeCount":71},[5415],{"nctId":5416,"briefTitle":5417,"status":107,"phases":5418,"primaryCompletion":4200,"completion":4200,"start":1620,"enrollment":4092,"conditions":5419,"interventions":5421},"NCT01407575","Buprenorphine for Treatment Resistant Depression",[62],[16,5420,5292],"Depressive Disorder",[5398],{"trials":5423,"activeCount":71},[],{"trials":5425,"activeCount":71},[5426],{"nctId":5427,"briefTitle":5428,"status":107,"phases":5429,"primaryCompletion":5430,"completion":5431,"start":5432,"enrollment":5433,"conditions":5434,"interventions":5436},"NCT03098407","Opioid Dependence Treatment Therapies in Pregnancy",[64],"2019-10-09","2020-10-05","2017-04-20",55,[5435,3331],"Opioid-Related Disorders",[5398,5437],"Methadone",{"intervention":656,"totalTrials":371,"cells":5439},{"EARLY_PHASE1":5440,"PHASE1":5442,"PHASE2":5448,"PHASE3":5450,"PHASE4":5452,"NA":5458},{"trials":5441,"activeCount":71},[],{"trials":5443,"activeCount":71},[5444],{"nctId":646,"briefTitle":647,"status":107,"phases":5445,"primaryCompletion":649,"completion":649,"start":650,"enrollment":410,"conditions":5446,"interventions":5447},[60],[652,653,654],[656,639,657],{"trials":5449,"activeCount":71},[],{"trials":5451,"activeCount":71},[],{"trials":5453,"activeCount":71},[5454],{"nctId":665,"briefTitle":666,"status":107,"phases":5455,"primaryCompletion":668,"completion":669,"start":670,"enrollment":632,"conditions":5456,"interventions":5457},[63],[672,28],[656,639],{"trials":5459,"activeCount":71},[5460],{"nctId":5461,"briefTitle":5462,"status":107,"phases":5463,"primaryCompletion":3446,"completion":3446,"start":2755,"enrollment":23,"conditions":5464,"interventions":5466},"NCT01495481","Dexmedetomidine and Adenosine: Therapeutic Use for SVT",[64],[5465],"Supraventricular Tachycardia",[656,5467],"Adenosine",{"intervention":5469,"totalTrials":92,"cells":5470},"Myfortic",{"EARLY_PHASE1":5471,"PHASE1":5473,"PHASE2":5475,"PHASE3":5477,"PHASE4":5479,"NA":5481},{"trials":5472,"activeCount":71},[],{"trials":5474,"activeCount":71},[],{"trials":5476,"activeCount":71},[],{"trials":5478,"activeCount":71},[],{"trials":5480,"activeCount":71},[],{"trials":5482,"activeCount":71},[5483,5491],{"nctId":5484,"briefTitle":5485,"status":107,"phases":5486,"primaryCompletion":2371,"completion":2371,"start":825,"enrollment":598,"conditions":5487,"interventions":5489},"NCT00336817","A Prospective Study on the Tolerability and Efficacy of the de Novo Use of Myfortic in Liver Transplant Recipients",[64],[5488],"Immunosuppression",[5469,5490],"CellCept",{"nctId":5492,"briefTitle":5493,"status":107,"phases":5494,"primaryCompletion":2371,"completion":2371,"start":825,"enrollment":5495,"conditions":5496,"interventions":5497},"NCT00336895","Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients",[64],29,[5488],[5469],{"intervention":5499,"totalTrials":92,"cells":5500},"zolpidem",{"EARLY_PHASE1":5501,"PHASE1":5503,"PHASE2":5505,"PHASE3":5507,"PHASE4":5509,"NA":5515},{"trials":5502,"activeCount":71},[],{"trials":5504,"activeCount":71},[],{"trials":5506,"activeCount":71},[],{"trials":5508,"activeCount":71},[],{"trials":5510,"activeCount":71},[5511],{"nctId":256,"briefTitle":257,"status":107,"phases":5512,"primaryCompletion":259,"completion":259,"start":260,"enrollment":261,"conditions":5513,"interventions":5514},[63],[263],[265,243],{"trials":5516,"activeCount":71},[5517],{"nctId":5518,"briefTitle":5519,"status":389,"phases":5520,"primaryCompletion":3936,"completion":3936,"start":2501,"enrollment":12,"conditions":5521,"interventions":5523},"NCT00936598","Sleep and Endometrial Cancer",[64],[30,5522,653],"Endometrial Neoplasms",[5499,5524],"sugar pill",{"intervention":5526,"totalTrials":92,"cells":5527},"Aripiprazole",{"EARLY_PHASE1":5528,"PHASE1":5530,"PHASE2":5532,"PHASE3":5534,"PHASE4":5536,"NA":5547},{"trials":5529,"activeCount":71},[],{"trials":5531,"activeCount":71},[],{"trials":5533,"activeCount":71},[],{"trials":5535,"activeCount":71},[],{"trials":5537,"activeCount":71},[5538],{"nctId":5539,"briefTitle":5540,"status":107,"phases":5541,"primaryCompletion":1932,"completion":1932,"start":5542,"enrollment":598,"conditions":5543,"interventions":5546},"NCT00222833","The Effect of Switching to Aripiprazole on Heart Health in Overweight and Obese Patients With Schizophrenia",[63],"2004-10",[5544,5545,22],"Overweight","Hyperlipidemia",[5526],{"trials":5548,"activeCount":71},[5549],{"nctId":5550,"briefTitle":5551,"status":389,"phases":5552,"primaryCompletion":303,"completion":303,"start":313,"enrollment":371,"conditions":5553,"interventions":5555},"NCT00665444","Study of Aripiprazole to Reduce Medical Risks in Bipolar Disorder",[64],[113,5554],"Metabolic Syndrome",[5526],{"intervention":5557,"totalTrials":92,"cells":5558},"L-carnosine",{"EARLY_PHASE1":5559,"PHASE1":5561,"PHASE2":5563,"PHASE3":5565,"PHASE4":5567,"NA":5569},{"trials":5560,"activeCount":71},[],{"trials":5562,"activeCount":71},[],{"trials":5564,"activeCount":71},[],{"trials":5566,"activeCount":71},[],{"trials":5568,"activeCount":71},[],{"trials":5570,"activeCount":71},[5571,5579],{"nctId":5572,"briefTitle":5573,"status":107,"phases":5574,"primaryCompletion":1285,"completion":1597,"start":5575,"enrollment":5576,"conditions":5577,"interventions":5578},"NCT00177177","L-carnosine for Schizophrenia",[64],"2004-03",84,[33,707],[5557],{"nctId":5580,"briefTitle":5581,"status":107,"phases":5582,"primaryCompletion":1597,"completion":1597,"start":292,"enrollment":4136,"conditions":5583,"interventions":5584},"NCT00177463","L-Carnosine for Bipolar I Disorder",[64],[2168],[5557],{"intervention":4970,"totalTrials":92,"cells":5586},{"EARLY_PHASE1":5587,"PHASE1":5589,"PHASE2":5595,"PHASE3":5597,"PHASE4":5599,"NA":5601},{"trials":5588,"activeCount":71},[],{"trials":5590,"activeCount":71},[5591],{"nctId":4964,"briefTitle":4965,"status":107,"phases":5592,"primaryCompletion":4967,"completion":4967,"start":507,"enrollment":26,"conditions":5593,"interventions":5594},[60],[4789],[4957,4970],{"trials":5596,"activeCount":71},[],{"trials":5598,"activeCount":71},[],{"trials":5600,"activeCount":71},[],{"trials":5602,"activeCount":71},[5603],{"nctId":5604,"briefTitle":5605,"status":107,"phases":5606,"primaryCompletion":303,"completion":303,"start":1147,"enrollment":1262,"conditions":5607,"interventions":5608},"NCT00628134","Self-dispersing Liquids as Aerosol Drug Carriers",[64],[4789],[5609,4970],"calfactant",{"intervention":5611,"totalTrials":92,"cells":5612},"Prazosin",{"EARLY_PHASE1":5613,"PHASE1":5615,"PHASE2":5617,"PHASE3":5619,"PHASE4":5621,"NA":5623},{"trials":5614,"activeCount":71},[],{"trials":5616,"activeCount":71},[],{"trials":5618,"activeCount":71},[],{"trials":5620,"activeCount":71},[],{"trials":5622,"activeCount":71},[],{"trials":5624,"activeCount":71},[5625,5634],{"nctId":5626,"briefTitle":5627,"status":107,"phases":5628,"primaryCompletion":5629,"completion":5629,"start":596,"enrollment":632,"conditions":5630,"interventions":5633},"NCT01637584","Neurobiology of Sleep and Sleep Treatment Response in Returning Veterans",[64],"2012-11",[5631,5632],"Non PTSD","PTSD",[5611],{"nctId":5635,"briefTitle":5636,"status":107,"phases":5637,"primaryCompletion":1007,"completion":2529,"start":5638,"enrollment":10,"conditions":5639,"interventions":5643},"NCT00393874","Efficacy of Sleep Interventions for Posttraumatic Stress Disorder (PTSD)",[64],"2006-10",[317,5640,5641,5642],"Mood Disorders","Insomnia","Nightmares",[5611],{"intervention":5645,"totalTrials":67,"cells":5646},"Raltegravir",{"EARLY_PHASE1":5647,"PHASE1":5649,"PHASE2":5651,"PHASE3":5653,"PHASE4":5655,"NA":5657},{"trials":5648,"activeCount":71},[],{"trials":5650,"activeCount":71},[],{"trials":5652,"activeCount":71},[],{"trials":5654,"activeCount":71},[],{"trials":5656,"activeCount":71},[],{"trials":5658,"activeCount":71},[5659],{"nctId":5660,"briefTitle":5661,"status":107,"phases":5662,"primaryCompletion":2262,"completion":2262,"start":270,"enrollment":1755,"conditions":5663,"interventions":5665},"NCT00618371","Pilot Study of Adding Raltegravir (MK-0518) to Antiretroviral Therapy in Patients With Low Level Viremia",[64],[5664],"HIV Infection",[5645],{"intervention":5667,"totalTrials":67,"cells":5668},"Inhaled corticosteroid",{"EARLY_PHASE1":5669,"PHASE1":5671,"PHASE2":5673,"PHASE3":5675,"PHASE4":5677,"NA":5679},{"trials":5670,"activeCount":71},[],{"trials":5672,"activeCount":71},[],{"trials":5674,"activeCount":71},[],{"trials":5676,"activeCount":71},[],{"trials":5678,"activeCount":71},[],{"trials":5680,"activeCount":71},[5681],{"nctId":5682,"briefTitle":5683,"status":107,"phases":5684,"primaryCompletion":5685,"completion":5685,"start":5686,"enrollment":5687,"conditions":5688,"interventions":5690},"NCT03134755","Stress and Treatment Response in Puerto Rican Children With Asthma",[],"2022-05-18","2018-05-15",249,[5689],"Asthma in Children",[5667],{"intervention":5692,"totalTrials":67,"cells":5693},"DMPA",{"EARLY_PHASE1":5694,"PHASE1":5696,"PHASE2":5698,"PHASE3":5700,"PHASE4":5702,"NA":5704},{"trials":5695,"activeCount":71},[],{"trials":5697,"activeCount":71},[],{"trials":5699,"activeCount":71},[],{"trials":5701,"activeCount":71},[],{"trials":5703,"activeCount":71},[],{"trials":5705,"activeCount":71},[5706],{"nctId":5707,"briefTitle":5708,"status":107,"phases":5709,"primaryCompletion":669,"completion":5710,"start":3328,"enrollment":5711,"conditions":5712,"interventions":5715},"NCT02038335","HIV-Target Cell Response in Women Initiating Various Contraceptive Methods in High HIV-Incidence Areas: Zim CHIC",[],"2020-12",451,[1668,1799,5713,5714],"Immune Cells (Mucosal and Systemic)","Microbiota",[5692,5716,5717],"NET-EN","MPA\u002FE2",{"intervention":5716,"totalTrials":67,"cells":5719},{"EARLY_PHASE1":5720,"PHASE1":5722,"PHASE2":5724,"PHASE3":5726,"PHASE4":5728,"NA":5730},{"trials":5721,"activeCount":71},[],{"trials":5723,"activeCount":71},[],{"trials":5725,"activeCount":71},[],{"trials":5727,"activeCount":71},[],{"trials":5729,"activeCount":71},[],{"trials":5731,"activeCount":71},[5732],{"nctId":5707,"briefTitle":5708,"status":107,"phases":5733,"primaryCompletion":669,"completion":5710,"start":3328,"enrollment":5711,"conditions":5734,"interventions":5735},[],[1668,1799,5713,5714],[5692,5716,5717],{"intervention":5717,"totalTrials":67,"cells":5737},{"EARLY_PHASE1":5738,"PHASE1":5740,"PHASE2":5742,"PHASE3":5744,"PHASE4":5746,"NA":5748},{"trials":5739,"activeCount":71},[],{"trials":5741,"activeCount":71},[],{"trials":5743,"activeCount":71},[],{"trials":5745,"activeCount":71},[],{"trials":5747,"activeCount":71},[],{"trials":5749,"activeCount":71},[5750],{"nctId":5707,"briefTitle":5708,"status":107,"phases":5751,"primaryCompletion":669,"completion":5710,"start":3328,"enrollment":5711,"conditions":5752,"interventions":5753},[],[1668,1799,5713,5714],[5692,5716,5717],{"intervention":5490,"totalTrials":67,"cells":5755},{"EARLY_PHASE1":5756,"PHASE1":5758,"PHASE2":5760,"PHASE3":5762,"PHASE4":5764,"NA":5766},{"trials":5757,"activeCount":71},[],{"trials":5759,"activeCount":71},[],{"trials":5761,"activeCount":71},[],{"trials":5763,"activeCount":71},[],{"trials":5765,"activeCount":71},[],{"trials":5767,"activeCount":71},[5768],{"nctId":5484,"briefTitle":5485,"status":107,"phases":5769,"primaryCompletion":2371,"completion":2371,"start":825,"enrollment":598,"conditions":5770,"interventions":5771},[64],[5488],[5469,5490],{"intervention":5773,"totalTrials":67,"cells":5774},"eszopiclone 3 mg qHS",{"EARLY_PHASE1":5775,"PHASE1":5777,"PHASE2":5779,"PHASE3":5781,"PHASE4":5783,"NA":5785},{"trials":5776,"activeCount":71},[],{"trials":5778,"activeCount":71},[],{"trials":5780,"activeCount":71},[],{"trials":5782,"activeCount":71},[],{"trials":5784,"activeCount":71},[],{"trials":5786,"activeCount":71},[5787],{"nctId":5788,"briefTitle":5789,"status":107,"phases":5790,"completion":2502,"start":629,"enrollment":691,"conditions":5791,"interventions":5793},"NCT00167375","Testing the Nocturnal Sleep Latency Profile in Primary Insomnia",[],[361,5792],"Sleep Initiation and Maintenance Disorders",[5773],{"intervention":5795,"totalTrials":67,"cells":5796},"Atenolol",{"EARLY_PHASE1":5797,"PHASE1":5799,"PHASE2":5801,"PHASE3":5803,"PHASE4":5805,"NA":5807},{"trials":5798,"activeCount":71},[],{"trials":5800,"activeCount":71},[],{"trials":5802,"activeCount":71},[],{"trials":5804,"activeCount":71},[],{"trials":5806,"activeCount":71},[],{"trials":5808,"activeCount":71},[5809],{"nctId":5810,"briefTitle":5811,"status":107,"phases":5812,"completion":597,"start":5813,"enrollment":10,"conditions":5814,"interventions":5815},"NCT00151138","Cognitive\u002FCerebrovascular Consequences of HTN Treatment",[64],"2002-09",[2050],[5795],{"intervention":5817,"totalTrials":67,"cells":5818},"Misoprostol",{"EARLY_PHASE1":5819,"PHASE1":5821,"PHASE2":5823,"PHASE3":5825,"PHASE4":5827,"NA":5829},{"trials":5820,"activeCount":71},[],{"trials":5822,"activeCount":71},[],{"trials":5824,"activeCount":71},[],{"trials":5826,"activeCount":71},[],{"trials":5828,"activeCount":71},[],{"trials":5830,"activeCount":71},[5831],{"nctId":5832,"briefTitle":5833,"status":389,"phases":5834,"primaryCompletion":5835,"completion":382,"start":2434,"enrollment":5495,"conditions":5836,"interventions":5838},"NCT01818414","Same-day Dilapan-S With Adjunctive Misoprostol",[64],"2014-03",[5837],"Therapeutic Abortion",[5817,5839],"Folic Acid",{"intervention":5839,"totalTrials":67,"cells":5841},{"EARLY_PHASE1":5842,"PHASE1":5844,"PHASE2":5846,"PHASE3":5848,"PHASE4":5850,"NA":5852},{"trials":5843,"activeCount":71},[],{"trials":5845,"activeCount":71},[],{"trials":5847,"activeCount":71},[],{"trials":5849,"activeCount":71},[],{"trials":5851,"activeCount":71},[],{"trials":5853,"activeCount":71},[5854],{"nctId":5832,"briefTitle":5833,"status":389,"phases":5855,"primaryCompletion":5835,"completion":382,"start":2434,"enrollment":5495,"conditions":5856,"interventions":5857},[64],[5837],[5817,5839],{"intervention":5859,"totalTrials":67,"cells":5860},"General Anesthesia",{"EARLY_PHASE1":5861,"PHASE1":5863,"PHASE2":5865,"PHASE3":5867,"PHASE4":5869,"NA":5871},{"trials":5862,"activeCount":71},[],{"trials":5864,"activeCount":71},[],{"trials":5866,"activeCount":71},[],{"trials":5868,"activeCount":71},[],{"trials":5870,"activeCount":71},[],{"trials":5872,"activeCount":71},[5873],{"nctId":5874,"briefTitle":5875,"status":107,"phases":5876,"primaryCompletion":5877,"completion":5877,"start":5878,"enrollment":3353,"conditions":5879,"interventions":5881},"NCT02267187","Structural Fat Grafting for Craniofacial Trauma Using Manual Technique for Processing Fat Graft Material",[64],"2017-06-21","2014-10-22",[5880],"Facial Injuries",[5859],{"intervention":5883,"totalTrials":67,"cells":5884},"Glycerol phenylbutyrate",{"EARLY_PHASE1":5885,"PHASE1":5887,"PHASE2":5889,"PHASE3":5891,"PHASE4":5893,"NA":5895},{"trials":5886,"activeCount":71},[],{"trials":5888,"activeCount":71},[],{"trials":5890,"activeCount":71},[],{"trials":5892,"activeCount":71},[],{"trials":5894,"activeCount":71},[],{"trials":5896,"activeCount":71},[5897],{"nctId":5898,"briefTitle":5899,"status":5900,"phases":5901,"conditions":5902,"interventions":5904},"NCT01949766","Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease","NO_LONGER_AVAILABLE",[],[5903],"Byler Disease",[5883],{"intervention":5906,"totalTrials":67,"cells":5907},"Ropivacaine",{"EARLY_PHASE1":5908,"PHASE1":5910,"PHASE2":5912,"PHASE3":5914,"PHASE4":5916,"NA":5918},{"trials":5909,"activeCount":71},[],{"trials":5911,"activeCount":71},[],{"trials":5913,"activeCount":71},[],{"trials":5915,"activeCount":71},[],{"trials":5917,"activeCount":71},[],{"trials":5919,"activeCount":71},[5920],{"nctId":5921,"briefTitle":5922,"status":389,"phases":5923,"primaryCompletion":5924,"completion":5924,"enrollment":20,"conditions":5925,"interventions":5927},"NCT03294174","Opioid Induced Loss of Local Anesthetic Potency in Patients Undergoing Total Knee Arthroplasty",[],"2017-06",[5926],"Opioid Tolerance, Opioid Naive, Opioid Exposure",[5906],{"intervention":5929,"totalTrials":67,"cells":5930},"FDC I\u002FH",{"EARLY_PHASE1":5931,"PHASE1":5933,"PHASE2":5935,"PHASE3":5937,"PHASE4":5939,"NA":5941},{"trials":5932,"activeCount":71},[],{"trials":5934,"activeCount":71},[],{"trials":5936,"activeCount":71},[],{"trials":5938,"activeCount":71},[],{"trials":5940,"activeCount":71},[],{"trials":5942,"activeCount":71},[5943],{"nctId":5944,"briefTitle":5945,"status":107,"phases":5946,"primaryCompletion":5947,"completion":5948,"start":5949,"enrollment":341,"conditions":5950,"interventions":5951},"NCT02305095","Genomic Response Analysis of Heart Failure Therapy in African Americans",[],"2020-12-31","2022-09-30","2015-05-01",[3713],[5929],{"intervention":5953,"totalTrials":67,"cells":5954},"Daptomycin",{"EARLY_PHASE1":5955,"PHASE1":5957,"PHASE2":5959,"PHASE3":5961,"PHASE4":5963,"NA":5965},{"trials":5956,"activeCount":71},[],{"trials":5958,"activeCount":71},[],{"trials":5960,"activeCount":71},[],{"trials":5962,"activeCount":71},[],{"trials":5964,"activeCount":71},[],{"trials":5966,"activeCount":71},[5967],{"nctId":5968,"briefTitle":5969,"status":389,"phases":5970,"primaryCompletion":2885,"completion":2885,"start":850,"enrollment":92,"conditions":5971,"interventions":5973},"NCT01025271","Cerebrospinal Fluid Pharmacokinetics of Daptomycin",[64],[5972],"Meningitis",[5953],{"intervention":5524,"totalTrials":67,"cells":5975},{"EARLY_PHASE1":5976,"PHASE1":5978,"PHASE2":5980,"PHASE3":5982,"PHASE4":5984,"NA":5986},{"trials":5977,"activeCount":71},[],{"trials":5979,"activeCount":71},[],{"trials":5981,"activeCount":71},[],{"trials":5983,"activeCount":71},[],{"trials":5985,"activeCount":71},[],{"trials":5987,"activeCount":71},[5988],{"nctId":5518,"briefTitle":5519,"status":389,"phases":5989,"primaryCompletion":3936,"completion":3936,"start":2501,"enrollment":12,"conditions":5990,"interventions":5991},[64],[30,5522,653],[5499,5524],{"intervention":5993,"totalTrials":67,"cells":5994},"Bupivacaine",{"EARLY_PHASE1":5995,"PHASE1":5997,"PHASE2":5999,"PHASE3":6001,"PHASE4":6003,"NA":6005},{"trials":5996,"activeCount":71},[],{"trials":5998,"activeCount":71},[],{"trials":6000,"activeCount":71},[],{"trials":6002,"activeCount":71},[],{"trials":6004,"activeCount":71},[],{"trials":6006,"activeCount":71},[6007],{"nctId":6008,"briefTitle":6009,"status":1328,"phases":6010,"primaryCompletion":3640,"completion":3640,"start":6011,"enrollment":71,"conditions":6012,"interventions":6014},"NCT02141178","Comparison of Bupivacaine and Exparel for Carpal Tunnel Release",[64],"2015-05",[6013],"Pain After Carpal Tunnel Release",[5993,6015],"Exparel",{"intervention":6015,"totalTrials":67,"cells":6017},{"EARLY_PHASE1":6018,"PHASE1":6020,"PHASE2":6022,"PHASE3":6024,"PHASE4":6026,"NA":6028},{"trials":6019,"activeCount":71},[],{"trials":6021,"activeCount":71},[],{"trials":6023,"activeCount":71},[],{"trials":6025,"activeCount":71},[],{"trials":6027,"activeCount":71},[],{"trials":6029,"activeCount":71},[6030],{"nctId":6008,"briefTitle":6009,"status":1328,"phases":6031,"primaryCompletion":3640,"completion":3640,"start":6011,"enrollment":71,"conditions":6032,"interventions":6033},[64],[6013],[5993,6015],{"intervention":6035,"totalTrials":67,"cells":6036},"pancreatic enzyme supplement",{"EARLY_PHASE1":6037,"PHASE1":6039,"PHASE2":6041,"PHASE3":6043,"PHASE4":6045,"NA":6047},{"trials":6038,"activeCount":71},[],{"trials":6040,"activeCount":71},[],{"trials":6042,"activeCount":71},[],{"trials":6044,"activeCount":71},[],{"trials":6046,"activeCount":71},[],{"trials":6048,"activeCount":71},[6049],{"nctId":6050,"briefTitle":6051,"status":107,"phases":6052,"primaryCompletion":2559,"completion":2709,"start":6053,"enrollment":2144,"conditions":6054,"interventions":6055},"NCT00510744","Pancreatic Enzymes to Restore Digestive Function in Malnourished Gastric Bypass Patients",[64],"2007-08",[19],[6035],{"intervention":6057,"totalTrials":67,"cells":6058},"Fidaxomicin",{"EARLY_PHASE1":6059,"PHASE1":6061,"PHASE2":6063,"PHASE3":6065,"PHASE4":6067,"NA":6069},{"trials":6060,"activeCount":71},[],{"trials":6062,"activeCount":71},[],{"trials":6064,"activeCount":71},[],{"trials":6066,"activeCount":71},[],{"trials":6068,"activeCount":71},[],{"trials":6070,"activeCount":71},[6071],{"nctId":6072,"briefTitle":6073,"status":1328,"phases":6074,"primaryCompletion":6075,"completion":6075,"start":6076,"enrollment":71,"conditions":6077,"interventions":6079},"NCT04070352","Evaluation of Fidaxomicin in the Treatment of Clostridium Difficile Infection (CDI)",[],"2023-05-01","2019-08-01",[6078],"Clostridium Difficile Infection (CDI)",[6057],{"intervention":6081,"totalTrials":67,"cells":6082},"Buphenyl",{"EARLY_PHASE1":6083,"PHASE1":6085,"PHASE2":6087,"PHASE3":6089,"PHASE4":6091,"NA":6093},{"trials":6084,"activeCount":71},[],{"trials":6086,"activeCount":71},[],{"trials":6088,"activeCount":71},[],{"trials":6090,"activeCount":71},[],{"trials":6092,"activeCount":71},[],{"trials":6094,"activeCount":71},[6095],{"nctId":6096,"briefTitle":6097,"status":5900,"phases":6098,"conditions":6099,"interventions":6100},"NCT01784718","Buphenyl Therapy for Byler's Disease",[],[5903],[6081],{"intervention":6102,"totalTrials":67,"cells":6103},"Rizatriptan",{"EARLY_PHASE1":6104,"PHASE1":6106,"PHASE2":6108,"PHASE3":6110,"PHASE4":6112,"NA":6114},{"trials":6105,"activeCount":71},[],{"trials":6107,"activeCount":71},[],{"trials":6109,"activeCount":71},[],{"trials":6111,"activeCount":71},[],{"trials":6113,"activeCount":71},[],{"trials":6115,"activeCount":71},[6116],{"nctId":6117,"briefTitle":6118,"status":107,"phases":6119,"primaryCompletion":1239,"completion":595,"start":561,"enrollment":6120,"conditions":6121,"interventions":6122},"NCT00360282","Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?",[64],36,[1576],[6102],{"intervention":6124,"totalTrials":67,"cells":6125},"Ceftazidime-avibactam",{"EARLY_PHASE1":6126,"PHASE1":6128,"PHASE2":6130,"PHASE3":6132,"PHASE4":6134,"NA":6136},{"trials":6127,"activeCount":71},[],{"trials":6129,"activeCount":71},[],{"trials":6131,"activeCount":71},[],{"trials":6133,"activeCount":71},[],{"trials":6135,"activeCount":71},[],{"trials":6137,"activeCount":71},[6138],{"nctId":6139,"briefTitle":6140,"status":107,"phases":6141,"primaryCompletion":6142,"completion":6142,"start":6143,"enrollment":26,"conditions":6144,"interventions":6146},"NCT04358991","Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF",[],"2019-12-31","2017-01-01",[6145],"Bacterial Infections",[6124],{"intervention":5609,"totalTrials":67,"cells":6148},{"EARLY_PHASE1":6149,"PHASE1":6151,"PHASE2":6153,"PHASE3":6155,"PHASE4":6157,"NA":6159},{"trials":6150,"activeCount":71},[],{"trials":6152,"activeCount":71},[],{"trials":6154,"activeCount":71},[],{"trials":6156,"activeCount":71},[],{"trials":6158,"activeCount":71},[],{"trials":6160,"activeCount":71},[6161],{"nctId":5604,"briefTitle":5605,"status":107,"phases":6162,"primaryCompletion":303,"completion":303,"start":1147,"enrollment":1262,"conditions":6163,"interventions":6164},[64],[4789],[5609,4970],{"intervention":6166,"totalTrials":67,"cells":6167},"Pharmacotherapy",{"EARLY_PHASE1":6168,"PHASE1":6170,"PHASE2":6172,"PHASE3":6174,"PHASE4":6176,"NA":6178},{"trials":6169,"activeCount":71},[],{"trials":6171,"activeCount":71},[],{"trials":6173,"activeCount":71},[],{"trials":6175,"activeCount":71},[],{"trials":6177,"activeCount":71},[],{"trials":6179,"activeCount":71},[6180],{"nctId":6181,"briefTitle":6182,"status":107,"phases":6183,"primaryCompletion":1008,"completion":506,"start":349,"enrollment":6184,"conditions":6185,"interventions":6186},"NCT00091962","Effectiveness of Depression Treatment Following Coronary Artery Bypass Surgery",[64],453,[22,2374,2375,16],[6166],{"intervention":6188,"totalTrials":67,"cells":6189},"quadrivalent human papillomavirus vaccine",{"EARLY_PHASE1":6190,"PHASE1":6192,"PHASE2":6194,"PHASE3":6196,"PHASE4":6198,"NA":6200},{"trials":6191,"activeCount":71},[],{"trials":6193,"activeCount":71},[],{"trials":6195,"activeCount":71},[],{"trials":6197,"activeCount":71},[],{"trials":6199,"activeCount":71},[],{"trials":6201,"activeCount":71},[6202],{"nctId":6203,"briefTitle":6204,"status":107,"phases":6205,"primaryCompletion":5410,"completion":5410,"start":392,"enrollment":281,"conditions":6206,"interventions":6209},"NCT01184079","Randomized Trial of Alternative HPV Vaccination Schedules in Males in a University Setting",[64],[6207,6208],"Quadrivalent HPV Vaccine","Human Papillomavirus Vaccine",[6188,6188],{"intervention":6211,"totalTrials":67,"cells":6212},"25% ethanol",{"EARLY_PHASE1":6213,"PHASE1":6215,"PHASE2":6217,"PHASE3":6219,"PHASE4":6221,"NA":6223},{"trials":6214,"activeCount":71},[],{"trials":6216,"activeCount":71},[],{"trials":6218,"activeCount":71},[],{"trials":6220,"activeCount":71},[],{"trials":6222,"activeCount":71},[],{"trials":6224,"activeCount":71},[6225],{"nctId":6226,"briefTitle":6227,"status":107,"phases":6228,"primaryCompletion":408,"completion":408,"start":1238,"enrollment":443,"conditions":6229,"interventions":6231},"NCT00948441","Pediatric Ethanol Lock Therapy Study.",[64],[6230],"Catheter-Related Infections",[6211],{"intervention":6233,"totalTrials":67,"cells":6234},"Nitrofurantoin",{"EARLY_PHASE1":6235,"PHASE1":6237,"PHASE2":6239,"PHASE3":6241,"PHASE4":6243,"NA":6245},{"trials":6236,"activeCount":71},[],{"trials":6238,"activeCount":71},[],{"trials":6240,"activeCount":71},[],{"trials":6242,"activeCount":71},[],{"trials":6244,"activeCount":71},[],{"trials":6246,"activeCount":71},[6247],{"nctId":6248,"briefTitle":6249,"status":389,"phases":6250,"primaryCompletion":2657,"completion":2657,"start":259,"enrollment":1755,"conditions":6251,"interventions":6253},"NCT00678041","Nitrofurantoin and Urinary Tract Infections (UTIs)",[64],[6252],"Urinary Tract Infections",[6233],{"intervention":6255,"totalTrials":67,"cells":6256},"Ibuprofen",{"EARLY_PHASE1":6257,"PHASE1":6259,"PHASE2":6261,"PHASE3":6263,"PHASE4":6265,"NA":6267},{"trials":6258,"activeCount":71},[],{"trials":6260,"activeCount":71},[],{"trials":6262,"activeCount":71},[],{"trials":6264,"activeCount":71},[],{"trials":6266,"activeCount":71},[],{"trials":6268,"activeCount":71},[6269],{"nctId":6270,"briefTitle":6271,"status":107,"phases":6272,"conditions":6273,"interventions":6275},"NCT00002276","The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia",[64],[6274,3038],"HIV Infections",[6255,6276],"Zidovudine",{"intervention":6276,"totalTrials":67,"cells":6278},{"EARLY_PHASE1":6279,"PHASE1":6281,"PHASE2":6283,"PHASE3":6285,"PHASE4":6287,"NA":6289},{"trials":6280,"activeCount":71},[],{"trials":6282,"activeCount":71},[],{"trials":6284,"activeCount":71},[],{"trials":6286,"activeCount":71},[],{"trials":6288,"activeCount":71},[],{"trials":6290,"activeCount":71},[6291],{"nctId":6270,"briefTitle":6271,"status":107,"phases":6292,"conditions":6293,"interventions":6294},[64],[6274,3038],[6255,6276],{"intervention":6296,"totalTrials":67,"cells":6297},"Diazepam",{"EARLY_PHASE1":6298,"PHASE1":6300,"PHASE2":6302,"PHASE3":6304,"PHASE4":6306,"NA":6308},{"trials":6299,"activeCount":71},[],{"trials":6301,"activeCount":71},[],{"trials":6303,"activeCount":71},[],{"trials":6305,"activeCount":71},[],{"trials":6307,"activeCount":71},[],{"trials":6309,"activeCount":71},[6310],{"nctId":6311,"briefTitle":6312,"status":107,"phases":6313,"primaryCompletion":6314,"completion":6314,"start":1958,"enrollment":6315,"conditions":6316,"interventions":6318},"NCT01652326","Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome",[],"2015-09",792,[6317],"Alcohol Withdrawal Syndrome",[6296],{"intervention":6320,"totalTrials":67,"cells":6321},"risedronate",{"EARLY_PHASE1":6322,"PHASE1":6324,"PHASE2":6326,"PHASE3":6328,"PHASE4":6330,"NA":6332},{"trials":6323,"activeCount":71},[],{"trials":6325,"activeCount":71},[],{"trials":6327,"activeCount":71},[],{"trials":6329,"activeCount":71},[],{"trials":6331,"activeCount":71},[],{"trials":6333,"activeCount":71},[6334],{"nctId":6335,"briefTitle":6336,"status":107,"phases":6337,"primaryCompletion":704,"completion":704,"start":271,"enrollment":6338,"conditions":6339,"interventions":6340},"NCT00118508","The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study)",[64],87,[2633],[6320],{"intervention":6342,"totalTrials":67,"cells":6343},"Erector Spinae Plane Block",{"EARLY_PHASE1":6344,"PHASE1":6346,"PHASE2":6348,"PHASE3":6350,"PHASE4":6352,"NA":6354},{"trials":6345,"activeCount":71},[],{"trials":6347,"activeCount":71},[],{"trials":6349,"activeCount":71},[],{"trials":6351,"activeCount":71},[],{"trials":6353,"activeCount":71},[],{"trials":6355,"activeCount":71},[6356],{"nctId":6357,"briefTitle":6358,"status":389,"phases":6359,"primaryCompletion":6360,"completion":6360,"start":6361,"enrollment":393,"conditions":6362,"interventions":6369},"NCT03540095","Erector Spinae Plane (ESP) Versus Paravertebral Nerve (PVB) Blockade for Acute Unilateral Rib Fracture Pain",[64],"2019-05-07","2018-07-23",[6363,6364,6365,6366,6367,6368],"Rib Fractures","Pain, Acute","Thoracic Injuries","Neuropathic Pain","Neuromuscular Blockade","Anesthesia, Local",[6342,6370],"Paravertebral Nerve Block",{"intervention":6370,"totalTrials":67,"cells":6372},{"EARLY_PHASE1":6373,"PHASE1":6375,"PHASE2":6377,"PHASE3":6379,"PHASE4":6381,"NA":6383},{"trials":6374,"activeCount":71},[],{"trials":6376,"activeCount":71},[],{"trials":6378,"activeCount":71},[],{"trials":6380,"activeCount":71},[],{"trials":6382,"activeCount":71},[],{"trials":6384,"activeCount":71},[6385],{"nctId":6357,"briefTitle":6358,"status":389,"phases":6386,"primaryCompletion":6360,"completion":6360,"start":6361,"enrollment":393,"conditions":6387,"interventions":6388},[64],[6363,6364,6365,6366,6367,6368],[6342,6370],{"intervention":6390,"totalTrials":67,"cells":6391},"Nexplanon",{"EARLY_PHASE1":6392,"PHASE1":6394,"PHASE2":6396,"PHASE3":6398,"PHASE4":6400,"NA":6402},{"trials":6393,"activeCount":71},[],{"trials":6395,"activeCount":71},[],{"trials":6397,"activeCount":71},[],{"trials":6399,"activeCount":71},[],{"trials":6401,"activeCount":71},[],{"trials":6403,"activeCount":71},[6404],{"nctId":6405,"briefTitle":6406,"status":107,"phases":6407,"primaryCompletion":6408,"completion":6408,"start":6409,"enrollment":1076,"conditions":6410,"interventions":6414},"NCT02657148","Immediate Postpartum Nexplanon Placement in Opioid Dependent Women",[],"2018-08","2016-05",[6411,3331,6412,6413],"Opiate Addiction","Contraceptive Behavior","Sexual Behavior",[6390,6415],"Standard postpartum contraceptive care",{"intervention":6415,"totalTrials":67,"cells":6417},{"EARLY_PHASE1":6418,"PHASE1":6420,"PHASE2":6422,"PHASE3":6424,"PHASE4":6426,"NA":6428},{"trials":6419,"activeCount":71},[],{"trials":6421,"activeCount":71},[],{"trials":6423,"activeCount":71},[],{"trials":6425,"activeCount":71},[],{"trials":6427,"activeCount":71},[],{"trials":6429,"activeCount":71},[6430],{"nctId":6405,"briefTitle":6406,"status":107,"phases":6431,"primaryCompletion":6408,"completion":6408,"start":6409,"enrollment":1076,"conditions":6432,"interventions":6433},[],[6411,3331,6412,6413],[6390,6415],{"intervention":6435,"totalTrials":67,"cells":6436},"I-123 radiolabeled metaiodobenzylguanidine cardiac imaging",{"EARLY_PHASE1":6437,"PHASE1":6439,"PHASE2":6441,"PHASE3":6443,"PHASE4":6445,"NA":6447},{"trials":6438,"activeCount":71},[],{"trials":6440,"activeCount":71},[],{"trials":6442,"activeCount":71},[],{"trials":6444,"activeCount":71},[],{"trials":6446,"activeCount":71},[],{"trials":6448,"activeCount":71},[6449],{"nctId":6450,"briefTitle":6451,"status":107,"phases":6452,"primaryCompletion":408,"completion":431,"start":1620,"enrollment":1755,"conditions":6453,"interventions":6455},"NCT01432626","Pathogenesis of Stress-Induced Cardiomyopathy by I-123 MIBG",[64],[6454],"Stress Induced Cardiomyopathy",[6435],{"intervention":6457,"totalTrials":67,"cells":6458},"Fluorescein",{"EARLY_PHASE1":6459,"PHASE1":6461,"PHASE2":6463,"PHASE3":6465,"PHASE4":6467,"NA":6469},{"trials":6460,"activeCount":71},[],{"trials":6462,"activeCount":71},[],{"trials":6464,"activeCount":71},[],{"trials":6466,"activeCount":71},[],{"trials":6468,"activeCount":71},[],{"trials":6470,"activeCount":71},[6471],{"nctId":6472,"briefTitle":6473,"status":107,"phases":6474,"primaryCompletion":6475,"completion":6475,"start":6011,"enrollment":3422,"conditions":6476,"interventions":6478},"NCT02389530","Use of Fluorescein Dye for the Removal of Brain Tumors",[],"2018-06",[6477],"Brain Neoplasms",[6457],{"intervention":6480,"totalTrials":67,"cells":6481},"L-baclofen",{"EARLY_PHASE1":6482,"PHASE1":6484,"PHASE2":6486,"PHASE3":6488,"PHASE4":6490,"NA":6492},{"trials":6483,"activeCount":71},[],{"trials":6485,"activeCount":71},[],{"trials":6487,"activeCount":71},[],{"trials":6489,"activeCount":71},[],{"trials":6491,"activeCount":71},[],{"trials":6493,"activeCount":71},[6494],{"nctId":6495,"briefTitle":6496,"status":107,"phases":6497,"completion":1982,"start":3962,"enrollment":598,"conditions":6498,"interventions":6500},"NCT00004431","Randomized Study of L-Baclofen in Patients With Refractory Trigeminal Neuralgia",[64],[6499],"Trigeminal Neuralgia",[6480],{"intervention":6502,"totalTrials":67,"cells":6503},"Valacyclovir",{"EARLY_PHASE1":6504,"PHASE1":6506,"PHASE2":6508,"PHASE3":6510,"PHASE4":6512,"NA":6514},{"trials":6505,"activeCount":71},[],{"trials":6507,"activeCount":71},[],{"trials":6509,"activeCount":71},[],{"trials":6511,"activeCount":71},[],{"trials":6513,"activeCount":71},[],{"trials":6515,"activeCount":71},[6516],{"nctId":6517,"briefTitle":6518,"status":1328,"phases":6519,"primaryCompletion":507,"completion":507,"start":1842,"enrollment":71,"conditions":6520,"interventions":6522},"NCT00682721","Valacyclovir Suppression to Improve the Stability of Vaginal Flora Among HSV-2 Seropositive Women",[64],[1599,6521],"Herpes Simplex Virus Type II",[6502],{"intervention":6524,"totalTrials":67,"cells":6525},"Amoxicillin potassium clavulanate",{"EARLY_PHASE1":6526,"PHASE1":6528,"PHASE2":6530,"PHASE3":6532,"PHASE4":6534,"NA":6536},{"trials":6527,"activeCount":71},[],{"trials":6529,"activeCount":71},[],{"trials":6531,"activeCount":71},[],{"trials":6533,"activeCount":71},[],{"trials":6535,"activeCount":71},[],{"trials":6537,"activeCount":71},[6538],{"nctId":6539,"briefTitle":6540,"status":107,"phases":6541,"completion":561,"start":705,"enrollment":6542,"conditions":6543,"interventions":6545},"NCT00132275","Guidelines for Acute Sinusitis",[64],240,[6544],"Sinusitis",[6524],{"intervention":5437,"totalTrials":67,"cells":6547},{"EARLY_PHASE1":6548,"PHASE1":6550,"PHASE2":6552,"PHASE3":6554,"PHASE4":6556,"NA":6558},{"trials":6549,"activeCount":71},[],{"trials":6551,"activeCount":71},[],{"trials":6553,"activeCount":71},[],{"trials":6555,"activeCount":71},[],{"trials":6557,"activeCount":71},[],{"trials":6559,"activeCount":71},[6560],{"nctId":5427,"briefTitle":5428,"status":107,"phases":6561,"primaryCompletion":5430,"completion":5431,"start":5432,"enrollment":5433,"conditions":6562,"interventions":6563},[64],[5435,3331],[5398,5437],{"intervention":6565,"totalTrials":67,"cells":6566},"SQ IVIG",{"EARLY_PHASE1":6567,"PHASE1":6569,"PHASE2":6571,"PHASE3":6573,"PHASE4":6575,"NA":6577},{"trials":6568,"activeCount":71},[],{"trials":6570,"activeCount":71},[],{"trials":6572,"activeCount":71},[],{"trials":6574,"activeCount":71},[],{"trials":6576,"activeCount":71},[],{"trials":6578,"activeCount":71},[6579],{"nctId":6580,"briefTitle":6581,"status":107,"phases":6582,"primaryCompletion":3421,"completion":3421,"start":3352,"enrollment":6583,"conditions":6584,"interventions":6586},"NCT01361178","Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement",[64],133,[6585],"Infections After Lung Transplant",[6565],{"intervention":6588,"totalTrials":67,"cells":6589},"basal insulin glargine",{"EARLY_PHASE1":6590,"PHASE1":6592,"PHASE2":6594,"PHASE3":6596,"PHASE4":6598,"NA":6600},{"trials":6591,"activeCount":71},[],{"trials":6593,"activeCount":71},[],{"trials":6595,"activeCount":71},[],{"trials":6597,"activeCount":71},[],{"trials":6599,"activeCount":71},[],{"trials":6601,"activeCount":71},[6602],{"nctId":6603,"briefTitle":6604,"status":107,"phases":6605,"primaryCompletion":670,"completion":3490,"start":2885,"enrollment":10,"conditions":6606,"interventions":6607},"NCT01424046","Health Care for Type 1 Diabetes in Developing World",[64],[4891],[6588,6608],"standard therapy",{"intervention":6608,"totalTrials":67,"cells":6610},{"EARLY_PHASE1":6611,"PHASE1":6613,"PHASE2":6615,"PHASE3":6617,"PHASE4":6619,"NA":6621},{"trials":6612,"activeCount":71},[],{"trials":6614,"activeCount":71},[],{"trials":6616,"activeCount":71},[],{"trials":6618,"activeCount":71},[],{"trials":6620,"activeCount":71},[],{"trials":6622,"activeCount":71},[6623],{"nctId":6603,"briefTitle":6604,"status":107,"phases":6624,"primaryCompletion":670,"completion":3490,"start":2885,"enrollment":10,"conditions":6625,"interventions":6626},[64],[4891],[6588,6608],{"intervention":6628,"totalTrials":67,"cells":6629},"Citalopram hydrobromide",{"EARLY_PHASE1":6630,"PHASE1":6632,"PHASE2":6634,"PHASE3":6636,"PHASE4":6638,"NA":6640},{"trials":6631,"activeCount":71},[],{"trials":6633,"activeCount":71},[],{"trials":6635,"activeCount":71},[],{"trials":6637,"activeCount":71},[],{"trials":6639,"activeCount":71},[],{"trials":6641,"activeCount":71},[6642],{"nctId":6643,"briefTitle":6644,"status":107,"phases":6645,"primaryCompletion":756,"completion":756,"start":2501,"enrollment":10,"conditions":6646,"interventions":6647},"NCT00930293","Efficacy and Feasibility of a Personalized Treatment for Depression With Co-Occurring Anxiety",[64],[16,28],[6628],{"intervention":5467,"totalTrials":67,"cells":6649},{"EARLY_PHASE1":6650,"PHASE1":6652,"PHASE2":6654,"PHASE3":6656,"PHASE4":6658,"NA":6660},{"trials":6651,"activeCount":71},[],{"trials":6653,"activeCount":71},[],{"trials":6655,"activeCount":71},[],{"trials":6657,"activeCount":71},[],{"trials":6659,"activeCount":71},[],{"trials":6661,"activeCount":71},[6662],{"nctId":5461,"briefTitle":5462,"status":107,"phases":6663,"primaryCompletion":3446,"completion":3446,"start":2755,"enrollment":23,"conditions":6664,"interventions":6665},[64],[5465],[656,5467],{"intervention":6667,"totalTrials":67,"cells":6668},"blood sampling",{"EARLY_PHASE1":6669,"PHASE1":6671,"PHASE2":6673,"PHASE3":6675,"PHASE4":6677,"NA":6679},{"trials":6670,"activeCount":71},[],{"trials":6672,"activeCount":71},[],{"trials":6674,"activeCount":71},[],{"trials":6676,"activeCount":71},[],{"trials":6678,"activeCount":71},[],{"trials":6680,"activeCount":71},[6681],{"nctId":6682,"briefTitle":6683,"status":107,"phases":6684,"primaryCompletion":670,"completion":670,"start":3873,"enrollment":6685,"conditions":6686,"interventions":6687},"NCT01545167","The North American Pancreatitis Study",[],2980,[3665],[6667],{"intervention":6689,"totalTrials":67,"cells":6690},"levonorgestrel exposure",{"EARLY_PHASE1":6691,"PHASE1":6693,"PHASE2":6695,"PHASE3":6697,"PHASE4":6699,"NA":6701},{"trials":6692,"activeCount":71},[],{"trials":6694,"activeCount":71},[],{"trials":6696,"activeCount":71},[],{"trials":6698,"activeCount":71},[],{"trials":6700,"activeCount":71},[],{"trials":6702,"activeCount":71},[6703],{"nctId":6704,"briefTitle":6705,"status":107,"phases":6706,"primaryCompletion":6707,"completion":6708,"start":4200,"enrollment":6709,"conditions":6710,"interventions":6711},"NCT01873170","Quantification of Immune Cells in Women Using Contraception (CHIC II)",[],"2017-02-20","2020-10",326,[1799,5713,1668],[6689,6712,6713],"DMPA exposure","etonogestrel exposure",{"intervention":6712,"totalTrials":67,"cells":6715},{"EARLY_PHASE1":6716,"PHASE1":6718,"PHASE2":6720,"PHASE3":6722,"PHASE4":6724,"NA":6726},{"trials":6717,"activeCount":71},[],{"trials":6719,"activeCount":71},[],{"trials":6721,"activeCount":71},[],{"trials":6723,"activeCount":71},[],{"trials":6725,"activeCount":71},[],{"trials":6727,"activeCount":71},[6728],{"nctId":6704,"briefTitle":6705,"status":107,"phases":6729,"primaryCompletion":6707,"completion":6708,"start":4200,"enrollment":6709,"conditions":6730,"interventions":6731},[],[1799,5713,1668],[6689,6712,6713],{"intervention":6713,"totalTrials":67,"cells":6733},{"EARLY_PHASE1":6734,"PHASE1":6736,"PHASE2":6738,"PHASE3":6740,"PHASE4":6742,"NA":6744},{"trials":6735,"activeCount":71},[],{"trials":6737,"activeCount":71},[],{"trials":6739,"activeCount":71},[],{"trials":6741,"activeCount":71},[],{"trials":6743,"activeCount":71},[],{"trials":6745,"activeCount":71},[6746],{"nctId":6704,"briefTitle":6705,"status":107,"phases":6747,"primaryCompletion":6707,"completion":6708,"start":4200,"enrollment":6709,"conditions":6748,"interventions":6749},[],[1799,5713,1668],[6689,6712,6713],{"intervention":6751,"totalTrials":67,"cells":6752},"Intravenous zoledronic acid",{"EARLY_PHASE1":6753,"PHASE1":6755,"PHASE2":6757,"PHASE3":6759,"PHASE4":6761,"NA":6763},{"trials":6754,"activeCount":71},[],{"trials":6756,"activeCount":71},[],{"trials":6758,"activeCount":71},[],{"trials":6760,"activeCount":71},[],{"trials":6762,"activeCount":71},[],{"trials":6764,"activeCount":71},[6765],{"nctId":6766,"briefTitle":6767,"status":107,"phases":6768,"primaryCompletion":3328,"completion":3328,"start":1597,"enrollment":6769,"conditions":6770,"interventions":6773},"NCT00558012","Zoledronic Acid for Osteoporosis in the Elderly",[64],181,[2633,6771,6772],"Bone Loss","Fragility Fractures",[6751],{"intervention":6775,"totalTrials":67,"cells":6776},"Quadrivalent human papillomavirus vaccine on-time administration",{"EARLY_PHASE1":6777,"PHASE1":6779,"PHASE2":6781,"PHASE3":6783,"PHASE4":6785,"NA":6787},{"trials":6778,"activeCount":71},[],{"trials":6780,"activeCount":71},[],{"trials":6782,"activeCount":71},[],{"trials":6784,"activeCount":71},[],{"trials":6786,"activeCount":71},[],{"trials":6788,"activeCount":71},[6789],{"nctId":6790,"briefTitle":6791,"status":107,"phases":6792,"primaryCompletion":824,"completion":303,"start":2213,"enrollment":1076,"conditions":6793,"interventions":6795},"NCT00572832","Randomized Trial of Alternative Quadrivalent Human Papilloma Virus (HPV) Vaccination Schedules in a University Setting",[64],[6794],"Human Papillomavirus Infection",[6775,6796],"Quadrivalent human papillomavirus vaccine delayed administration",{"intervention":6796,"totalTrials":67,"cells":6798},{"EARLY_PHASE1":6799,"PHASE1":6801,"PHASE2":6803,"PHASE3":6805,"PHASE4":6807,"NA":6809},{"trials":6800,"activeCount":71},[],{"trials":6802,"activeCount":71},[],{"trials":6804,"activeCount":71},[],{"trials":6806,"activeCount":71},[],{"trials":6808,"activeCount":71},[],{"trials":6810,"activeCount":71},[6811],{"nctId":6790,"briefTitle":6791,"status":107,"phases":6812,"primaryCompletion":824,"completion":303,"start":2213,"enrollment":1076,"conditions":6813,"interventions":6814},[64],[6794],[6775,6796],{"intervention":6816,"totalTrials":67,"cells":6817},"Nortriptyline",{"EARLY_PHASE1":6818,"PHASE1":6820,"PHASE2":6822,"PHASE3":6824,"PHASE4":6826,"NA":6828},{"trials":6819,"activeCount":71},[],{"trials":6821,"activeCount":71},[],{"trials":6823,"activeCount":71},[],{"trials":6825,"activeCount":71},[],{"trials":6827,"activeCount":71},[],{"trials":6829,"activeCount":71},[6830],{"nctId":6831,"briefTitle":6832,"status":107,"phases":6833,"primaryCompletion":6834,"completion":6834,"start":6835,"conditions":6836,"interventions":6837},"NCT00000377","Preventing the Return of Depression in Elderly Patients",[64],"2000-04","1989-03",[16],[6816],{"intervention":6839,"totalTrials":67,"cells":6840},"Lidocaine",{"EARLY_PHASE1":6841,"PHASE1":6843,"PHASE2":6845,"PHASE3":6847,"PHASE4":6849,"NA":6851},{"trials":6842,"activeCount":71},[],{"trials":6844,"activeCount":71},[],{"trials":6846,"activeCount":71},[],{"trials":6848,"activeCount":71},[],{"trials":6850,"activeCount":71},[],{"trials":6852,"activeCount":71},[6853],{"nctId":6854,"briefTitle":6855,"status":107,"phases":6856,"primaryCompletion":6857,"completion":6857,"start":756,"enrollment":3329,"conditions":6858,"interventions":6859},"NCT01534520","Self-administered Intravaginal 2% Lidocaine Gel Prior to Intrauterine Device Insertion in Nulliparous Women",[64],"2013-05",[653],[6839],{"intervention":6861,"totalTrials":67,"cells":6862},"Corticosteroid",{"EARLY_PHASE1":6863,"PHASE1":6865,"PHASE2":6867,"PHASE3":6869,"PHASE4":6871,"NA":6873},{"trials":6864,"activeCount":71},[],{"trials":6866,"activeCount":71},[],{"trials":6868,"activeCount":71},[],{"trials":6870,"activeCount":71},[],{"trials":6872,"activeCount":71},[],{"trials":6874,"activeCount":71},[6875],{"nctId":6876,"briefTitle":6877,"status":107,"phases":6878,"primaryCompletion":6879,"completion":6879,"start":6880,"enrollment":6881,"conditions":6882,"interventions":6884},"NCT04017949","Do Knee Injections Offer Benefit With Knee Arthritis Pain",[],"2020-03-01","2019-08-21",75,[6883],"Knee Osteoarthritis",[6861],{"intervention":6886,"totalTrials":67,"cells":6887},"Midazolam Hydrochloride 2Mg\u002FmL Syrup",{"EARLY_PHASE1":6888,"PHASE1":6890,"PHASE2":6892,"PHASE3":6894,"PHASE4":6896,"NA":6898},{"trials":6889,"activeCount":71},[],{"trials":6891,"activeCount":71},[],{"trials":6893,"activeCount":71},[],{"trials":6895,"activeCount":71},[],{"trials":6897,"activeCount":71},[],{"trials":6899,"activeCount":71},[6900],{"nctId":6901,"briefTitle":6902,"status":107,"phases":6903,"primaryCompletion":6904,"completion":6904,"start":6905,"enrollment":323,"conditions":6906,"interventions":6908},"NCT03360123","Comparison of Triazolam and Midazolam for Anxiolysis During Dental Treatment in the Pediatric Patient",[64],"2018-04-11","2018-01-26",[6907],"Dental Anxiety",[6886,6909],"Triazolam 0.125 MG",{"intervention":6909,"totalTrials":67,"cells":6911},{"EARLY_PHASE1":6912,"PHASE1":6914,"PHASE2":6916,"PHASE3":6918,"PHASE4":6920,"NA":6922},{"trials":6913,"activeCount":71},[],{"trials":6915,"activeCount":71},[],{"trials":6917,"activeCount":71},[],{"trials":6919,"activeCount":71},[],{"trials":6921,"activeCount":71},[],{"trials":6923,"activeCount":71},[6924],{"nctId":6901,"briefTitle":6902,"status":107,"phases":6925,"primaryCompletion":6904,"completion":6904,"start":6905,"enrollment":323,"conditions":6926,"interventions":6927},[64],[6907],[6886,6909],{"intervention":6929,"totalTrials":67,"cells":6930},"prednisone",{"EARLY_PHASE1":6931,"PHASE1":6933,"PHASE2":6935,"PHASE3":6937,"PHASE4":6939,"NA":6941},{"trials":6932,"activeCount":71},[],{"trials":6934,"activeCount":71},[],{"trials":6936,"activeCount":71},[],{"trials":6938,"activeCount":71},[],{"trials":6940,"activeCount":71},[],{"trials":6942,"activeCount":71},[6943],{"nctId":6944,"briefTitle":6945,"status":1328,"phases":6946,"primaryCompletion":6947,"completion":6947,"start":2613,"enrollment":71,"conditions":6948,"interventions":6950},"NCT00853411","Asthma Exacerbation Study",[64],"2011-02",[6949],"Asthma",[6929],{"intervention":6952,"totalTrials":67,"cells":6953},"Whole blood for genotyping",{"EARLY_PHASE1":6954,"PHASE1":6956,"PHASE2":6958,"PHASE3":6960,"PHASE4":6962,"NA":6964},{"trials":6955,"activeCount":71},[],{"trials":6957,"activeCount":71},[],{"trials":6959,"activeCount":71},[],{"trials":6961,"activeCount":71},[],{"trials":6963,"activeCount":71},[],{"trials":6965,"activeCount":71},[6966],{"nctId":6967,"briefTitle":6968,"status":107,"phases":6969,"primaryCompletion":6970,"completion":6971,"start":1481,"enrollment":6972,"conditions":6973,"interventions":6976},"NCT01557751","Acute Pain Genomic Study",[64],"2011-04-08","2012-04-08",156,[6974,6975],"Osteoarthritis","Postoperative Pain",[6952]]